US20060251684A1 - Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof - Google Patents
Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof Download PDFInfo
- Publication number
- US20060251684A1 US20060251684A1 US11/080,629 US8062905A US2006251684A1 US 20060251684 A1 US20060251684 A1 US 20060251684A1 US 8062905 A US8062905 A US 8062905A US 2006251684 A1 US2006251684 A1 US 2006251684A1
- Authority
- US
- United States
- Prior art keywords
- nanoemulsion
- composition
- species
- oil
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 227
- 238000000034 method Methods 0.000 title claims abstract description 71
- 244000000010 microbial pathogen Species 0.000 title claims abstract description 28
- 230000000415 inactivating effect Effects 0.000 title claims abstract description 13
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 394
- 244000005700 microbiome Species 0.000 claims abstract description 57
- 239000004094 surface-active agent Substances 0.000 claims abstract description 51
- 239000008346 aqueous phase Substances 0.000 claims abstract description 43
- 239000012071 phase Substances 0.000 claims abstract description 40
- 239000003960 organic solvent Substances 0.000 claims abstract description 26
- 239000002245 particle Substances 0.000 claims description 161
- 239000003921 oil Substances 0.000 claims description 97
- 235000019198 oils Nutrition 0.000 claims description 95
- 241000894006 Bacteria Species 0.000 claims description 63
- 241000700605 Viruses Species 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 38
- 238000009472 formulation Methods 0.000 claims description 33
- 241000193738 Bacillus anthracis Species 0.000 claims description 31
- 241000233866 Fungi Species 0.000 claims description 31
- 210000004666 bacterial spore Anatomy 0.000 claims description 27
- -1 squalene oil Substances 0.000 claims description 27
- 230000002163 immunogen Effects 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 239000003549 soybean oil Substances 0.000 claims description 15
- 235000012424 soybean oil Nutrition 0.000 claims description 15
- 239000003623 enhancer Substances 0.000 claims description 14
- 241000894007 species Species 0.000 claims description 14
- 239000000422 germination enhancer Substances 0.000 claims description 13
- 230000003993 interaction Effects 0.000 claims description 13
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 12
- 239000000654 additive Substances 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 241000700647 Variola virus Species 0.000 claims description 9
- 239000003599 detergent Substances 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 229920000136 polysorbate Polymers 0.000 claims description 8
- 235000002639 sodium chloride Nutrition 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 230000000241 respiratory effect Effects 0.000 claims description 7
- 241000228212 Aspergillus Species 0.000 claims description 6
- 241000701806 Human papillomavirus Species 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229920004890 Triton X-100 Polymers 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000003349 gelling agent Substances 0.000 claims description 6
- 241001480043 Arthrodermataceae Species 0.000 claims description 5
- 241000192125 Firmicutes Species 0.000 claims description 5
- 206010048461 Genital infection Diseases 0.000 claims description 5
- 241000712907 Retroviridae Species 0.000 claims description 5
- 241000700618 Vaccinia virus Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 235000019270 ammonium chloride Nutrition 0.000 claims description 5
- 230000037304 dermatophytes Effects 0.000 claims description 5
- 230000000813 microbial effect Effects 0.000 claims description 5
- 241000304886 Bacilli Species 0.000 claims description 4
- 241000588807 Bordetella Species 0.000 claims description 4
- 240000001817 Cereus hexagonus Species 0.000 claims description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 4
- 241000588914 Enterobacter Species 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 241000589989 Helicobacter Species 0.000 claims description 4
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 4
- 229930010555 Inosine Natural products 0.000 claims description 4
- 241000588748 Klebsiella Species 0.000 claims description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 241000589248 Legionella Species 0.000 claims description 4
- 241000588621 Moraxella Species 0.000 claims description 4
- 241000711408 Murine respirovirus Species 0.000 claims description 4
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 241000607720 Serratia Species 0.000 claims description 4
- 241000710960 Sindbis virus Species 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229960003767 alanine Drugs 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 229960003786 inosine Drugs 0.000 claims description 4
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 239000002736 nonionic surfactant Substances 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical group CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 claims description 3
- 241000701386 African swine fever virus Species 0.000 claims description 3
- 241000223600 Alternaria Species 0.000 claims description 3
- 241000193752 Bacillus circulans Species 0.000 claims description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 241000222290 Cladosporium Species 0.000 claims description 3
- 241000193155 Clostridium botulinum Species 0.000 claims description 3
- 241000193468 Clostridium perfringens Species 0.000 claims description 3
- 241000193449 Clostridium tetani Species 0.000 claims description 3
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 241000223208 Curvularia Species 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 241000711950 Filoviridae Species 0.000 claims description 3
- 241000710781 Flaviviridae Species 0.000 claims description 3
- 241000223218 Fusarium Species 0.000 claims description 3
- 241000207201 Gardnerella vaginalis Species 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 241000700739 Hepadnaviridae Species 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 3
- 208000007514 Herpes zoster Diseases 0.000 claims description 3
- 241000186781 Listeria Species 0.000 claims description 3
- 241000192041 Micrococcus Species 0.000 claims description 3
- 241000893980 Microsporum canis Species 0.000 claims description 3
- 241000203736 Mobiluncus Species 0.000 claims description 3
- 241000893976 Nannizzia gypsea Species 0.000 claims description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 3
- 241000187654 Nocardia Species 0.000 claims description 3
- 241000712464 Orthomyxoviridae Species 0.000 claims description 3
- 241000711504 Paramyxoviridae Species 0.000 claims description 3
- 241000228143 Penicillium Species 0.000 claims description 3
- 241000193804 Planococcus <bacterium> Species 0.000 claims description 3
- 241000711931 Rhabdoviridae Species 0.000 claims description 3
- 241000316848 Rhodococcus <scale insect> Species 0.000 claims description 3
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 241000710924 Togaviridae Species 0.000 claims description 3
- 241001045770 Trichophyton mentagrophytes Species 0.000 claims description 3
- 241000223229 Trichophyton rubrum Species 0.000 claims description 3
- 241000607626 Vibrio cholerae Species 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 235000011148 calcium chloride Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 108010001478 Bacitracin Proteins 0.000 claims description 2
- 235000008499 Canella winterana Nutrition 0.000 claims description 2
- 244000080208 Canella winterana Species 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 206010018612 Gonorrhoea Diseases 0.000 claims description 2
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 2
- 235000011613 Pinus brutia Nutrition 0.000 claims description 2
- 241000018646 Pinus brutia Species 0.000 claims description 2
- 108010040201 Polymyxins Proteins 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 229930189077 Rifamycin Natural products 0.000 claims description 2
- 235000019485 Safflower oil Nutrition 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 208000005448 Trichomonas Infections Diseases 0.000 claims description 2
- 206010044620 Trichomoniasis Diseases 0.000 claims description 2
- 108010059993 Vancomycin Proteins 0.000 claims description 2
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims description 2
- RRDRHWJDBOGQHN-JWCTVYNTSA-N [2-[(2s,5r,8s,11s,14r,17s,22s)-17-[(1r)-1-hydroxyethyl]-22-[[(2s)-2-[[(2s,3r)-3-hydroxy-2-[[(2s)-2-[6-methyloctanoyl(sulfomethyl)amino]-4-(sulfomethylamino)butanoyl]amino]butyl]amino]-4-(sulfomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15 Chemical compound CCC(C)CCCCC(=O)N(CS(O)(=O)=O)[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O RRDRHWJDBOGQHN-JWCTVYNTSA-N 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 235000021302 avocado oil Nutrition 0.000 claims description 2
- 239000008163 avocado oil Substances 0.000 claims description 2
- 229960003071 bacitracin Drugs 0.000 claims description 2
- 229930184125 bacitracin Natural products 0.000 claims description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 2
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 229960005091 chloramphenicol Drugs 0.000 claims description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 2
- 229940017545 cinnamon bark Drugs 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 229940108538 colistimethate Drugs 0.000 claims description 2
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 239000002385 cottonseed oil Substances 0.000 claims description 2
- 229960003077 cycloserine Drugs 0.000 claims description 2
- 150000002009 diols Chemical class 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 229940013317 fish oils Drugs 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 201000004946 genital herpes Diseases 0.000 claims description 2
- 208000001786 gonorrhea Diseases 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 229940087419 nonoxynol-9 Drugs 0.000 claims description 2
- 229920004918 nonoxynol-9 Polymers 0.000 claims description 2
- 229960000988 nystatin Drugs 0.000 claims description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 229940038774 squalene oil Drugs 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 208000006379 syphilis Diseases 0.000 claims description 2
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 229940040944 tetracyclines Drugs 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001082 trimethoprim Drugs 0.000 claims description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 2
- 229960003165 vancomycin Drugs 0.000 claims description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 2
- 229960003636 vidarabine Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 2
- 229960002555 zidovudine Drugs 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- 241000150452 Orthohantavirus Species 0.000 claims 3
- 241000710886 West Nile virus Species 0.000 claims 3
- 241001480036 Epidermophyton floccosum Species 0.000 claims 2
- 241000058827 Megasphaera hominis Species 0.000 claims 2
- 239000003093 cationic surfactant Substances 0.000 claims 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 229940070891 pyridium Drugs 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 229960003292 rifamycin Drugs 0.000 claims 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000002779 inactivation Effects 0.000 abstract description 6
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 description 97
- 238000000926 separation method Methods 0.000 description 37
- 239000004743 Polypropylene Substances 0.000 description 28
- 238000012360 testing method Methods 0.000 description 25
- 235000019441 ethanol Nutrition 0.000 description 21
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 19
- 238000011282 treatment Methods 0.000 description 18
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- 238000002156 mixing Methods 0.000 description 17
- 238000005202 decontamination Methods 0.000 description 16
- 230000003588 decontaminative effect Effects 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 14
- 235000013305 food Nutrition 0.000 description 13
- 244000052769 pathogen Species 0.000 description 13
- 210000004215 spore Anatomy 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 239000000645 desinfectant Substances 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 12
- 239000000969 carrier Substances 0.000 description 11
- 229920001213 Polysorbate 20 Polymers 0.000 description 10
- 230000035784 germination Effects 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 10
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 238000011109 contamination Methods 0.000 description 9
- 101710194807 Protective antigen Proteins 0.000 description 8
- 239000002738 chelating agent Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 7
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002632 lipids Chemical group 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 231100000283 hepatitis Toxicity 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000003330 sporicidal effect Effects 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 201000008827 tuberculosis Diseases 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 241001138501 Salmonella enterica Species 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000008365 aqueous carrier Substances 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 239000006152 selective media Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 238000012430 stability testing Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000006150 trypticase soy agar Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 239000004278 EU approved seasoning Substances 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000007764 Legionnaires' Disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000249 desinfective effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 241000606860 Pasteurella Species 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 239000003897 fog Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 238000002962 plaque-reduction assay Methods 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002210 silicon-based material Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241001533362 Astroviridae Species 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241000701412 Baculoviridae Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241001115395 Caulimoviridae Species 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 241000702221 Cystoviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 101000859679 Homo sapiens Non-lysosomal glucosylceramidase Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000006154 MacConkey agar Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000204048 Mycoplasma hominis Species 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 241000701553 Myoviridae Species 0.000 description 1
- 102100027814 Non-lysosomal glucosylceramidase Human genes 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000701253 Phycodnaviridae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035718 Pneumonia legionella Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001533393 Potyviridae Species 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 241000701521 Tectiviridae Species 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 208000022338 anthrax infection Diseases 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 229960004830 cetylpyridinium Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 235000021581 juice product Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 1
- 229940081192 rifamycins Drugs 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000009662 stress testing Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
Definitions
- the present disclosure relates to compositions and methods for decreasing the infectivity, morbidity, and/or rate of mortality associated with a variety of pathogenic microorganisms.
- Pathogenic microorganisms such as bacteria, fungi, viruses, and bacterial spores are responsible for a plethora of human and animal ailments.
- bacteria of the Bacillus genus and others form stable spores that resist harsh conditions and extreme temperatures.
- contamination of farmlands with B. anthracis can lead to a fatal disease in domestic, agricultural, and wild animals, as well as in humans in contact with infected animals or animal products.
- B. anthracis infection in humans is no longer common due to effective animal controls that include vaccines, antibiotics, and appropriate disposal of infected livestock.
- animal anthrax infection still represents a significant problem due to the difficulty of decontaminating land and farms.
- B. anthracis spores can be used as a biological weapon. While an anthrax vaccine is available and can be used for the prevention of classic anthrax, genetic mixing of different bacterial strains can render it ineffective.
- B. cereus is a common pathogen involved in food borne diseases due to the ability of the spores to survive cooking procedures. It is also associated with local sepsis, wound and systemic infection.
- antibiotic and antimicrobial therapy is very effective and a mainstay of modern medicine, these therapies suffer from several disadvantages.
- bacterial strains can develop antibiotic resistance.
- a person infected with an antibiotic resistant strain of bacteria faces serious and potentially life-threatening consequences because antibiotics cannot eliminate the infection.
- Pneumococci which cause pneumonia and meningitis
- Salmonella and E. coli which cause diarrhea
- enterococci which cause blood stream, surgical wound, and urinary tract infections
- antibiotics are not effective in eliminating or inactivating bacterial spores and viruses.
- Disinfectants and biocides such as sodium hypochlorite, formaldehyde and phenols can be effective against bacterial spores, but are not well suited for decontamination of the environment, equipment, or casualties. The toxicity of these compounds can result in tissue necrosis and severe pulmonary injury following contact or inhalation of volatile fumes. Furthermore, the corrosive nature of commonly used disinfectants and biocides renders them unsuitable for decontamination of sensitive equipment.
- influenza A virus is a common respiratory pathogen widely used as a model system to test anti-viral agents in vitro and in vivo.
- Current anti-viral compounds and neuraminidase inhibitors are minimally effective and viral resistance is common.
- the present invention provides emulsions comprising an aqueous phase, an oil phase comprising an oil and an organic solvent, and at least one surfactant.
- the emulsion comprises particles preferably having an average diameter of less than 150 nm.
- the invention provides a method of reducing the average nanoemulsion particle size of a composition comprising a nanoemulsion, comprising treating a nanoemulsion comprising an aqueous phase, an oil phase comprising an oil and an organic solvent, and a surfactant, and having nanoemulsion particles of an average diameter of greater than or equal to about 250 nm, so as to reduce the average diameter of the nanoemulsion particles to less than 150 nm.
- the invention provides a method of making a nanoemulsion, comprising passing a first nanoemulsion through a high pressure homogenizer or a microfluidizer under conditions effective to reduce the average diameter of the nanoemulsion particles less than 150 nm.
- the nanoemulsion comprises an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants.
- the initial nanoemulsion particles have an average diameter of greater than or equal to about 250 nm.
- the invention also provides a method of inactivating a microorganism, comprising contacting the microorganism with a composition comprising a nanoemulsion for a time effective to inactivate the microorganism.
- the nanoemulsion comprises an aqueous phase; an oil phase comprising an oil and an organic solvent and one or more surfactants.
- the nanoemulsion particles have an average diameter of less than 150 nm.
- the invention further provides a method of inactivating a pathogenic microorganism comprising contacting a subject infected with the microorganism with a composition comprising a nanoemulsion.
- the nanoemulsion comprises an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants, wherein the nanoemulsion comprises particles having an average diameter of less than 150 nm.
- the invention provides an immunogenic composition comprising a nanoemulsion, wherein the nanoemulsion comprises an aqueous phase, an oil phase comprising an oil and an organic solvent, and a surfactant, wherein the nanoemulsion comprises nanoemulsion particles having an average diameter of less than or equal to about 250 nm and a microorganism or a portion thereof.
- the invention provides method of vaccinating against a microorganism comprising administering to a subject the a composition comprising a nanoemulsion, wherein the nanoemulsion comprises an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants, wherein the nanoemulsion comprises particles having an average diameter of less than or equal to about 250 nm.
- the microorganism is inactivated by the composition and an immunological response by the subject is elicited.
- the invention provides a method of preventing an infected state caused by a microorganism, comprising administering to a subject, either before or after exposure to a microorganism, a composition comprising a nanoemulsion.
- the nanoemulsion comprises an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants, wherein the nanoemulsion comprises particles having an average diameter of less than 150 nm.
- the invention further provides a kit comprising a composition comprising a nanoemulsion, wherein the composition is provided in a single formulation or a binary formulation, wherein the binary formulation is mixed prior to using the composition.
- FIG. 1 Average separation of neat (100%) emulsions stored at 55° C.
- FIG. 2 Average settling of 10% emulsions stored at 55° C.
- FIG. 3 Average settling of 2.5% emulsions stored at 55° C.
- FIG. 4 Change in pH after accelerated stability testing. pH of neat and diluted emulsions is measured on day 0 and after 31 days incubation at 55° C.
- FIG. 5 Dependence of nanoemulsion particle size of passage number and pressure in Avestin EmulsiFlex® C3.
- compositions having emulsion particles with an average particle diameter of less than 250 nm (“small particle size nanoemulsion”) have improved stability and/or activity. These small particle size nanoemulsions are useful in a wide range of applications for decreasing the infectivity, morbidity, and/or rate of mortality associated with a variety of pathogenic microorganisms.
- pathogenic microorganism refers to a biological microorganism that is capable of producing an undesirable effect upon a host animal, and includes, for example, without limitation, bacteria, viruses, bacterial spores, molds, mildews, fungi, and the like. This includes all such biological microorganisms, regardless of their origin or of their method of production, and regardless of whether they exist in facilities, in munitions, weapons, or elsewhere.
- Small particle size nanoemulsion compositions are useful, for example, as therapeutics for humans or animals, for decontaminating surfaces, individuals or locations colonized or otherwise infected by pathogenic microorganisms, for prophylaxis, treatment, and vaccine compositions, for decreasing the infectivity of pathogenic microorganisms in foodstuffs, and the like.
- Particle size reduction to produce a small particle size nanoemulsion from a standard emulsion is efficiently and economically accomplished by high-pressure homogenizer or microfluidizer. Small particle size nanoemulsions can be rapidly produced in large quantities and are stable for many months at a broad range of temperatures.
- An emulsion is a composition containing an aqueous phase and an oil phase.
- the term “emulsion” refers to, without limitation, any oil-in-water dispersions or droplets, including lipid structures that can form as a result of hydrophobic forces that drive apolar residues (e.g., long hydrocarbon chains) away from water and polar head groups toward water, when a water immiscible phase is mixed with an aqueous phase.
- lipid structures include, but are not limited to, unilamellar, paucilamellar, and multilamellar lipid vesicles, micelles, and lamellar phases.
- Classical or standard emulsions comprise lipid structures having an average particle size of greater than about 5 ⁇ m in diameter.
- Standard nanomulsions having smaller particle sizes are known, and comprise lipid structures having an average particle diameter of about 500 nm to about 5 ⁇ m.
- a standard nanoemulsion has an average particle size of about
- small particle size nanoemulsions refers to emulsions having an average particle diameters of less than or equal to about 250 nm.
- average particle diameter is less than or equal to about 200 nm, less than or equal to about 150 nm, less than or equal to about 100 nm, or less than or equal to about 50 nm.
- the term “nanoemulsion” can encompass both standard and small particle size nanoemulsions.
- Emulsion particle size can be determined using any means known in the art, such as, for example, using laser light scattering.
- a nanoemulsion composition contains about 5 to about 50 percent by volume (vol %) of aqueous phase. As used herein, percent by volume (vol %) is based on the total volume of an emulsion or small particle size nanoemulsion.
- the aqueous phase is about 10 to about 40 vol %. In another embodiment, the aqueous phase is about 15 to about 30 vol %.
- the aqueous phase ranges from a pH of about 4 to about 10. In one embodiment the pH of the aqueous phase ranges from about 6 to about 8.
- the pH of the aqueous phase can be adjusted by addition of an acid or a base such as, for example, hydrochloric acid or sodium hydroxide.
- the aqueous phase is deionized water (hereinafter “diH2O”) or distilled water.
- the oil phase of a nanoemulsion contains an oil and an organic solvent.
- the oil phase of a nanoemulsion contains about 30 to about 90 vol % oil, based on the total volume of the nanoemulsion.
- the nanoemulsion contains about 60 to about 80 vol % oil.
- the nanoemulsion contains about 60 to about 70 vol % oil.
- the oil phase also contains from about 3 to about 15 vol % of an organic solvent based on the total volume of the nanoemulsion.
- the nanoemulsion contains about 5 to about 10 vol % of an organic solvent.
- Suitable oils include, but are not limited to, soybean oil, avocado oil, squalene oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, sunflower oil, fish oils, cinnamon bark, coconut oil, cottonseed oil, flaxseed oil, pine needle oil, silicon oil, mineral oil, essential oil, flavor oils, water insoluble vitamins, and combinations comprising one or more of the foregoing oils.
- the oil is soybean oil.
- Suitable organic solvents include, but are not limited to, organic phosphate solvents, alcohols, and combinations comprising one or more of the foregoing solvents.
- Suitable organic phosphate solvents include, but are not limited to, dialkyl and trialkyl phosphates having one to ten carbon atoms, more preferably two to eight carbon atoms.
- the alkyl groups of the di- or trialkyl phosphate can all the same or the alkyl groups can be different.
- the trialkyl phosphate is tri-n-butyl phosphate.
- Suitable alcohols include, for example, C 1 -C 12 alcohols, diols, and triols, for example glycerol, methanol, ethanol, propanol, octanol, and combinations comprising one or more of the foregoing alcohols.
- the alcohol is ethanol or glycerol, or a combinations thereof.
- Small particle size nanoemulsion compositions can also contain one or more surfactants, present in the aqueous phase, the oil phase, or both phases of a nanoemulsion. While not limited to any particular proposed mechanism, a nanoemulsion composition may function to remove proteins from bacterial membranes, such that a surfactant that will “strip” a membrane of its proteins may be useful.
- a nanoemulsion can contain about 3 to about 15 vol % of surfactant, based on the total volume of nanoemulsion. In one embodiment, the nanoemulsion contains about 5 to about 10 vol % of surfactant.
- Suitable surfactants include, but are not limited to, a variety of ionic and nonionic surfactants, as well as other emulsifiers capable of promoting the formation of nanoemulsions.
- Surfactants that allow the oil phase to remain suspended in the water phase can be used.
- the nanoemulsion comprises a non-ionic surfactant such as a polysorbate surfactant, i.e., polyoxyethylene ether.
- surfactants include, but are not limited to, the polysorbate detergents sold under the tradenames TWEEN® 20, TWEEN® 40, TWEEN® 60, TWEEN® 80, phenoxypolyethoxyethanols and polymers thereof, such as Triton® (i.e., X-100, X-301, X-165, X-102, X-200), Poloxamer® 407, Spans (20, 40, 60, and 80), tyloxapol, and combinations comprising one or more of the foregoing surfactants.
- Triton® i.e., X-100, X-301, X-165, X-102, X-200
- Poloxamer® 407 Spans (20, 40, 60, and 80
- tyloxapol tyloxapol
- surfactants include Brij®30, Brij®35, Brij®52, Brij®56, Brij®58, Brij®72, Brij®76, Brij®78, Brij®92, Brij®97, Brij®98, and Brij® 700.
- Anionic surfactants include, but are not limited to sodium dodecyl sulfate (SDS). Mixtures of surfactants are also contemplated.
- the surfactant is TWEEN® 20 or Triton® X-100 or a combination thereof. Triton X-100 is a strong non-ionic detergent and dispersing agent widely used to extract lipids and proteins from biological structures. It also has virucidal effect against a broad spectrum of enveloped viruses.
- the surfactant is nonoxynol-9.
- Nanoemulsion compositions can further contain various additives.
- exemplary additives include, for example, activity modulators, gelling agents, thickeners, auxiliary surfactants, other agents that augment cleaning and aesthetics, and combinations comprising at least one of the foregoing, so long as they do not significantly adversely affect the activity and/or stability of the emulsions.
- Additives can be incorporated into the nanoemulsion or formulated separately from the nanoemulsion, i.e., as a part of a composition containing a nanoemulsion.
- Activity modulators are additives that affect the activity of a nanoemulsion against the target microorganism.
- exemplary activity modulators are interaction enhancers such as germination enhancers, therapeutic agents, buffers, and the like, which are described below.
- One class of activity modulators thus includes “interaction enhancers,” compounds, or compositions that increase the interaction of the nanoemulsion with the cell wall of a bacterium (e.g., a Gram positive or a Gram negative bacteria) or a fungus, or with a virus envelope.
- a bacterium e.g., a Gram positive or a Gram negative bacteria
- fungus e.g., a virus envelope
- virus envelope e.g., a virus envelope.
- Suitable interaction enhancers include compounds that increase the interaction of the nanoemulsion with the cell wall of Gram negative bacteria such as Vibrio, Salmonella, Shigella, Pseudomonas, Escherichia, Klebsiella, Proteus, Enterobacter, Serratia, Moraxella, Legionella, Bordetella, Helicobacter, Haemophilus, Neisseria, Brucella, Yersinia, Pasteurella, Bacteiods, and the like.
- Gram negative bacteria such as Vibrio, Salmonella, Shigella, Pseudomonas, Escherichia, Klebsiella, Proteus, Enterobacter, Serratia, Moraxella, Legionella, Bordetella, Helicobacter, Haemophilus, Neisseria, Brucella, Yersinia, Pasteurella, Bacteiods, and the like.
- One exemplary interaction enhancer is a chelating agent.
- Suitable chelating agents include ethylenediaminetetraacetic acid (EDTA), ethylenebis(oxyethylenenitrilo)tetraacetic acid (EGTA), and combinations thereof.
- Chelating agents can be prepared in water or in a buffer, such as, for example, TRIS buffer. Chelating agents can be premixed with the aqueous phase or can be added to a diluent. Chelating agents can be used at a concentration of about 1 ⁇ M to about 50 mM, based on the total volume of the nanoemulsion composition. In one embodiment, the concentration of the chelating agent is between about 100 ⁇ M to about 50 mM.
- the concentration of chelating agent can be greater than or equal to about 25 ⁇ M, greater than or equal to about 50 ⁇ M, greater than or equal to about 70 ⁇ M greater than or equal to about 80 ⁇ M, greater than or equal to about 100 ⁇ M, greater than or equal to about 1 mM, or greater than or equal to about 2 mM. In an additional embodiment, the concentration of chelating agent can be less than or equal to about 40 mM, less than or equal to about 27 mM, less than or equal to about 25 mM, less than or equal to about 10 mM, or less than or equal to about 5 mM.
- a cationic halogen-containing compound can be premixed with the aqueous phase, or it may can be provided in combination with a nanoemulsion in a distinct formulation.
- a cationic halogen-containing compound can be used at a concentration of about 0.5 to about 7 vol. %, based on the total volume of the nanoemulsion.
- a cationic halogen-containing compound can be used at a concentration of about 0.5 to about 3 vol. %, based on the total volume of the nanoemulsion.
- Suitable cationic halogen-containing compounds include, but are not limited to, cetylpyridinium halides, cetyltrimethylammonium halides, cetyldimethylethylammonium halides, cetyldimethylbenzylammonium halides, cetyltributylphosphonium halides, dodecyltrimethylammonium halides, tetradecyltrimethylammonium halides, alkylbenzyldimethylammonium salts and combinations comprising one or more of the foregoing compounds.
- Suitable halides in the cationic halogen-containing compounds include chloride, fluoride, bromide and iodide. In one embodiment, the halide is chloride or bromide. In another embodiment the cationic halogen-containing compound is cetylpyridinium chloride or benzalkonium chloride or a combination thereof.
- a “germination enhancer” enhances the germination of, for example, spores.
- Suitable germination enhancing agents include nucleosides, ⁇ -amino acids, salts and combinations thereof.
- Useful nucleosides include inosine.
- Useful ⁇ -amino acids include, for example, glycine and the L-enantiomers of alanine, valine, leucine, isoleucine, serine, threonine, lysine, phenylalanine, tyrosine, and the alkyl esters thereof.
- Suitable salts include, for example, sodium chloride, ammonium chloride, magnesium chloride, calcium chloride, phosphate buffered saline (PBS), and potassium chloride.
- the germination enhancer is a mixture of glucose, fructose, asparagine, sodium chloride, ammonium chloride, calcium chloride, and potassium chloride.
- the germination enhancer is a combination containing L-alanine, inosine, PBS, and ammonium chloride.
- Certain growth media contain germination enhancers and buffers. Thus, when testing nanoemulsions for their ability to inactivate spores, addition of germination enhancers may not be required, if the tests are conducted using media containing such germination enhancers. Similarly, the addition of certain growth media to emulsions can enhance sporicidal activity.
- Nucleosides and amino acids can be used in amounts of about 0.5 mM to about 100 mM. In one embodiment, nucleosides and amino acids are used at a concentration of about 1 mM to about 50 mM. In another embodiment, nucleosides and amino acids are used at a concentration of about 0.5 mM to about 5 mM. Salts can be present in amounts of about 0.5 mM to about 100 mM and PBS can be used at concentrations of about 0.05 ⁇ to about 1 ⁇ .
- a germination enhancer can be incorporated into the aqueous phase prior to formation of the nanoemulsion.
- a germination enhancer is active at approximately neutral pH.
- a germination enhancer can be active between pH of about 6 to about 8. Adjustment of pH of a nanoemulsion composition containing a germination enhancer can be achieved by any suitable means, such as, for example, dilution of a nanoemulsions in PBS or by preparations of a neutral nanoemulsion or by the addition of hydrochloric acid or sodium hydroxide.
- “Therapeutic agent” refers to an agent that decreases the infectivity, morbidity, and/or rate of mortality associated with a pathogenic microorganism when administered to a subject affected by a pathogenic microorganism.
- Suitable therapeutic agents include, for example, antimicrobial agents, antiviral agents, antifungal agents, and the like, and combinations comprising one or more of the foregoing agents.
- antimicrobial agents currently available for use in treating bacterial, fungal and viral infections.
- these agents include agents that inhibit cell wall synthesis (e.g., penicillins, cephalosporins, cycloserine, vancomycin, bacitracin), imidazole antifungal agents (e.g., miconazole, ketoconazole and clotrimazole), agents that act directly to disrupt the cell membrane of the microorganism (e.g., polymyxin and colistimethate and the antifungals nystatin and amphotericin B), agents that affect the ribosomal subunits to inhibit protein synthesis (e.g. chloramphenicol, the tetracyclines, erythromycin and clindamycin), agents that alter protein synthesis and lead to cell death (e.g.
- agents that inhibit cell wall synthesis e.g., penicillins, cephalosporins, cycloserine, vancomycin, bacitracin
- imidazole antifungal agents e.g., miconazole, ketoconazo
- nucleic acid metabolism e.g. the rifamycins and the quinolones
- antimetabolites e.g., trimethoprim and sulfonamides
- nucleic acid analogues e.g. zidovudine, gangcyclovir, vidarabine, and acyclovir
- useful therapeutic agents include, but are not limited to antimicrobials such as phenylphenol, propyl paraben and poly(hexamethylene biguanide) hydrochloride (PHMB).
- nanoemulsion compositions can be formed into gels by adding a gelling agent.
- suitable gelling agents include, for example, hydrogels such as, for example, Natrosol® 250H NF (Hercules, Inc. Wilmington, Del.).
- a hydrogel can be added at concentration of about 0.5 wt % to about 5 wt %, based on the total volume of the gel.
- Suitable gelling agents include, but are not limited to, about 0.05 wt % to about 3 wt % cellulose polymer, such as cellulose gum or cationic guar derivatives, and up to about 10 wt % petrolatum, glycerin, polyethylene glycol, incroquat behenyl TMS, cetyl palmitate, glycerol stearate, and the like.
- auxiliary surfactants can optionally be used to enhance the properties of a nanoemulsion composition.
- the choice of auxiliary surfactant depends on the desire of the user with regard to the intended purpose of the composition and the commercial availability of the surfactant.
- the auxiliary surfactant is an organic, water-soluble surfactant.
- Detergent builders sequester calcium and magnesium ions that might otherwise bind with and render less effective the auxiliary surfactants or co-surfactants. Detergent builders are particularly useful when auxiliary surfactants are used, and when the compositions are diluted prior to use with hard tap water, especially water having a hardness of, above about 12 grains/gallon.
- a nanoemulsion composition can contain a suds suppressor.
- a suds suppressor is a low-foaming co-surfactant that prevents excessive sudsing during employment of the compositions on hard surfaces. Suds suppressors are also useful in formulations for no-rinse application of the composition. Concentrations of about 0.5 vol % to about 5 vol % are generally effective. Selection of a suds suppressor depends on its ability to formulate in a nanoemulsion composition and the residue as well as the cleaning profile of the composition. The suds suppressor should be chemically compatible with the components in a nanoemulsion composition and functional at the pH of a given composition. In one embodiment the suds suppressor or composition containing a suds suppressor does not leave a visible residue on surfaces on which a composition is applied.
- Low-foaming co-surfactants can be used as a suds suppressor to mediate the suds profile in a nanoemulsion composition.
- suitable suds suppressors include block copolymers, alkylated primary and secondary alcohols, and silicone-based materials.
- Exemplary block co-polymers include, e.g., Pluronic® and Tetronic® (BASF Company).
- Alkylated alcohols include those which are ethoxylated and propoxylated, such as, tergitol (Union Carbide) or poly-tergent® (Olin Corp.).
- Silicone-based materials include DSE (Dow Corning).
- the suds suppressors can be incorporated into the composition by any means known in the art.
- Small particle size nanoemulsions and compositions containing small particle size nanoemulsions can be produced by any suitable means.
- a small particle size nanoemulsion can be formed in the first instance or can be formed from a nanoemulsion having larger particles.
- a small particle size nanoemulsion can be produced by reducing the particle size of a classical or standard nanoemulsion (hereinafter “standard nanoemulsion”), to produce a small particle size nanoemulsion wherein the average nanoemulsion particle size is less than about 250 nm.
- standard nanoemulsion reducing the particle size of a classical or standard nanoemulsion
- a nanoemulsion having an average particle diameter of greater than about 250 nm is treated in a manner effective to produce particles having an average diameter of less than or equal to about 250 nm.
- small particle size nanoemulsion particles have an average diameter of less than or equal to about 200 nm, less than or equal to about 150 nm, less than or equal to about 100 nm, and less than or
- a nanoemulsion can be formed by blending an oil phase with an aqueous phase on a volume-to-volume basis ranging from about 1:9 to about 5:1, about 5:1 to about 3:1, or about 4:1, oil phase to aqueous phase.
- the oil and aqueous phases can be blended using an apparatus capable of producing shear forces sufficient to form a nanoemulsion such as, for example, a French press or a commercial low shear or high shear mixer.
- the standard emulsions are prepared under conditions of high shear to produce a nanoemulsion having a substantially uniform particle size distribution.
- a standard nanoemulsion for use in preparing a nanoemulsion composition is comprised of particles having an average diameter of about 500 nm to about 5 ⁇ m, about 500 nm to about 1 ⁇ m, 400 nm to about 5 ⁇ m, 400 nm to about 1 ⁇ m, from about 250 nm to about 5 ⁇ m, and from about 250 nm to about 1 ⁇ m.
- the pH of the aqueous phase can be adjusted using hydrochloric acid or sodium hydroxide.
- Forming a small particle size nanoemulsion from a standard nanoemulsion can be accomplished, for example, by passing the standard nanoemulsion though a microfluidizer (Microfluidics Corp., Newton, Mass.) several times at a pressure sufficient to produce a desired particle size.
- a microfluidizer is a homogenizer that operates by pumping a fluid stream into an interaction chamber.
- the interaction chamber contains fixed-geometry microchannels that accelerate the fluid stream, resulting in high turbulence, shear, and cavitation.
- a H230Z (chamber 400 ⁇ m upstream of H210Z chamber (200 ⁇ m) can be used.
- a nanoemulsion can be circulated through a heat exchanger coil or otherwise cooled to keep the temperature of the nanoemulsion from increasing significantly.
- a standard nanoemulsion is passed though the microfluidizer for two to five passes at a pressure of about 2,000 to about 10,000 psi. In another embodiment, the pressure is from 3,000 to about 4,000 pounds per square inch.
- Another means of forming a small particle size nanoemulsion is passage of a standard nanoemulsion through a high pressure homogenizer, like an EmulsiFlex® high pressure homogenizer (Avestin, Inc., Ottawa, Canada).
- a high pressure homogenizer like an EmulsiFlex® high pressure homogenizer (Avestin, Inc., Ottawa, Canada).
- the number of passages through the homogenizer as well as the flow rate will depend on the particle size of the standard nanoemulsion, nanoemulsion composition, and the desired particle size of the resulting small particle size nanoemulsion.
- Operating pressure is independent from flow rate and will remain at the set value over the process time. In one embodiment, the operating pressure is from about 2,500 to about 20,000 psi.
- a nanoemulsion can be cooled using a heat exchanger or other method and the nanoemulsion can be passed though the homogenizer from about two to about five times.
- the particle size depends inversely on both the number of passages and on the operating pressure. See FIG. 5 .
- the direct use of, for example, either a microfluidizer or a high pressure homogenizer, as described above, can result in a small particle size nanoemulsion with the properties discussed above for a small particle size nanoemulsion produced from a premixed standard nanoemulsion.
- Small particle size nanoemulsions can have a consistency ranging from a semi-solid cream to a watery liquid similar to skim milk. Creamy emulsions can be used as-is or mixed with water.
- a nanoemulsion can be prepared in a diluted or an undiluted form.
- a nanoemulsion shows suitable stability in both diluted and undiluted forms.
- suitable stability it is meant that the emulsions do not show any signs of separation (oil phase from aqueous phase) for at least 6 months.
- a nanoemulsion does not show any sign of separation up to about 2 years.
- a nanoemulsion does not show any sign of separation for up to about 3 years. Settling of the diluted emulsions is an acceptable characteristic and does not indicate separation of an oil phase from an aqueous phase.
- the emulsions can also contain a first nanoemulsion emulsified within a second nanoemulsion, wherein the first and second emulsions can each contain an aqueous phase, an oil phase, and a surfactant.
- the oil phase of each of the first and second nanoemulsion can contain an oil and an organic solvent.
- the first and second nanoemulsion can be the same or different.
- a nanoemulsion can also contain a first nanoemulsion re-emulsified to form a second nanoemulsion.
- Zeta potential is the electrical potential of a shear plane (an imaginary surface separating a thin layer of liquid that shows elastic behavior) bound to a solid surface that shows normal viscous behavior.
- the stability of hydrophobic colloids depends, in part, on the zeta potential.
- Zeta potential of a nanoemulsion can be about ⁇ 50 mV to about +50.
- the zeta potential of the emulsions can be greater than or equal to about +10 mV.
- the zeta potential is greater than or equal to about +20 mV.
- the zeta potential of the emulsions can be less than or equal to about +45 mV, less than or equal to about +40 mV or less than or equal to about +30 mV.
- a nanoemulsion comprising optional therapeutic agents, can be provided in the form of pharmaceutically acceptable compositions.
- pharmaceutically acceptable or “pharmacologically acceptable” refer to compositions that do not produce significant adverse, allergic, or other untoward reactions when administered to an animal or a human
- compositions for pharmaceutical use typically comprise a pharmaceutically acceptable carrier, for example, solvents, dispersion media, coatings, isotonic and absorption delaying agents and the like, and combinations comprising one or more of the foregoing carriers as described, for instance, in R EMINGTON'S P HARMACEUTICAL S CIENCES, 15th Ed. Easton: Mack Publishing Co. pp. 1405-1412 and 1461-1487 (1975), and T HE N ATIONAL F ORMULARY XIV 14th Ed., Washington: American Pharmaceutical Association (1975).
- a pharmaceutically acceptable carrier for example, solvents, dispersion media, coatings, isotonic and absorption delaying agents and the like, and combinations comprising one or more of the foregoing carriers as described, for instance, in R EMINGTON'S P HARMACEUTICAL S CIENCES, 15th Ed. Easton: Mack Publishing Co. pp. 1405-1412 and 1461-1487 (1975), and T HE N ATIONAL F ORMULARY XIV 14
- Suitable carriers include, but are not limited to, calcium carbonate, carboxymethylcellulose, cellulose, citric acid, dextrate, dextrose, ethyl alcohol, glucose, hydroxymethylcellulose, lactose, magnesium stearate, maltodextrin, mannitol, microcrystalline cellulose, oleate, polyethylene glycols, potassium diphosphate, potassium phosphate, saccharose, sodium diphosphate, sodium phosphate, sorbitol, starch, stearic acid and its salts, sucrose, talc, vegetable oils, water, and combinations comprising one or more of the foregoing carriers.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the emulsions of the present invention, their use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
- the pharmaceutically acceptable carriers can take the form of a liquid, cream, foam, lotion, or gel, and may additionally comprise organic solvents, emulsifiers, gelling agents, moisturizers, stabilizers, surfactants, wetting agents, preservatives, time release agents, and minor amounts of humectants, sequestering agents, dyes, perfumes, and other components commonly used in pharmaceutical compositions for topical administration.
- Nanoemulsion compositions are particularly useful in applications where inactivation of pathogenic microorganisms is desired.
- inactivating means killing, eliminating, neutralizing, or reducing the capacity of a pathogenic microorganism to infect a host on contact.
- Nanoemulsion compositions are useful for decreasing the infectivity, morbidity, and/or rate of mortality associated with a variety of pathogenic microorganisms.
- a method of inactivating a pathogenic microorganism comprises contacting the pathogenic microorganism with an amount a nanoemulsion composition which is effective to inactivate the microorganism.
- the step of contacting can involve contacting any substrate which may be or is suspected to be contaminated with a nanoemulsion composition.
- substrate it is meant, without limitation any subject, such as a human or an animal (contact can be in vivo or ex vivo, any article, any surface, or any enclosure.
- a pathogenic microorganism can be, without limitation, a bacteria, a virus, a fungus, a protozoan or a combination thereof.
- the step of contacting can be performed for any amount of time sufficient to inactivate a microorganism.
- inactivation occurs within about 5 minutes to about 10 minutes after initial contact.
- the inactivation may occur over a longer period of time, for example, 5, 10, 15, 20, 25 30, 60 minutes or longer after administration.
- compositions can be administered by spraying, fogging, misting, exposure to aerosols, wiping with a wet or saturated cloth or towlette, drenching, immersing.
- Nanoemulsion compositions can be used to inactivate vegetative bacteria and bacterial spores upon contact.
- Bacteria inactivated by nanoemulsion compositions can be Gram negative or Gram positive bacteria.
- Gram negative bacteria include, for example and without limitation, Vibrio, Salmonella, Shigella, Pseudomonas, Escherichia, Klebsiella, Proteus, Enterobacter, Serratia, Moraxella, Legionella, Bordetella, Gardnerella, Haemophilus, Neisseria, Brucella, Yersinia, Pasteurella, Bacteroids, and Helicobacter.
- Gram positive bacteria include, for example, and without limitation, Bacillus, Clostridium, Arthrobacter, Micrococcus, Staphylococcus, Streptococcus, Listeria, Corynebacteria, Planococcus, Mycobacterium, Nocardia, Rhodococcus, and acid fast Bacilli such as Mycobacterium.
- nanoemulsion compositions can be used to inactivate Bacillus, including, without limitation B. anthracis, B. cereus, B. circulans, B. subtilis, and B. megaterium. Nanoemulsion compositions can also be used to inactivate Clostridium, e.g., C. botulinum, C. perfringens, and C. tetani.
- bacteria that can be inactivated by a nanoemulsion include, but are not limited to, H. influenzae, N. gonorrhoeae, S. agalactiae, S. pneumonia, S. pyogenes and V. cholerae (classical and Eltor), and Yersinia, including, Y. pestis, Y. enterocolitica, and Y. pseudotuberculosis.
- the bacteria is B. anthracis.
- the bacteria is Mycobaterium tuberculosis.
- sporicidal ability of the nanoemulsions is by initiation of germination without complete reversion to the vegetative form, leaving the spore susceptible to disruption by the emulsions.
- Induction of germination using germination enhancers such as inosine and L-alanine can result in acceleration of the sporicidal activity of the nanoemulsion, while inhibition of initiation of germination with D-alanine can delay sporicidal activity.
- nanoemulsion compositions can inactivate a virus.
- the effect of nanoemulsion compositions on viral agents can be monitored using any suitable means, such as, for example, plaque reduction assay (PRA), cellular enzyme-linked immunosorbent assay (ELISA), P-galactosidase assay, and electron microscopy (EM).
- PRA plaque reduction assay
- ELISA cellular enzyme-linked immunosorbent assay
- EM electron microscopy
- Viruses which can be inactivated by contact with a nanoemulsion composition include, without limitation, and virus of the families Baculoviridae, Herpesviridae, Iridoviridae, Poxviridae, “African Swine Fever Viruses,” Adenoviridae, Caulimoviridae, Myoviridae, Phycodnaviridae, Tectiviridae, Papovaviridae, Circoviridae, Parvoviridae, Hepadnaviridae, Cystoviridae, Bimaviridae, Reoviridae, Coronaviridae, Flaviviridae, Togaviridae, “Arterivirus,” Astroviridae, Caliciviridae, Picomaviridae, Potyviridae, Retroviridae, Orthomyxoviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, and
- the virus is herpes, pox, papilloma, corona, influenza, hepatitis, sendai, Sindbis and vaccinia viruses, west nile, hanta, and viruses which cause the common cold.
- contacting a nanoemulsion with a fungus inactivates the fungus.
- the fungus is a yeast, such as, for example various species of Candida (e.g., Candida albicans ) or filamentous yeast including but not limited to Aspergillus species or dermatophytes such as Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Microsporum gypseum, and Epiderophyton floccosum, and types thereof, as well as others.
- kits for use against microbial infections, decontaminating instruments and the like.
- kits may contain all of the essential materials and reagents required for the delivery of the formulations to the site of their intended action as well as any desired instructions.
- the methods and compositions may be formulated into a single or separate pharmaceutically acceptable syringeable composition.
- the container means may itself be an inhalant, syringe, pipette, eye dropper, or other like apparatus, from which the formulation may be applied to an infected area of the body, such as the lungs, injected into an animal, or even applied to and mixed with the other components of the kit.
- kits also can include a means for containing the vials in close confinement for commercial sale (e.g., injection or blow-molded plastic containers into which the desired vials are retained). Irrespective of the number or type of containers, the kits also may comprise, or be packaged with, an instrument for assisting with the injection/administration or placement of the ultimate complex composition within the body of an animal.
- an instrument may be an inhalant, syringe, pipette, forceps, measured spoon, eyedropper, or any such medically approved delivery vehicle.
- a nanoemulsion composition can comprise, for example, about 0.001% to about 100% nanoemulsion per milliliter of liquid composition. In one embodiment, a nanoemulsion composition can contain about 0.01% to about 90% nanoemulsion per milliliter of liquid. These are merely exemplary ranges.
- a nanoemulsion composition can also comprise greater than about 0.25%, about 1.0%, about 5%, about 10%, about 20%, about 35%, about 50%, about 65%, about 80%, about 90%, or about 95% of nanoemulsion per milliliter of liquid composition.
- the small particle size nanoemulsions as described herein are more stable than standard emulsions under a variety of conditions, showing substantially no observable separation or settling for up to one month, preferably up to four months, more preferably up to or more than one year, up to about 21° C., preferably up to 40° C.
- Such stability is at no dilution, up to 2.5% dilution, up to 10% dilution, more preferably up to 50% dilution or higher.
- the small particle size nanoemulsions perform equal to or better than standard emulsions in inactivating a pathogenic microorganism, exhibiting a less than 10% failure rate, preferably a less than 5% failure rate, more preferably a less than 1% failure rate, and most preferably a 0% failure rate against pathogens.
- the invention is further illustrated by the following non-limiting examples.
- Nanoemulsion compositions are useful for the prevention and treatment of infection.
- a method of inactivating a pathogenic microorganism comprises contacting a subject infected with or suspected to be infected with the microorganism with a nanoemulsion composition comprising an aqueous phase, an oil phase, and one or more surfactants.
- the oil phase comprises an oil and an organic solvent, as discussed above.
- the nanoemulsion particles have an average diameter of less than or equal to about 250 nm. In one embodiment, the particles have an average diameter of less than or equal to about 200 nm, less than or equal to about 150 nm, less than or equal to about 100 nm, or less than or equal to about 50 nm.
- the pathogenic microorganism may have systemically infected the subject or on the surface of the subject. Where the microorganism is not on the subject, the is delivered to the site of infection by any suitable method, for example injection, oral administration, suppositories, and the like.
- the subject is an animal. In a further embodiment, the animal is a human.
- Exemplary infected states that can be treated or prevented with nanoemulsions include, but are not limited to, bacterial, fungal, protozoal, and/or viral vaginal infection, sexually transmitted diseases (STDs), skin infections such as, acne, impetigo, athlete's foot, onychomycosis, candidiasis and other acute fungal infections, herpes simplex and zoster and infections associated with psoriasis or other skin inflammatory diseases.
- STDs sexually transmitted diseases
- skin infections such as, acne, impetigo, athlete's foot, onychomycosis, candidiasis and other acute fungal infections, herpes simplex and zoster and infections associated with psoriasis or other skin inflammatory diseases.
- an infected state is particularly susceptible to topical treatment.
- infected states is inclusive of contamination with pathogenic microorganisms, and treatment and prevention of such infected states includes, but is not limited to, wound decontamination, decontamination of skin, airways, and/or mucosal surfaces (e.g., with anthrax spores, viruses, bacteria, and/or fungi); and the like.
- Nanoemulsion compositions can also be used as a surgical irrigant. The emulsions can be used in the personal health care industry in deodorants, soaps, body wash, acne/dermatophyte treatment agents, treatments for halitosis, and skin disinfecting.
- Nanoemulsions can be used in a variety of combination therapies, particularly those directed to microorganisms. This approach is often advantageous in avoiding the problems encountered as a result of multidrug resistance, for example.
- a nanoemulsion can be used in the prevention or treatment of genital infections.
- Such sexually transmitted genital infections include, but are not limited to genital herpes, human papilloma virus (HPV), human immunodeficiency virus (HIV), trichomoniasis, gonorrhea, syphilis, and chlamydia.
- a nanoemulsion can be applied to the genitals either before or after sexual intercourse or both before and after sexual intercourse.
- a nanoemulsion is introduced into the vagina of a female, at about the time of sexual.
- a nanoemulsion is introduced into the vagina of a female prior to intercourse.
- a nanoemulsion can also be administered to other mucous membranes.
- Application of a nanoemulsion composition to genitalia can be accomplished using any appropriate means including, for example, ointments, jellies, inserts (suppositories, sponges, and the like), foams, and douches.
- a nanoemulsion can also be used in the treatment of nonsexually transmitted genital infections, such as fungal, protozoan, bacterial infections.
- Fungal infections treatable with a nanoemulsion include, but are not limited, to tinea, candida (e.g., Candida albicans ).
- Nonsexually treated bacterial infections treatable with a nanoemulation include, but are not limited, nonspecific vaginitis and bacterial vaginitis caused by, for example, Gardnerella vaginalis, Gardneralla mobiluncus, and Mycoplasma hominis.
- Nanoemulsion compositions can also be used for the prevention and treatment of respiratory infection.
- Nanoemulsion compositions can be used to prevent infection by, without limitation, the common cold, influenza, tuberculosis, legionnaire's disease, and acute respiratory syndrome (SARS).
- a nanoemulsion composition is applied to the respiratory passages using, for example, a nasal spray, such that the spray coats the respiratory passages before exposure to these pathogens.
- this use can substantially inactivate or eliminate a respiratory pathogen preventing the pathogen from inducing a pathogenic response.
- the use of a nanoemulsion in the prevention and treatment of a respiratory infection can also stimulate an immunological response against a specific pathogen which can protect from further exposure to the same pathogen.
- a nanoemulsion can be mixed with a microorganism, a recombinant antigen, or a combination thereof to yield an immunogenic composition.
- concentration of microorganism can range from approximately 10 2 to approximately 10 10 .
- concentration of antigen can range from approximately 1 ⁇ g to approximately 1 mg, either alone or mixed with other adjuvants which include but are not limited to CpG oligonucleotides.
- immunogenic composition refers to any composition capable of eliciting an immune response. In one embodiment, the immune response results in production of protective antibodies.
- An immunogenic nanoemulsion composition can be administered topically on the skin or on mucosal membranes of a subject. Administration of an immunogenic composition can be performed using any appropriate means and using any appropriate formulation known in the art.
- a nanoemulsion composition contains substantially inactivated B. anthracis.
- a nanoemulsion composition contains a peptide comprising at least a portion of anthrax protective antigen (PA).
- PA is known to provide protection against infection in conventional vaccines.
- a vaccine can also contain an attenuated strain of B. anthracis.
- PA is isolated from B. anthracis extract.
- PA is recombinant PA.
- B. anthracis PA concentration can range from about 1 ⁇ g to about 1 mg. In one embodiment, B. anthracis PA concentration ranged from between about 2.3 ⁇ g to about 30 ⁇ g.
- a nanoemulsion contains substantially inactivated vaccinia for use as can be used as a small pox vaccination.
- a nanoemulsion in a further embodiment, a nanoemulsion.
- a nanoemulsion can be used to create a vaccine against influenza virus.
- a vaccine composition can contain an inactivated influenza virus or a portion thereof.
- a nanoemulsion composition can contain substantially inactivated Mycobateria tuberculosis or a portion thereof.
- the Mycobateria tuberculosis -containing nanoemulsion composition is efficacious as a vaccine against tuberculosis.
- a nanoemulsion composition can contain substantially inactivated hepatitis virus or an portion thereof.
- the hepatitis-containing nanoemulsion is efficacious as a vaccine against hepatitis infection.
- the hepatitis virus is hepatitis A, hepatitis B, or hepatitis C, or a mixture thereof.
- the hepatitis virus is hepatitis B.
- a nanoemulsion composition can contain substantially inactivated HIV or a portion thereof.
- the HIV-containing nanoemulsion is efficacious as a vaccine against HIV infection.
- a nanoemulsion composition can be applied to mucosa to prevent infection by a microorganism both as a prophylaxis and as a broad spectrum immunogenic composition.
- This administration results in a broad spectrum prophylactic immunogenic composition which can both prevent infection by a pathogenic microorganism and also cause an immune response against a pathogenic microorganism which comes in contact with the nanoemulsion-coated mucosa of a subject.
- this immunogenic response can provide protection or future protection to the subject against a microorganism.
- the microorganism causes influenza, tuberculosis, the common cold, SARS or other respiratory diseases.
- a nanoemulsion composition can be administered prior to contact with microorganisms. Upon contact with a pathogenic microorganism, the microorganism is inactivated. The nanoemulsion-inactivated microorganism can stimulate an immune response in a subject.
- a nanoemulsion composition can inactivate a microorganism and also function an as an adjuvant to aid in stimulating an immune response against the microorganism or its antigens.
- the immune response results in antibodies capable of neutralizing a microorganism and thus providing immunological protection of the subject against the microorganism. Examples of microorganisms which can be used in conjunction with a nanomemulsion include, but are not limited to bacteria, bacterial spores , viruses, protozoa, and fungi.
- Nanoemulsion compositions are useful for decontaminating surfaces colonized or otherwise infected by pathogenic microorganisms. These applications include, for example, disinfecting or sterilizing medical devices, contact lenses and the like, particularly when the devices or lenses are intended to be used in contact with a patient or wearer.
- medical devices includes any material or device that is used on, in, or through a patient's body in the course of medical treatment, whether prophylactic or therapeutic treatment.
- Medical devices include, but are not limited to, such items as implants, for example urinary catheters, intravascular catheters, dialysis shunts, wound drain tubes, skin sutures, vascular grafts, implantable meshes, intraocular devices, heart valves, and the like; wound care devices, for example wound dressings, surgical sutures, biologic graft materials, tape closures and dressings, surgical incise drapes, and the like; drug delivery devices, for example skin patches, mucosal patches and medical sponges; and body cavity and personal protection devices, for example tampons, sponges, surgical and examination gloves, toothbrushes, birth control devices such as IUD's and IUD strings, diaphragms and condoms; and the like.
- implants for example urinary catheters, intravascular catheters, dialysis shunts, wound drain tubes, skin sutures, vascular grafts, implantable meshes, intraocular devices, heart valves, and the like
- wound care devices for example wound dressings, surgical sutures
- compositions may be conveniently provided in the form of a liquid or foam, and may be provided with emulsifiers, surfactants, buffering agents, wetting agents, preservatives, and other components commonly found in compositions of this type.
- the nanoemulsion compositions can be impregnated into absorptive materials, such as sutures, bandages, and gauze, or coated onto the surface of solid phase materials, such as staples, zippers, and catheters to deliver the compositions to a site for the prevention or therapy.
- the present invention is also useful for disinfection and sterilization for medical, hospital, ambulance, institutional, educational, agricultural, food processing, and industrial applications.
- a nanoemulsion composition can be used to prevent contamination, disinfect or sterilize other surfaces, including surfaces used in the food industry, for example equipment and areas where food is processed, packaged and stored; vehicles; machinery; household surfaces, and other surfaces.
- a nanoemulsion composition can be used to eliminate contamination in meat processing plants, particularly of microorganisms such as Listeria monocytogenes, Salmonellae species and Escherichia species by cleaning slaughterhouses or food packaging facilities on a continual basis with the composition.
- nanoemulsion compositions can be formulated into sprays for hospital, food processing and serving facilities, and household uses such as cleaning and disinfecting patient rooms, household appliances, kitchen and bath surfaces, and the like.
- the emulsions When used in liquid form to decontaminate surfaces, the emulsions can be admixed with an aqueous carrier liquid.
- the aqueous carrier liquid is preferably not toxic and is chemically compatible with the inventive emulsions.
- the aqueous carrier liquid can comprise solvents commonly used in hard surface cleaning compositions. Such solvents are preferably chemically stable at the pH of the emulsions, have good filming/residue properties, and are miscible with water.
- Preferred carrier liquids comprise water or a miscible mixture of a C 2 -C 4 alcohol and water.
- the aqueous carrier liquid is water or a water-ethanol mixture containing from about 0 to about 50% ethanol or other solvents.
- the emulsions may be in the form of a gel, foam, or cream, preferably a gel, and may be provided with emulsifiers, surfactants, buffering agents, wetting agents, preservatives, and other components commonly found in compositions of this type.
- a nanoemulsion can also be used for mold remediation for building, equipment, and facilities.
- molds include, but are not limited to Cladosporium, Fusarium, Alternaria, Curvularia, Aspergillus, and Penicillium.
- a nanoemulsion composition can also be used in the food industry in preventing and treating food contaminated with pathogens. Thus, such compositions may be used to reduce or inhibit microbial growth or otherwise abrogate the deleterious effects of microbial contamination of food.
- a nanoemulsion composition can be used to kill bacteria and fungus on poultry eggs, fruit, vegetables, and meat. Also, the inclusion of a nanoemulsion compositions within the food product itself would be effective in killing bacteria that may have been accidentally contaminated meat or poultry.
- a nanoemulsion composition can be included in juice products to prevent growth of certain fungi, which cause contamination and lead to production of mycotoxins.
- the nanoemulsion compositions are applied in food industry acceptable forms such as washes, dips, additives, preservatives, or seasonings.
- food industry acceptable forms such as washes, dips, additives, preservatives, or seasonings.
- media and agents for additives, preservatives, and seasonings that are acceptable in food industry is well known in the art. Except insofar as any conventional additives, preservatives and seasonings are incompatible with the emulsions, their use in preventing or treating food born microbes and their toxic products is contemplated. Supplementary active ingredients may also be incorporated into the compositions.
- Nanoemulsion compositions are also useful for biodefense applications, such as, for example, decontamination of a building, surface, garment, and personnel, and disinfection or sterilization of soil and/or waterways contaminated with a pathogenic microorganism, for example as a result of a biological warfare attack.
- Nanoemulsion compositions can be delivered and applied for detoxification and decontamination using any appropriate means. Such decontamination procedures are well known to those of skill in the art and may involve simple application of the formulation in the form of a liquid spray or may require a more rigorous regimen.
- nanoemulsion compositions can be applied by, without limitation, spraying, fogging, misting, exposure to aerosols, wiping with a wet or saturated cloth or towlette for personal skin decontamination; drenching, immersing, spraying with a hand-held spray bottle or backpack-mounted spray apparatus, showering, spraying with a curtain spray, pouring, dripping, and bathing in the liquid formulation.
- a nanoemulsion can be deployed in a semi-solid carrier, such as in gels, lotions, creams, and pastes. Deployment can be accomplished by people, deployed from aircraft, helicopters, trucks, tanks, railroad, boats, bicycle, or by automated systems, including mobile robots.
- Deployment can include applying the formulation to a surface inside of an industrial setting selected from, for example, a food processing plant, a hospital, an agricultural facility, an institutional building, an ambulance, and a cooking area.
- an industrial setting selected from, for example, a food processing plant, a hospital, an agricultural facility, an institutional building, an ambulance, and a cooking area.
- a fog e.g., aerosols with particulate sizes ranging from 1-30 ⁇ m
- a fog can be used to achieve effective decontamination in areas where decontamination by a foam would be difficult, if not impossible.
- One example is the interior of air conditioning ducts.
- a fog can be generated at registers and other openings in the duct and travel a significant distance inside of the duct to decontaminate hard to reach places.
- a relatively automated fog-based decontamination system can be set-up at the scene of an attack. Remotely activated foggers can be placed inside of a facility and turned on at periodic intervals (from a remote location) to completely decontaminate the facility. This method greatly decreases the potential for decontamination personnel to be exposed to a biological warfare agent.
- a nanoemulsion can be used to decontaminate wounds contaminated with or suspected to be contaminated with bacteria, bacterial spores, virus, fungus, protazoa or combinations thereof.
- bacteria is B. anthracis.
- virus is smallpox.
- bacteria is a Yersinia species.
- a nanoemulsion can also be used to decontaminate skin contaminated with or suspected to be contaminated with bacteria, bacterial spores, virus, fungus, protazoa or combinations thereof.
- bacteria is B. anthracis.
- virus is smallpox.
- bacteria is Yersinia species.
- a nanoemulsion is also useful for prophylaxis treatment of skin against bacteria, bacterial spores, virus, fungus, protazoa, or combinations thereof.
- the bacteria is B. anthracis.
- the bacterial spore is cutaneous B. anthracis spore.
- the virus is smallpox.
- the bacteria is Yersinia species.
- a nanoemulsion is also useful for battlefield prophylaxis treatment of mucosa against bacteria, bacterial spores, virus, fungus, protazoa or combinations thereof.
- the bacteria is B. anthracis.
- the bacterial spore is B. anthracis spore.
- the virus is smallpox.
- the bacteria is Yersinia species.
- nanoemuslions can be applied intranasally prior to and/or immediately after suspected contamination by bacteria, bacterial spores, virus, fungus, or combinations thereof.
- a nanoemulsion composition is also useful for decontamination of surfaces contaminated by or suspected to be contaminated by bacteria, bacterial spores, virus, fungus, protazoa or combinations thereof as the result of, for example, a biological warfare attack.
- the bacteria is B. anthracis.
- the bacterial spore is B. anthracis spore.
- the virus is smallpox.
- the bacteria is Yersinia species.
- a nanoemulsion composition can be applied prior to and/or immediately after suspected contamination by bacteria, bacterial spores, virus, fungus, or combinations thereof.
- the nanoemulsion composition is applied intranasally. Nanoemulsion can be applied to surfaces using any appropriate means.
- a nanoemulsion is delivered as a spray, liquid, fog, foam, or aerosol to contaminated or suspected contaminated surfaces.
- a nanoemulsion composition is also useful for decontamination buildings contaminated by or suspected to be contaminated by bacteria, bacterial spores, virus, fungus, or combinations thereof.
- the bacteria is B. anthracis.
- the bacterial spore is B. anthracis spore.
- the virus is smallpox.
- the virus is Yersinia species.
- nanoemuslions can be applied intranasally prior to and/or immediately after suspected contamination by bacteria, bacterial spores, virus, fungus, or combinations thereof. Nanoemulsion can be applied to surfaces using any appropriate means.
- a nanoemulsion is delivered as a spray, liquid, fog, foam, or aerosol to contaminated or suspected contaminated surfaces.
- the nanoemulsions are described by the components of the nanoemulsion according to Table 1. Unless otherwise noted, the oil is soybean oil.
- the detergent is listed first, followed by the volume percentage of the detergent (e.g., W 20 5 refers to 5 vol % of Tween 20).
- the designation L2 refers to a small particle size nanoemulsion produced by a microfluidizer, while the absence of the L2 designation refers to a standard nanoemulsion (i.e., average particle sizes of 250 nm to about 1 micrometer).
- the designation L3 refers to nanoemulsions produced using an Avesting high pressure homogenizer. TABLE 1 Component Symbol Tween 20 W 20 Ethanol E Cetylpyridinium chloride C EDTA ED Triton X-100 X Tributyl phosphate P Glycerol G Benzalkonium chloride BA
- a first nanoemulsion is produced from a mixture containing 548 milliliters of water, 2.24 grams of EDTA, 25 grams of cetylpyridiunium chloride, 125 milliliters of Tween 20, 200 milliliters of ethanol and 1600 milliliters of soybean oil.
- the first nanoemulsion is pre-mixed with a Silverson L4RT mixer and a fine emulsifier screen for 10 minutes at 10,000 ⁇ 500 revolutions per minute.
- the first nanoemulsion is then processed in a Microfluidics M-110EH microfluidizer processor using an H210Z (200 ⁇ m) chamber downstream of an H230Z (400 ⁇ m) chamber.
- the first nanoemulsion is passed through the microfluidizer 3 to 4 times at a pressure of 3,500 ⁇ 500 pounds per square inch (psi) using cooling ice in the tray surrounding the chambers.
- the small particle size nanoemulsion produced is referred to as W 20 EC ED L2.
- the second nanoemulsion is then diluted with distilled water to produce a series of diluted nanoemulsions.
- the water and the nanoemulsion can be mixed by shaking, for example, until the nanoemulsion is incorporated into the water.
- Exemplary diluted nanoemulsions are as shown in Table 2. The percentage shown refers to the volume percentage of the nanoemulsion in the dilution.
- a standard nanoemulsion (i.e., particles sizes of 250 nm to 5 micrometers) is formed as follows. A mixture of 22 vol % distilled water, 1 wt/vol % cetylpyridinium chloride, 5 vol % Tween 20, 64 vol % soybean oil, and 8 vol % ethanol based on the total volume of the mixture is formed. The nanoemulsion is formed by mixing for 5 minutes at 10,000 ⁇ 500 revolutions per minute with a Silverson L4RT mixer with a standard mixing assembly and a fine emulsion screen. The standard nanoemulsion is denoted as W 20 5EC.
- a small particle size nanoemulsion is formed by passing the W 20 5EC nanoemulsion 4 times through a Microfluidics M-110EH microfluidizer processor using an H210Z (200 ⁇ m) chamber downstream of an H230Z (400 ⁇ m) chamber.
- the small particle size nanoemulsion is denoted as W 20 5EC L2.
- the W 20 5EC and W 20 5EC L2 emulsions are diluted with water for further testing.
- Particle sizes are determined by Particle Sizing Systems (PSS) Nicomp Model 380. The samples are diluted 1/2000 in distilled water to measure the particle size. The formulations and data are shown in Table 3. TABLE 3 Formulation Amount of Amount of Average Particle No.
- Formulation nanoemulsion water Size nm 1 W 20 5EC — — 421.4 2 50% W 20 5EC 90 mL 90 mL 454 3 20% W 20 5EC 36 mL 144 mL 437.5 4 10% W 20 5EC 18 mL 162 mL 418.8 5 5% W 20 5EC 9 mL 171 mL 427.4 6 2.5% W 20 5EC 4.5 mL 175.5 mL 470.3 7 W 20 5EC L2 — — 152 8 50% W 20 5EC L2 90 mL 90 mL 99.3, 219.5* 9 20% W 20 5EC L2 36 mL 144 mL 144.2 10 10% W 20 5EC L2 18 mL 162 mL 153 11 5% W 20 5EC L2 9 mL 171 mL 177.8 12 2.5% W 20 5EC L2 4.5 mL 175.5 mL 157.7 *When there is wide range of particle sizes (Nicomp reading), two methods of calculation are used
- the average particle size for the W 20 5EC emulsions is about 400 to about 500 nm (samples 1-6) and for the W 20 5EC L2 emulsions is about 140 to about 220 nm (samples 7-12).
- a W 20 5G BA2 nanoemulsion is passed through different combinations of microfluidizer chambers as shown in Table 4.
- the W 20 5G BA2 L2 small particle size nanoemulsion is made with 1 pass with a Silverson L4RT mixer and 4 passes through a microfluidizer.
- Combinations of chamber having 75, 200, 400 micrometer microchannels are used to determine the relationship between the size of the microchannels and the size of the particles produced.
- the chamber size utilized in the microfluidizer when varied between 75 and 400 ⁇ m, does not significantly affect the particle size of the emulsions. In all cases, the particle size is less than or equal to about 250 nm.
- a W 20 5G BA2 nanoemulsion is formed using either a Silverson L4RT mixer (high shear) or a household hand mixer (low shear).
- the nanoemulsion is then passed through the microfluidizer for 1 to 6 passes and the particle size measured.
- the relationship between the number of passes in the microfluidizer and the particle size of the emulsions are shown in Table 5 and FIG. 5 .
- Nanoemulsion Particle Size (nm) (three independent Number of Passes experiments Type of First Through with different Sample Mixer Microfluidizer emulsion lots) 1 High shear 1 183, 221, 267 2 High shear 2 183, 205, 195 3 High shear 3 210, 202, 201 4 High shear 4 155, 156, 156 5 High shear 4 220, 157, 180 6 High shear 5 157, 132, 158 7 High shear 6 196, 161, 168 8 Low shear 0 426, 529, 522 9 Low shear 1 275, 210, 205 10 Low shear 2 218, 168, 218 11 Low shear 3 183, 151, 129 12 Low shear 4 182, 179, 180
- the number of passes through the microfluidizer does not have a large effect on the nanoemulsion particle size.
- 4 passes through the microfluidizer produces particle sizes consistently below 250 nm.
- high shear versus low shear mixing of the starting emulsion while high shear mixing can produce a more consistent particle size distribution than the low shear mixing, high shear mixing of the starting emulsion is not required to produce the small particle size nanoemulsions.
- the effect of both the number of passes through the microfluidizer and the chamber size in the microfluidizer are studied for different formulations.
- the starting emulsions are prepared using either a Silverson L4RT mixer (“Silv”) or a Ross HSM-410X high shear mixer with a 3 inch X-series rotor/stator pre-set to a 0.010 gap (Ross) in order to determine the effect of mixing method on the particle size of the starting nanoemulsion (i.e., prior to passage through the microfluidizer).
- the L2 emulsions are produced by passing a standard nanoemulsion produced by Silverson mixing through a microfluidizer. The particle sizes are shown in Table 6.
- the Silverson high shear mixer (samples 1-6) produces particle sizes of about 300 nm to about 500 nm.
- the Ross high shear mixer (Samples 7-10) produces particle sizes of 260 nm after 1 pass to about 229 to 254 nm after 4 passes.
- the Ross high shear mixer is thus capable of producing smaller particle sizes than the Silverson mixer.
- the samples passed through the microfluidizer (samples 11-23) have smaller particle sizes than the samples mixed with either high shear mixer (samples 1 -10).
- samples 11 and 12 similar particle sizes are obtained with either 2 or 3 passes through the microfluidizer.
- Samples 13-16 show that changing the microchannel size of the microfluidizer chamber does not decrease the particle size of the emulsions.
- Samples 17-23 illustrate that, independent of the formulation of the emulsions, emulsions having particle sizes of less than about 250 nm can be formed by passing the emulsions through a microfluidizer.
- the particle sizes and zeta potentials for different small particle size nanoemulsion formulations are determined.
- the emulsions are formed by passing a starting nanoemulsion through the microfluidizer for 3 passes using the H230Z+H210Z chambers.
- the particle size and zeta potential are measured by Nicomp 380 Particle sizer. The data are shown in Table 7.
- a W 20 5EC nanoemulsion was formed containing 5% Tween-20, 8% ethanol, 1% cetylpyridinium chloride, 64% soybean oil, and the balance water.
- a W 20 5EC L2 nanoemulsion is formed using 2 passes on a microfluidizer.
- a W 20 5GC nanoemulsion is formed containing 5% Tween-20, 8% glycerol, 1% cetylpyridinium chloride, 64% soybean oil, and the balance water.
- a W 20 5GC L2 nanoemulsion is formed using 2 passes on a microfluidizer.
- An X8P nanoemulsion is formed using 8% Triton X-100, 8% tributyl phosphate, and the balance water.
- Stability is determined by evaluating the physical appearance of the emulsions.
- creaming is the presence of a white layer of creamy material on top of the nanoemulsion that is more opaque than the rest of the nanoemulsion.
- Settling is a gradual decrease in opacity of the nanoemulsion from top to bottom due to separation of the more dense diluent (water) at the bottom from the less dense nanoemulsion at the top. The water appears as transparent layer at the bottom of the vial.
- Settling is classified as follows: Mild settling: the nanoemulsion appears cloudy with a gradient of “cloudiness” where it gets more opaque as you go upwards.
- Moderate settling a partially clear aqueous solution appears on the bottom of the sample.
- nanoemulsion has the appearance of three distinct layers, a partially clear bottom, cloudy middle, and creamy top. Extreme settling: only two layers, a thick partially clear bottom and a thin creamy top.
- Separation is the phase separation of the nanoemulsion ingredients. Separation is classified as follows: Mild separation: the surface of the nanoemulsion shows few visible oil droplets. Moderate separation: the surface of the nanoemulsion has a film of oil. The bottom of the nanoemulsion may have a clear aqueous layer. Severe separation: nanoemulsion has the appearance of three distinct layers, a clear aqueous layer on the bottom, a white or cloudy middle layer and a dense oily layer on the top. Extreme separation: total separation into an oil layer on top and water on bottom.
- the ambient storage stability test includes storing the neat emulsions in polypropylene bottles or centrifuge tubes at room temperature (22-25° C.). Containers may be mixed or opened during the observation period. The emulsions are observed for separation or any other changes in appearance. The observation period is varied due to different manufacturing dates of the emulsions.
- the data for W 20 5EC emulsions are shown in Table 8.
- the small particle size nanoemulsions are more stable at room temperature than comparable standard emulsions.
- Batches of standard W 20 5EC neat nanoemulsion stored at ambient temperatures longer than 5 months show oil forming a film or layer on the surface of the nanoemulsion.
- the thickness of the oil layer is variable and may be related in part to the amount of air in the storage container in addition to the number of times the container has been entered.
- Accelerated stability testing is also performed as follows. Glass vials are filled with 20 milliliters of neat, 10% diluted and 2.5% diluted nanoemulsion. The emulsions are stored at 55° C. and observed 3 times a week for changes in physical apperrance. One additional set of vials for the W 20 5EC L2 emulsions is filled completely (about 25 milliliters) to eliminate air during storage. These full vials are inverted at day 7 to facilitate observation of creaming and separation.
- Neat emulsions (100%) of standard W 20 5EC and small particle size nanoemulsion W 20 5EC L2 under accelerated stability testing at 55° C. show a film of oil separating after 4 and 5 days, respectively ( FIG. 1 and Table 10).
- the X8P neat nanoemulsion shows signs of instability with a distinct clear aqueous layer on the bottom and a 5% oil layer on the surface.
- Neat emulsions of both W 20 5GC and W 20 5GC L2 show yellowing of the oil film on the surface of the nanoemulsion, whereas for W 20 5EC and W 20 5EC L2, the oil film is colorless.
- the neat small particle size nanoemulsions are stable for 1-3 days longer than the standard emulsions.
- Table 11 shows the settling observed for the nanoemulsions after accelerated aging. TABLE 11 Average Days Average Days to Mild or to Severe or Moderate Settling Extreme Settling Nanoemulsion Neat 10% 2.50% Neat 10% 2.50% X8P N 3 3 N 10 10 W 20 5EC N 3 3 N 19 10 W 20 5EC L2 N 10.6 5 N N N W 20 5EC L2 full* N N 5 N N N W 20 5GC N 5 3 N 26 19 W 20 5GC L2 N 10 3 N N N N N
- the small particle size nanoemulsions exhibit less oil separation and less separation of the oil and water layers than the standard emulsions (Table 10).
- the small particle size nanoemulsions exhibit comparable settling and creaming to the standard emulsions when undiluted and improved stability when diluted to 10% or 2.5% (Table 11).
- Table 12 shows the separation and settling of emulsions under accelerated aging conditions TABLE 12 Separation Settling Neat 10% 2.50% Nanoemulsion Oil Water Cream Settling Cream Settling X8P 9 17 13 86 6 94 W 20 5EC 2 0 14 83 5 94 W 20 5EC L2 3 0 2 9 2 42 W 20 5EC L2 full* 0 0 2 ⁇ 14 2 28 W 20 5GC 0.3** 0 13 77 5 93 W 20 5GC L2 0.7** 0 0 11 2 41
- the W 20 5EC L2 nanoemulsion that is stored in vials that are completely full show no separation and less settling compared to the same nanoemulsion stored in vials containing an air space (Table 12). Interestingly, the bottom breaks off at the seam at day 10 and day 21 for 2 of the full vials of diluted nanoemulsion.
- the change in pH after accelerated stability testing is measured.
- the pH of each nanoemulsion is measured at the beginning and at the end of the accelerated stability incubation at 55° C.
- Diluted emulsions are measured using a 3-in-1 combination electrode and neat emulsions are measured with a semi-micro electrode.
- the initial pH of the neat W 20 5EC, and W 20 5EC L2, W 20 5GC, and W 20 5GC L2 emulsions is similar for each nanoemulsion, ranging from 4.2-4.4.
- the pH increases with increasing dilution of these nanoemulsion to a pH of 5.6 for the 2.5 % dilutions.
- This example demonstrates using a high pressure homogenizer (Avestin Emulsiflex C3) to reduce the particle size of a standard nanoemulsion to particles having a diameter of 50-150 nm.
- the size of the nanoemulsion particles depends on the pressure and number of passages.
- a standard nanoemulsion containing particles having an average diameter of 250 nm to 5 micrometers, preferably about 300 nanometer to 1 micrometer is formed.
- the standard nanoemulsion contains 22 vol % distilled water, 1 wt/vol % cetylpyridinium chloride, 5 vol % Tween 20, 64 vol % soybean oil, 8 vol % ethanol and 2 mM EDTA, based on the total volume of the mixture formed.
- the nanoemulsion is formed by mixing for 5 minutes at 10,000 ⁇ 500 revolutions per minute with a Silverson L4RT mixer with a standard mixing assembly and a fine emulsion screen.
- the standard nanoemulsion is denoted as W 20 5EC ED.
- Small particle size nanoemulsions containing particles of various sizes are then formed by passing the standard nanoemulsion through an Avestin EmulsiFlex under different pressures ranging from 3,500-17,000 psi.
- the nanoemulsion was passed between 4-5 times under the same conditions.
- the machine applies high pressure to push the nanoemulsion through a dynamic homogenizing valve.
- Table 13 describes the different nanoemulsion particle size resulting from different passages into the emulsifier.
- Table 13 and FIG. 5 demonstrate that particle size is inversely dependent on the amount of pressure applied during homogenization as well as the number of passages to which the nanoemulsion is subjected.
- Example 9 compares the efficacy of a standard nanoemulsion versus a small particle size nanoemulsion (denoted L2) as a disinfectant.
- the AOAC (Association of Official Analytical Chemist) dilution test is a carrier-based test.
- Carriers i.e., stainless steel cylinders
- Carriers are inoculated with a test microorganism, dried, exposed to a dilution of a disinfectant product, and cultured to assess the survival of the bacteria.
- a single test involves the evaluation of 60 inoculated carriers contaminated with one microorganism against one product sample. In addition to the 60 carriers, 6 carriers are required to estimate carrier bacterial load and 6 more are included as extras. Thus, a total of 72 seeded carriers are required to perform a single test.
- a contaminated dried cylinder carrier is added to the medication tubes. Immediately after placing carrier in medication tube, tubes are swirled 3 times before placing tube into bath. Ten minutes after each carrier is deposited into the disinfectant, each carrier is removed from the medication tube with a sterile hook, tapped against the interior sides of the tube to remove the excess disinfectant, and transferred into the primary subculture tube containing the appropriate neutralizer (Letheen broth, 10 mL in 20 ⁇ 150 mm tubes). The subculture tubes are swirled for 3-4 seconds. Transfer into the primary subculture tubes should be within ⁇ 5 seconds of the actual time of transfer (10 minutes). The bacterial carrier load on at least 2 carriers is assayed.
- each carrier is transferred using a sterile wire hook to a second subculture tube containing 10 mL of the appropriate neutralizer.
- the carriers are transferred in order, but the intervals do not have to be timed.
- the tubes are swirled for 3-4 seconds and the subcultures incubated at 37° C. for 48 hours. If the broth culture appears turbid, the result is positive. A negative result is one in which the broth appears clear.
- Each tube is shaken prior to recording results to determine the presence or absence of turbidity.
- the primary and secondary subculture tubes for each carrier represent a “carrier set.” A positive result in either the primary or secondary subculture tube is considered a positive result for a carrier set.
- Gram stains are performed on smears taken from the positive culture tubes. For additional confirmatory tests, a loop of broth is streaked on the selective media appropriate for the test microorganism and incubated for 24 hours at 37° C.
- Table 15 show the results for a W 20 5G BA2+2 mM EDTA at pH 7.2 nanoemulsion and a W 20 5G BA2 L2+2 mM EDTA at pH 7.2 nanoemulsion with Staphylococcus aureus. TABLE 15 Carriers Total Number of Percentage Sample Formulation failed tested experiments failed 1 1% W 20 5G 16 304 6 5.26% BA2 + 2 mM EDTA 2 1% W 20 5G BA2 2 240 4 0.83% L2 + 2 mM EDTA 3 1% W 20 5G BA2 L2 1 300 6 0.33%
- a disinfectant made with the small particle size nanoemulsions has a lower failure ratio than a standard nanoemulsion.
- the standard nanoemulsion has a failure rate of about 5%.
- the small particle size nanoemulsions have a failure rate of less than 1%.
- Table 16 also shows results obtained for various formulations exposed to Staphylococcus aureus. TABLE 16 Number of No. of Sam- Ex- Failed Percentage ple Formulation periments Cylinders failed 1 1% W 20 5G BA2 + 2 mM 6 304 5.3% EDTA pH 7.2 2 1% W 20 5G BA2 + 2 mM 9 272 11.4% EDTA pH 8.0 3 1% W 20 5G BA2 L2 + 2 mM 4 240 0.83% EDTA pH 7.2 4 1% W 20 5G BA2 pH 7.2 6 300 0.33%
- Table 16 demonstrates that the small particle size nanoemulsions (Samples 3 and 4) show greater efficacy against Staphylococcus aureus than the standard emulsions (Samples 1 and 2).
- Table 17 shows the results obtained for various formulations exposed to Salmonella choleraesuis. TABLE 17 Number of No. of Sam- Ex- Cylinders Percentage ple Formulation periments tested failed 1 1% W 20 5G BA2 + 2 mM 2 120 0% EDTA pH 7.2 2 1% W 20 5G BA2 + 2 mM 1 30 0% EDTA pH 8.0 3 1% W 20 5G BA2 L2 + 2 mM 1 60 0% EDTA pH 7.2 4 1% W 20 5G BA2 (L 2 ) pH 7.2 60 240 0%
- Table 17 demonstrates that the small particle size nanoemulsions (Samples 3 and 4) show similar efficacy against Salmonella choleraesuis compared to the standard emulsions (Samples 1 and 2). Overall in the disinfectant test, the small particle size nanoemulsions perform as well as or better than the standard emulsions.
- the bactericidal activity of the nanoemulsions is tested using a tube rotation test.
- a culture is prepared by picking one colony from the stock culture plate of Staphylococcus aureus, streaking fresh TSA and incubating overnight at 37° C. The next morning, one colony is picked from the agar plate and transferred into 25 mL of TSB in a 50 mL screw-cap tube and incubated at 37° C. on a tube rotator for 4-5 hours until the culture becomes turbid. Bacteria grown for 4-6 hours is added to 10 mL TSB until the culture media becomes slightly turbid.
- W 20 5EC and W 20 5EC L2 are used as previously described.
- the emulsions are then diluted to 2%, 1%, 0.2%, 0.1%, and 0.02% by volume with water.
- Bactericidal testing is performed as follows. In 1.7 mL microfuge tubes, 0.5 mL cell suspension and 0.5 mL of each of the nanoemulsion dilutions is mixed and the tubes capped. A positive control containing 0.5 mL of cell suspension and 0.5 mL of sterile distilled water is prepared in parallel. The tubes are incubated on a tube rotator at 37° C. for 10 minutes. Each of the preparations is serially diluted (5 log diluation) in a 96-well plate using PBS. 25 ⁇ L from each dilution on is incubated on TSA at 37° C. overnight. The colonies on the control and test plates are counted. The count on the control plate provides the initial bacterial count.
- Small particle size nanoemulsions have several advantages over standard emulsions.
- the small particle size nanoemulsions can be more stable than the standard emulsions when stored at room temperature or at 55° C.
- the small particle size nanoemulsions are capable of resisting separation or settling when stored at room temperature for four months.
- the undiluted small particle size nanoemulsions can take about 1 to 3 days longer to exhibit moderate separation than the standard emulsions.
- the 2.5 % to 10 % diluted small particle size nanoemulsions can take about 2 to 7 days longer to exhibit moderate to extreme settling than the standard emulsions.
- the onset of phase separation in the small particle size nanoemulsions at 55° C. is later than for the standard emulsions.
- the small particle size nanoemulsions perform equal to or better than standard emulsions in inactivating bacteria.
- the small particle size nanoemulsions exhibit a less than 1% failure rate against Staphylococcus aureus compared to greater than 5% for a standard nanoemulsion.
- both the and standard nanoemulsions have a 0% failure rate against Salmonella choleraesuis.
- the small particle size nanoemulsions have a slightly improved killing compared with the standard emulsions against Staphylococcus aureus killing activity.
Abstract
Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided.
Description
- This application is a continuation of co-pending U.S. patent application Ser. No. 11/067,626, which is a continuation of U.S. patent application Ser. No. 10/860,582, which claims the benefit under 35 USC § 119(e) of U.S. application Ser. No. 60/475,633, filed Jun. 4, 2003, incorporated herein by reference in its entirety.
- The present disclosure relates to compositions and methods for decreasing the infectivity, morbidity, and/or rate of mortality associated with a variety of pathogenic microorganisms.
- Pathogenic microorganisms such as bacteria, fungi, viruses, and bacterial spores are responsible for a plethora of human and animal ailments. In addition to vegetatively growing bacteria, bacteria of the Bacillus genus and others form stable spores that resist harsh conditions and extreme temperatures. For example, contamination of farmlands with B. anthracis can lead to a fatal disease in domestic, agricultural, and wild animals, as well as in humans in contact with infected animals or animal products. B. anthracis infection in humans is no longer common due to effective animal controls that include vaccines, antibiotics, and appropriate disposal of infected livestock. However, animal anthrax infection still represents a significant problem due to the difficulty of decontaminating land and farms. Moreover, B. anthracis spores can be used as a biological weapon. While an anthrax vaccine is available and can be used for the prevention of classic anthrax, genetic mixing of different bacterial strains can render it ineffective.
- Other members of the Bacillus genus are also reported to be etiological agents for many human diseases. B. cereus is a common pathogen involved in food borne diseases due to the ability of the spores to survive cooking procedures. It is also associated with local sepsis, wound and systemic infection.
- Although antibiotic and antimicrobial therapy is very effective and a mainstay of modern medicine, these therapies suffer from several disadvantages. For example, bacterial strains can develop antibiotic resistance. A person infected with an antibiotic resistant strain of bacteria faces serious and potentially life-threatening consequences because antibiotics cannot eliminate the infection. Pneumococci, which cause pneumonia and meningitis, Salmonella and E. coli which cause diarrhea, and enterococci which cause blood stream, surgical wound, and urinary tract infections can all develop antibiotic resistance resulting in fatal infections.
- Moreover, antibiotics are not effective in eliminating or inactivating bacterial spores and viruses. Disinfectants and biocides, such as sodium hypochlorite, formaldehyde and phenols can be effective against bacterial spores, but are not well suited for decontamination of the environment, equipment, or casualties. The toxicity of these compounds can result in tissue necrosis and severe pulmonary injury following contact or inhalation of volatile fumes. Furthermore, the corrosive nature of commonly used disinfectants and biocides renders them unsuitable for decontamination of sensitive equipment.
- Viruses are additional pathogens that infect human and animals which currently lack effective means of inactivation. For example, influenza A virus is a common respiratory pathogen widely used as a model system to test anti-viral agents in vitro and in vivo. The envelope glycoproteins of influenza A, hemagglutinin (HA) and neuraminidase (NA), which determine the antigenic specificity of viral subtypes, mutate readily, rendering antibodies incapable of neutralizing the virus. Current anti-viral compounds and neuraminidase inhibitors are minimally effective and viral resistance is common.
- Accordingly, there remains a need in the art for anti-pathogenic compositions and methods that decrease the infectivity, morbidity, and/or mortality associated with pathogenic exposure while minimizing microbial resistance, toxicity to the recipient, and deleterious effects to equipment and the environment.
- To address these and other needs, the present invention provides emulsions comprising an aqueous phase, an oil phase comprising an oil and an organic solvent, and at least one surfactant. The emulsion comprises particles preferably having an average diameter of less than 150 nm.
- In one embodiment, the invention provides a method of reducing the average nanoemulsion particle size of a composition comprising a nanoemulsion, comprising treating a nanoemulsion comprising an aqueous phase, an oil phase comprising an oil and an organic solvent, and a surfactant, and having nanoemulsion particles of an average diameter of greater than or equal to about 250 nm, so as to reduce the average diameter of the nanoemulsion particles to less than 150 nm.
- In another embodiment, the invention provides a method of making a nanoemulsion, comprising passing a first nanoemulsion through a high pressure homogenizer or a microfluidizer under conditions effective to reduce the average diameter of the nanoemulsion particles less than 150 nm. The nanoemulsion comprises an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. The initial nanoemulsion particles have an average diameter of greater than or equal to about 250 nm.
- The invention also provides a method of inactivating a microorganism, comprising contacting the microorganism with a composition comprising a nanoemulsion for a time effective to inactivate the microorganism. The nanoemulsion comprises an aqueous phase; an oil phase comprising an oil and an organic solvent and one or more surfactants. The nanoemulsion particles have an average diameter of less than 150 nm.
- The invention further provides a method of inactivating a pathogenic microorganism comprising contacting a subject infected with the microorganism with a composition comprising a nanoemulsion. The nanoemulsion comprises an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants, wherein the nanoemulsion comprises particles having an average diameter of less than 150 nm.
- In an additional embodiment, the invention provides an immunogenic composition comprising a nanoemulsion, wherein the nanoemulsion comprises an aqueous phase, an oil phase comprising an oil and an organic solvent, and a surfactant, wherein the nanoemulsion comprises nanoemulsion particles having an average diameter of less than or equal to about 250 nm and a microorganism or a portion thereof.
- In a further embodiment, the invention provides method of vaccinating against a microorganism comprising administering to a subject the a composition comprising a nanoemulsion, wherein the nanoemulsion comprises an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants, wherein the nanoemulsion comprises particles having an average diameter of less than or equal to about 250 nm. The microorganism is inactivated by the composition and an immunological response by the subject is elicited.
- In another embodiment, the invention provides a method of preventing an infected state caused by a microorganism, comprising administering to a subject, either before or after exposure to a microorganism, a composition comprising a nanoemulsion. The nanoemulsion comprises an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants, wherein the nanoemulsion comprises particles having an average diameter of less than 150 nm.
- The invention further provides a kit comprising a composition comprising a nanoemulsion, wherein the composition is provided in a single formulation or a binary formulation, wherein the binary formulation is mixed prior to using the composition.
- The above described and other features are exemplified by the following figures and detailed description.
-
FIG. 1 . Average separation of neat (100%) emulsions stored at 55° C. -
FIG. 2 . Average settling of 10% emulsions stored at 55° C. -
FIG. 3 . Average settling of 2.5% emulsions stored at 55° C. -
FIG. 4 . Change in pH after accelerated stability testing. pH of neat and diluted emulsions is measured onday 0 and after 31 days incubation at 55° C. -
FIG. 5 . Dependence of nanoemulsion particle size of passage number and pressure in Avestin EmulsiFlex® C3. - Unless otherwise specified, “a” or “an” means “one or more”. The present inventors discovered that compositions having emulsion particles with an average particle diameter of less than 250 nm (“small particle size nanoemulsion”) have improved stability and/or activity. These small particle size nanoemulsions are useful in a wide range of applications for decreasing the infectivity, morbidity, and/or rate of mortality associated with a variety of pathogenic microorganisms. As used herein, the term “pathogenic microorganism” refers to a biological microorganism that is capable of producing an undesirable effect upon a host animal, and includes, for example, without limitation, bacteria, viruses, bacterial spores, molds, mildews, fungi, and the like. This includes all such biological microorganisms, regardless of their origin or of their method of production, and regardless of whether they exist in facilities, in munitions, weapons, or elsewhere.
- Small particle size nanoemulsion compositions are useful, for example, as therapeutics for humans or animals, for decontaminating surfaces, individuals or locations colonized or otherwise infected by pathogenic microorganisms, for prophylaxis, treatment, and vaccine compositions, for decreasing the infectivity of pathogenic microorganisms in foodstuffs, and the like. The inactivation of a broad range of pathogenic microrganisms, including, for example, vegetative bacteria and enveloped viruses and bacterial spores, combined with low toxicity, make small particle size nanoemulsions well-suited for use as a general decontamination agent before a specific pathogen is identified.
- A. Nanoemulsion Compositions
- Particle size reduction to produce a small particle size nanoemulsion from a standard emulsion is efficiently and economically accomplished by high-pressure homogenizer or microfluidizer. Small particle size nanoemulsions can be rapidly produced in large quantities and are stable for many months at a broad range of temperatures.
- An emulsion is a composition containing an aqueous phase and an oil phase. The term “emulsion” refers to, without limitation, any oil-in-water dispersions or droplets, including lipid structures that can form as a result of hydrophobic forces that drive apolar residues (e.g., long hydrocarbon chains) away from water and polar head groups toward water, when a water immiscible phase is mixed with an aqueous phase. These other lipid structures include, but are not limited to, unilamellar, paucilamellar, and multilamellar lipid vesicles, micelles, and lamellar phases. Classical or standard emulsions comprise lipid structures having an average particle size of greater than about 5 μm in diameter. Standard nanomulsions having smaller particle sizes are known, and comprise lipid structures having an average particle diameter of about 500 nm to about 5 μm. In one embodiment, a standard nanoemulsion has an average particle size of about As used herein, “small particle size nanoemulsions” refers to emulsions having an average particle diameters of less than or equal to about 250 nm. In one embodiment, average particle diameter is less than or equal to about 200 nm, less than or equal to about 150 nm, less than or equal to about 100 nm, or less than or equal to about 50 nm. As used herein, the term “nanoemulsion” can encompass both standard and small particle size nanoemulsions.
- Emulsion particle size can be determined using any means known in the art, such as, for example, using laser light scattering.
- A nanoemulsion composition contains about 5 to about 50 percent by volume (vol %) of aqueous phase. As used herein, percent by volume (vol %) is based on the total volume of an emulsion or small particle size nanoemulsion. In one embodiment, the aqueous phase is about 10 to about 40 vol %. In another embodiment, the aqueous phase is about 15 to about 30 vol %. The aqueous phase ranges from a pH of about 4 to about 10. In one embodiment the pH of the aqueous phase ranges from about 6 to about 8. The pH of the aqueous phase can be adjusted by addition of an acid or a base such as, for example, hydrochloric acid or sodium hydroxide. In one embodiment, the aqueous phase is deionized water (hereinafter “diH2O”) or distilled water.
- The oil phase of a nanoemulsion contains an oil and an organic solvent. The oil phase of a nanoemulsion contains about 30 to about 90 vol % oil, based on the total volume of the nanoemulsion. In one embodiment, the nanoemulsion contains about 60 to about 80 vol % oil. In another embodiment, the nanoemulsion contains about 60 to about 70 vol % oil. The oil phase also contains from about 3 to about 15 vol % of an organic solvent based on the total volume of the nanoemulsion. In one embodiment, the nanoemulsion contains about 5 to about 10 vol % of an organic solvent.
- Suitable oils include, but are not limited to, soybean oil, avocado oil, squalene oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, sunflower oil, fish oils, cinnamon bark, coconut oil, cottonseed oil, flaxseed oil, pine needle oil, silicon oil, mineral oil, essential oil, flavor oils, water insoluble vitamins, and combinations comprising one or more of the foregoing oils. In one embodiment, the oil is soybean oil.
- Suitable organic solvents include, but are not limited to, organic phosphate solvents, alcohols, and combinations comprising one or more of the foregoing solvents. Suitable organic phosphate solvents include, but are not limited to, dialkyl and trialkyl phosphates having one to ten carbon atoms, more preferably two to eight carbon atoms. The alkyl groups of the di- or trialkyl phosphate can all the same or the alkyl groups can be different. In one embodiment, the trialkyl phosphate is tri-n-butyl phosphate. Without being held to theory, it is believed that organic solvents used in the small particle size nanoemulsions serve to stabilize the nanoemulsion and remove or disrupt the lipids in the membranes of pathogens.
- Suitable alcohols include, for example, C1-C12 alcohols, diols, and triols, for example glycerol, methanol, ethanol, propanol, octanol, and combinations comprising one or more of the foregoing alcohols. In one embodiment, the alcohol is ethanol or glycerol, or a combinations thereof.
- Small particle size nanoemulsion compositions can also contain one or more surfactants, present in the aqueous phase, the oil phase, or both phases of a nanoemulsion. While not limited to any particular proposed mechanism, a nanoemulsion composition may function to remove proteins from bacterial membranes, such that a surfactant that will “strip” a membrane of its proteins may be useful. A nanoemulsion can contain about 3 to about 15 vol % of surfactant, based on the total volume of nanoemulsion. In one embodiment, the nanoemulsion contains about 5 to about 10 vol % of surfactant.
- Suitable surfactants include, but are not limited to, a variety of ionic and nonionic surfactants, as well as other emulsifiers capable of promoting the formation of nanoemulsions. Surfactants that allow the oil phase to remain suspended in the water phase can be used. In one embodiment, the nanoemulsion comprises a non-ionic surfactant such as a polysorbate surfactant, i.e., polyoxyethylene ether. Other useful surfactants include, but are not limited to, the polysorbate detergents sold under the
tradenames TWEEN® 20,TWEEN® 40,TWEEN® 60,TWEEN® 80, phenoxypolyethoxyethanols and polymers thereof, such as Triton® (i.e., X-100, X-301, X-165, X-102, X-200), Poloxamer® 407, Spans (20, 40, 60, and 80), tyloxapol, and combinations comprising one or more of the foregoing surfactants. Additional appropriate surfactants includeBrij® 30,Brij® 35, Brij®52, Brij®56, Brij®58, Brij®72, Brij®76, Brij®78, Brij®92, Brij®97, Brij®98, and Brij® 700. Anionic surfactants include, but are not limited to sodium dodecyl sulfate (SDS). Mixtures of surfactants are also contemplated. In one embodiment, the surfactant isTWEEN® 20 or Triton® X-100 or a combination thereof. Triton X-100 is a strong non-ionic detergent and dispersing agent widely used to extract lipids and proteins from biological structures. It also has virucidal effect against a broad spectrum of enveloped viruses. In another embodiment, the surfactant is nonoxynol-9. - Nanoemulsion compositions can further contain various additives. Exemplary additives include, for example, activity modulators, gelling agents, thickeners, auxiliary surfactants, other agents that augment cleaning and aesthetics, and combinations comprising at least one of the foregoing, so long as they do not significantly adversely affect the activity and/or stability of the emulsions. Additives can be incorporated into the nanoemulsion or formulated separately from the nanoemulsion, i.e., as a part of a composition containing a nanoemulsion.
- “Activity modulators” are additives that affect the activity of a nanoemulsion against the target microorganism. Exemplary activity modulators are interaction enhancers such as germination enhancers, therapeutic agents, buffers, and the like, which are described below.
- One class of activity modulators thus includes “interaction enhancers,” compounds, or compositions that increase the interaction of the nanoemulsion with the cell wall of a bacterium (e.g., a Gram positive or a Gram negative bacteria) or a fungus, or with a virus envelope. Again, without being bound by theory, it is proposed that the activity of the emulsions is due, in part, to the interaction of a nanoemulsion with a microorganism membrane or envelope. Suitable interaction enhancers include compounds that increase the interaction of the nanoemulsion with the cell wall of Gram negative bacteria such as Vibrio, Salmonella, Shigella, Pseudomonas, Escherichia, Klebsiella, Proteus, Enterobacter, Serratia, Moraxella, Legionella, Bordetella, Helicobacter, Haemophilus, Neisseria, Brucella, Yersinia, Pasteurella, Bacteiods, and the like.
- One exemplary interaction enhancer is a chelating agent. Suitable chelating agents include ethylenediaminetetraacetic acid (EDTA), ethylenebis(oxyethylenenitrilo)tetraacetic acid (EGTA), and combinations thereof. Chelating agents can be prepared in water or in a buffer, such as, for example, TRIS buffer. Chelating agents can be premixed with the aqueous phase or can be added to a diluent. Chelating agents can be used at a concentration of about 1 μM to about 50 mM, based on the total volume of the nanoemulsion composition. In one embodiment, the concentration of the chelating agent is between about 100 μM to about 50 mM. In a further embodiment, the concentration of chelating agent can be greater than or equal to about 25 μM, greater than or equal to about 50 μM, greater than or equal to about 70 μM greater than or equal to about 80 μM, greater than or equal to about 100 μM, greater than or equal to about 1 mM, or greater than or equal to about 2 mM. In an additional embodiment, the concentration of chelating agent can be less than or equal to about 40 mM, less than or equal to about 27 mM, less than or equal to about 25 mM, less than or equal to about 10 mM, or less than or equal to about 5 mM.
- Another exemplary interaction enhancer is a cationic halogen-containing compound. A cationic halogen-containing compound can be premixed with the aqueous phase, or it may can be provided in combination with a nanoemulsion in a distinct formulation. A cationic halogen-containing compound can be used at a concentration of about 0.5 to about 7 vol. %, based on the total volume of the nanoemulsion. In one embodiment, a cationic halogen-containing compound can be used at a concentration of about 0.5 to about 3 vol. %, based on the total volume of the nanoemulsion.
- Suitable cationic halogen-containing compounds include, but are not limited to, cetylpyridinium halides, cetyltrimethylammonium halides, cetyldimethylethylammonium halides, cetyldimethylbenzylammonium halides, cetyltributylphosphonium halides, dodecyltrimethylammonium halides, tetradecyltrimethylammonium halides, alkylbenzyldimethylammonium salts and combinations comprising one or more of the foregoing compounds. Suitable halides in the cationic halogen-containing compounds include chloride, fluoride, bromide and iodide. In one embodiment, the halide is chloride or bromide. In another embodiment the cationic halogen-containing compound is cetylpyridinium chloride or benzalkonium chloride or a combination thereof.
- A “germination enhancer” enhances the germination of, for example, spores. Suitable germination enhancing agents include nucleosides, α-amino acids, salts and combinations thereof. Useful nucleosides include inosine. Useful α-amino acids include, for example, glycine and the L-enantiomers of alanine, valine, leucine, isoleucine, serine, threonine, lysine, phenylalanine, tyrosine, and the alkyl esters thereof. Suitable salts, include, for example, sodium chloride, ammonium chloride, magnesium chloride, calcium chloride, phosphate buffered saline (PBS), and potassium chloride. In one embodiment, the germination enhancer is a mixture of glucose, fructose, asparagine, sodium chloride, ammonium chloride, calcium chloride, and potassium chloride. In another embodiment, the germination enhancer is a combination containing L-alanine, inosine, PBS, and ammonium chloride.
- Certain growth media contain germination enhancers and buffers. Thus, when testing nanoemulsions for their ability to inactivate spores, addition of germination enhancers may not be required, if the tests are conducted using media containing such germination enhancers. Similarly, the addition of certain growth media to emulsions can enhance sporicidal activity.
- An effective amount of germination enhancer can be readily determined by one of ordinary skill in the art. Nucleosides and amino acids can be used in amounts of about 0.5 mM to about 100 mM. In one embodiment, nucleosides and amino acids are used at a concentration of about 1 mM to about 50 mM. In another embodiment, nucleosides and amino acids are used at a concentration of about 0.5 mM to about 5 mM. Salts can be present in amounts of about 0.5 mM to about 100 mM and PBS can be used at concentrations of about 0.05× to about 1×.
- A germination enhancer can be incorporated into the aqueous phase prior to formation of the nanoemulsion. In one embodiment a germination enhancer is active at approximately neutral pH. In another embodiment, a germination enhancer can be active between pH of about 6 to about 8. Adjustment of pH of a nanoemulsion composition containing a germination enhancer can be achieved by any suitable means, such as, for example, dilution of a nanoemulsions in PBS or by preparations of a neutral nanoemulsion or by the addition of hydrochloric acid or sodium hydroxide.
- “Therapeutic agent” refers to an agent that decreases the infectivity, morbidity, and/or rate of mortality associated with a pathogenic microorganism when administered to a subject affected by a pathogenic microorganism. Suitable therapeutic agents include, for example, antimicrobial agents, antiviral agents, antifungal agents, and the like, and combinations comprising one or more of the foregoing agents. There are many antimicrobial agents currently available for use in treating bacterial, fungal and viral infections. Generally, these agents include agents that inhibit cell wall synthesis (e.g., penicillins, cephalosporins, cycloserine, vancomycin, bacitracin), imidazole antifungal agents (e.g., miconazole, ketoconazole and clotrimazole), agents that act directly to disrupt the cell membrane of the microorganism (e.g., polymyxin and colistimethate and the antifungals nystatin and amphotericin B), agents that affect the ribosomal subunits to inhibit protein synthesis (e.g. chloramphenicol, the tetracyclines, erythromycin and clindamycin), agents that alter protein synthesis and lead to cell death (e.g. aminoglycosides), agents that affect nucleic acid metabolism (e.g. the rifamycins and the quinolones), antimetabolites (e.g., trimethoprim and sulfonamides), and the nucleic acid analogues (e.g. zidovudine, gangcyclovir, vidarabine, and acyclovir) which act to inhibit viral enzymes essential for DNA synthesis. Other useful therapeutic agents include, but are not limited to antimicrobials such as phenylphenol, propyl paraben and poly(hexamethylene biguanide) hydrochloride (PHMB).
- Optionally, nanoemulsion compositions can be formed into gels by adding a gelling agent. Suitable gelling agents include, for example, hydrogels such as, for example, Natrosol® 250H NF (Hercules, Inc. Wilmington, Del.). A hydrogel can be added at concentration of about 0.5 wt % to about 5 wt %, based on the total volume of the gel. Other suitable gelling agents include, but are not limited to, about 0.05 wt % to about 3 wt % cellulose polymer, such as cellulose gum or cationic guar derivatives, and up to about 10 wt % petrolatum, glycerin, polyethylene glycol, incroquat behenyl TMS, cetyl palmitate, glycerol stearate, and the like.
- A variety of auxiliary surfactants can optionally be used to enhance the properties of a nanoemulsion composition. The choice of auxiliary surfactant depends on the desire of the user with regard to the intended purpose of the composition and the commercial availability of the surfactant. In one embodiment, the auxiliary surfactant is an organic, water-soluble surfactant.
- Other optional additives such as perfumes, brighteners, enzymes, colorants, detergent builders, suds suppressors, and the like can also be used in the compositions to enhance aesthetics and/or cleaning performance. Detergent builders sequester calcium and magnesium ions that might otherwise bind with and render less effective the auxiliary surfactants or co-surfactants. Detergent builders are particularly useful when auxiliary surfactants are used, and when the compositions are diluted prior to use with hard tap water, especially water having a hardness of, above about 12 grains/gallon.
- A nanoemulsion composition can contain a suds suppressor. A suds suppressor is a low-foaming co-surfactant that prevents excessive sudsing during employment of the compositions on hard surfaces. Suds suppressors are also useful in formulations for no-rinse application of the composition. Concentrations of about 0.5 vol % to about 5 vol % are generally effective. Selection of a suds suppressor depends on its ability to formulate in a nanoemulsion composition and the residue as well as the cleaning profile of the composition. The suds suppressor should be chemically compatible with the components in a nanoemulsion composition and functional at the pH of a given composition. In one embodiment the suds suppressor or composition containing a suds suppressor does not leave a visible residue on surfaces on which a composition is applied.
- Low-foaming co-surfactants can be used as a suds suppressor to mediate the suds profile in a nanoemulsion composition. Examples of suitable suds suppressors include block copolymers, alkylated primary and secondary alcohols, and silicone-based materials. Exemplary block co-polymers include, e.g., Pluronic® and Tetronic® (BASF Company). Alkylated alcohols include those which are ethoxylated and propoxylated, such as, tergitol (Union Carbide) or poly-tergent® (Olin Corp.). Silicone-based materials include DSE (Dow Corning). The suds suppressors can be incorporated into the composition by any means known in the art.
- B. Method of Making Small Particle Size Nanoemulsions
- Small particle size nanoemulsions and compositions containing small particle size nanoemulsions can be produced by any suitable means. A small particle size nanoemulsion can be formed in the first instance or can be formed from a nanoemulsion having larger particles. For example, a small particle size nanoemulsion can be produced by reducing the particle size of a classical or standard nanoemulsion (hereinafter “standard nanoemulsion”), to produce a small particle size nanoemulsion wherein the average nanoemulsion particle size is less than about 250 nm. In other words, a nanoemulsion having an average particle diameter of greater than about 250 nm is treated in a manner effective to produce particles having an average diameter of less than or equal to about 250 nm. In one embodiment, small particle size nanoemulsion particles have an average diameter of less than or equal to about 200 nm, less than or equal to about 150 nm, less than or equal to about 100 nm, and less than or equal to about 50 nm.
- Methods for the production of a standard nanoemulsion by mixing an oil phase with an aqueous phase are well-known. A nanoemulsion can be formed by blending an oil phase with an aqueous phase on a volume-to-volume basis ranging from about 1:9 to about 5:1, about 5:1 to about 3:1, or about 4:1, oil phase to aqueous phase. The oil and aqueous phases can be blended using an apparatus capable of producing shear forces sufficient to form a nanoemulsion such as, for example, a French press or a commercial low shear or high shear mixer. In one embodiment, the standard emulsions are prepared under conditions of high shear to produce a nanoemulsion having a substantially uniform particle size distribution. In one embodiment, a standard nanoemulsion for use in preparing a nanoemulsion composition is comprised of particles having an average diameter of about 500 nm to about 5 μm, about 500 nm to about 1 μm, 400 nm to about 5 μm, 400 nm to about 1 μm, from about 250 nm to about 5 μm, and from about 250 nm to about 1 μm. To obtain the desired pH, the pH of the aqueous phase can be adjusted using hydrochloric acid or sodium hydroxide.
- Forming a small particle size nanoemulsion from a standard nanoemulsion can be accomplished, for example, by passing the standard nanoemulsion though a microfluidizer (Microfluidics Corp., Newton, Mass.) several times at a pressure sufficient to produce a desired particle size. A microfluidizer is a homogenizer that operates by pumping a fluid stream into an interaction chamber. The interaction chamber contains fixed-geometry microchannels that accelerate the fluid stream, resulting in high turbulence, shear, and cavitation. A H230Z (chamber 400 μm upstream of H210Z chamber (200 μm) can be used. Other chamber size and configurations (Y or Z) can be used in forming a nanoemulsion using a microfluidizer. During homogenization, a nanoemulsion can be circulated through a heat exchanger coil or otherwise cooled to keep the temperature of the nanoemulsion from increasing significantly. In one embodiment, a standard nanoemulsion is passed though the microfluidizer for two to five passes at a pressure of about 2,000 to about 10,000 psi. In another embodiment, the pressure is from 3,000 to about 4,000 pounds per square inch. These conditions can vary depending on factors such as standard nanoemulsion particle size, nanoemulsion composition, and desired final particle size
- Another means of forming a small particle size nanoemulsion is passage of a standard nanoemulsion through a high pressure homogenizer, like an EmulsiFlex® high pressure homogenizer (Avestin, Inc., Ottawa, Canada). The number of passages through the homogenizer as well as the flow rate will depend on the particle size of the standard nanoemulsion, nanoemulsion composition, and the desired particle size of the resulting small particle size nanoemulsion. Operating pressure is independent from flow rate and will remain at the set value over the process time. In one embodiment, the operating pressure is from about 2,500 to about 20,000 psi. As with the microfluidizing method discussed above, a nanoemulsion can be cooled using a heat exchanger or other method and the nanoemulsion can be passed though the homogenizer from about two to about five times. The particle size depends inversely on both the number of passages and on the operating pressure. See
FIG. 5 . - In addition to the above described methods, one can produce a small particle size nanoemulsion directly, without premixing. The direct use of, for example, either a microfluidizer or a high pressure homogenizer, as described above, can result in a small particle size nanoemulsion with the properties discussed above for a small particle size nanoemulsion produced from a premixed standard nanoemulsion.
- Small particle size nanoemulsions can have a consistency ranging from a semi-solid cream to a watery liquid similar to skim milk. Creamy emulsions can be used as-is or mixed with water.
- A nanoemulsion can be prepared in a diluted or an undiluted form. In one embodiment a nanoemulsion shows suitable stability in both diluted and undiluted forms. By suitable stability, it is meant that the emulsions do not show any signs of separation (oil phase from aqueous phase) for at least 6 months. In another embodiment a nanoemulsion does not show any sign of separation up to about 2 years. In a further embodiment, a nanoemulsion does not show any sign of separation for up to about 3 years. Settling of the diluted emulsions is an acceptable characteristic and does not indicate separation of an oil phase from an aqueous phase. Settling is due to separation of emulsions from its diluent, not an oil phase separating from an aqueous phase. Such settling is readily reversed by simple shaking of the nanoemulsion, while separation of the concentrated emulsions are not reversed by simple mixing, requiring instead re-emulsification.
- The emulsions can also contain a first nanoemulsion emulsified within a second nanoemulsion, wherein the first and second emulsions can each contain an aqueous phase, an oil phase, and a surfactant. The oil phase of each of the first and second nanoemulsion can contain an oil and an organic solvent. The first and second nanoemulsion can be the same or different. A nanoemulsion can also contain a first nanoemulsion re-emulsified to form a second nanoemulsion.
- One useful parameter for characterizing a nanoemulsion is “zeta potential.” Zeta potential is the electrical potential of a shear plane (an imaginary surface separating a thin layer of liquid that shows elastic behavior) bound to a solid surface that shows normal viscous behavior. The stability of hydrophobic colloids depends, in part, on the zeta potential. Zeta potential of a nanoemulsion can be about −50 mV to about +50. In one embodiment, the zeta potential of the emulsions can be greater than or equal to about +10 mV. In another embodiment, the zeta potential is greater than or equal to about +20 mV. In a further embodiment, the zeta potential of the emulsions can be less than or equal to about +45 mV, less than or equal to about +40 mV or less than or equal to about +30 mV.
- In one embodiment a nanoemulsion, comprising optional therapeutic agents, can be provided in the form of pharmaceutically acceptable compositions. The terms “pharmaceutically acceptable” or “pharmacologically acceptable” refer to compositions that do not produce significant adverse, allergic, or other untoward reactions when administered to an animal or a human
- Compositions for pharmaceutical use typically comprise a pharmaceutically acceptable carrier, for example, solvents, dispersion media, coatings, isotonic and absorption delaying agents and the like, and combinations comprising one or more of the foregoing carriers as described, for instance, in R
EMINGTON'S PHARMACEUTICAL SCIENCES, 15th Ed. Easton: Mack Publishing Co. pp. 1405-1412 and 1461-1487 (1975), and THE NATIONAL FORMULARY XIV 14th Ed., Washington: American Pharmaceutical Association (1975). Suitable carriers include, but are not limited to, calcium carbonate, carboxymethylcellulose, cellulose, citric acid, dextrate, dextrose, ethyl alcohol, glucose, hydroxymethylcellulose, lactose, magnesium stearate, maltodextrin, mannitol, microcrystalline cellulose, oleate, polyethylene glycols, potassium diphosphate, potassium phosphate, saccharose, sodium diphosphate, sodium phosphate, sorbitol, starch, stearic acid and its salts, sucrose, talc, vegetable oils, water, and combinations comprising one or more of the foregoing carriers. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the emulsions of the present invention, their use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions. - For topical applications, the pharmaceutically acceptable carriers can take the form of a liquid, cream, foam, lotion, or gel, and may additionally comprise organic solvents, emulsifiers, gelling agents, moisturizers, stabilizers, surfactants, wetting agents, preservatives, time release agents, and minor amounts of humectants, sequestering agents, dyes, perfumes, and other components commonly used in pharmaceutical compositions for topical administration.
- C. Methods of Using Nanoemulsion Compositions to Inactivate a Pathogenic Microorganism
- Nanoemulsion compositions are particularly useful in applications where inactivation of pathogenic microorganisms is desired. The term inactivating means killing, eliminating, neutralizing, or reducing the capacity of a pathogenic microorganism to infect a host on contact. Nanoemulsion compositions are useful for decreasing the infectivity, morbidity, and/or rate of mortality associated with a variety of pathogenic microorganisms.
- A method of inactivating a pathogenic microorganism comprises contacting the pathogenic microorganism with an amount a nanoemulsion composition which is effective to inactivate the microorganism. The step of contacting can involve contacting any substrate which may be or is suspected to be contaminated with a nanoemulsion composition. By substrate it is meant, without limitation any subject, such as a human or an animal (contact can be in vivo or ex vivo, any article, any surface, or any enclosure. A pathogenic microorganism can be, without limitation, a bacteria, a virus, a fungus, a protozoan or a combination thereof.
- The step of contacting can be performed for any amount of time sufficient to inactivate a microorganism. In one embodiment, inactivation occurs within about 5 minutes to about 10 minutes after initial contact. However, it is understood that when the emulsions are used in a therapeutic context and applied topically or systemically, the inactivation may occur over a longer period of time, for example, 5, 10, 15, 20, 25 30, 60 minutes or longer after administration.
- The step of contacting can be performed using any appropriate means of application. For example, compositions can be administered by spraying, fogging, misting, exposure to aerosols, wiping with a wet or saturated cloth or towlette, drenching, immersing.
- Nanoemulsion compositions can be used to inactivate vegetative bacteria and bacterial spores upon contact. Bacteria inactivated by nanoemulsion compositions can be Gram negative or Gram positive bacteria. Gram negative bacteria include, for example and without limitation, Vibrio, Salmonella, Shigella, Pseudomonas, Escherichia, Klebsiella, Proteus, Enterobacter, Serratia, Moraxella, Legionella, Bordetella, Gardnerella, Haemophilus, Neisseria, Brucella, Yersinia, Pasteurella, Bacteroids, and Helicobacter. Gram positive bacteria include, for example, and without limitation, Bacillus, Clostridium, Arthrobacter, Micrococcus, Staphylococcus, Streptococcus, Listeria, Corynebacteria, Planococcus, Mycobacterium, Nocardia, Rhodococcus, and acid fast Bacilli such as Mycobacterium. In one embodiment, nanoemulsion compositions can be used to inactivate Bacillus, including, without limitation B. anthracis, B. cereus, B. circulans, B. subtilis, and B. megaterium. Nanoemulsion compositions can also be used to inactivate Clostridium, e.g., C. botulinum, C. perfringens, and C. tetani. Other bacteria that can be inactivated by a nanoemulsion include, but are not limited to, H. influenzae, N. gonorrhoeae, S. agalactiae, S. pneumonia, S. pyogenes and V. cholerae (classical and Eltor), and Yersinia, including, Y. pestis, Y. enterocolitica, and Y. pseudotuberculosis. In another embodiment, the bacteria is B. anthracis. In another embodiment, the bacteria is Mycobaterium tuberculosis.
- Contacting a bacterial spore with a nanoemulsion inactivates the spore. Without being bound to any theory, it is proposed that the sporicidal ability of the nanoemulsions is by initiation of germination without complete reversion to the vegetative form, leaving the spore susceptible to disruption by the emulsions. Induction of germination using germination enhancers such as inosine and L-alanine can result in acceleration of the sporicidal activity of the nanoemulsion, while inhibition of initiation of germination with D-alanine can delay sporicidal activity. This unique action of a nanoemulsion, which can be better in efficiency than 1% bleach, is interesting because Bacillus spores are generally resistant to most disinfectants including many commonly used detergents. The sporicidal effect can start almost immediately. In one embodiment the sporicidal effect occurs within 30 minutes of contact with a nanoemulsion.
- Contacting a nanoemulsion composition with a virus can inactivate a virus. The effect of nanoemulsion compositions on viral agents can be monitored using any suitable means, such as, for example, plaque reduction assay (PRA), cellular enzyme-linked immunosorbent assay (ELISA), P-galactosidase assay, and electron microscopy (EM). Viruses which can be inactivated by contact with a nanoemulsion composition include, without limitation, and virus of the families Baculoviridae, Herpesviridae, Iridoviridae, Poxviridae, “African Swine Fever Viruses,” Adenoviridae, Caulimoviridae, Myoviridae, Phycodnaviridae, Tectiviridae, Papovaviridae, Circoviridae, Parvoviridae, Hepadnaviridae, Cystoviridae, Bimaviridae, Reoviridae, Coronaviridae, Flaviviridae, Togaviridae, “Arterivirus,” Astroviridae, Caliciviridae, Picomaviridae, Potyviridae, Retroviridae, Orthomyxoviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, and Bunyaviridae. In one embodiment, the virus is herpes, pox, papilloma, corona, influenza, hepatitis, sendai, sindbis and vaccinia viruses, west nile, hanta, and viruses which cause the common cold.
- In yet another embodiment, contacting a nanoemulsion with a fungus inactivates the fungus. In one embodiment, the fungus is a yeast, such as, for example various species of Candida (e.g., Candida albicans) or filamentous yeast including but not limited to Aspergillus species or dermatophytes such as Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Microsporum gypseum, and Epiderophyton floccosum, and types thereof, as well as others.
- The methods and compositions, or components of the methods and compositions can be formulated in a single formulation, or can be separated into binary formulations for later mixing during use, as may be desired for a particular application. Such components can advantageously be placed in kits for use against microbial infections, decontaminating instruments and the like. Such kits may contain all of the essential materials and reagents required for the delivery of the formulations to the site of their intended action as well as any desired instructions.
- For in vivo use, the methods and compositions may be formulated into a single or separate pharmaceutically acceptable syringeable composition. In this case, the container means may itself be an inhalant, syringe, pipette, eye dropper, or other like apparatus, from which the formulation may be applied to an infected area of the body, such as the lungs, injected into an animal, or even applied to and mixed with the other components of the kit.
- A kit also can include a means for containing the vials in close confinement for commercial sale (e.g., injection or blow-molded plastic containers into which the desired vials are retained). Irrespective of the number or type of containers, the kits also may comprise, or be packaged with, an instrument for assisting with the injection/administration or placement of the ultimate complex composition within the body of an animal. Such an instrument may be an inhalant, syringe, pipette, forceps, measured spoon, eyedropper, or any such medically approved delivery vehicle.
- Actual amounts of nanoemulsions and additives in the compositions can be varied so as to provide amounts effective to inactivate vegetative as well as sporular microorganisms and pathogens. Accordingly, the selected amounts will depend on the nature and site for treatment, the desired response, the desired duration of biocidal action, the condition of the subject being treated, and other factors. A nanoemulsion composition can comprise, for example, about 0.001% to about 100% nanoemulsion per milliliter of liquid composition. In one embodiment, a nanoemulsion composition can contain about 0.01% to about 90% nanoemulsion per milliliter of liquid. These are merely exemplary ranges. A nanoemulsion composition can also comprise greater than about 0.25%, about 1.0%, about 5%, about 10%, about 20%, about 35%, about 50%, about 65%, about 80%, about 90%, or about 95% of nanoemulsion per milliliter of liquid composition.
- The small particle size nanoemulsions as described herein are more stable than standard emulsions under a variety of conditions, showing substantially no observable separation or settling for up to one month, preferably up to four months, more preferably up to or more than one year, up to about 21° C., preferably up to 40° C. Such stability is at no dilution, up to 2.5% dilution, up to 10% dilution, more preferably up to 50% dilution or higher.
- The small particle size nanoemulsions perform equal to or better than standard emulsions in inactivating a pathogenic microorganism, exhibiting a less than 10% failure rate, preferably a less than 5% failure rate, more preferably a less than 1% failure rate, and most preferably a 0% failure rate against pathogens. The invention is further illustrated by the following non-limiting examples.
- 1. Prevention and Treatment of Infection
- Nanoemulsion compositions are useful for the prevention and treatment of infection. A method of inactivating a pathogenic microorganism comprises contacting a subject infected with or suspected to be infected with the microorganism with a nanoemulsion composition comprising an aqueous phase, an oil phase, and one or more surfactants. The oil phase comprises an oil and an organic solvent, as discussed above. The nanoemulsion particles have an average diameter of less than or equal to about 250 nm. In one embodiment, the particles have an average diameter of less than or equal to about 200 nm, less than or equal to about 150 nm, less than or equal to about 100 nm, or less than or equal to about 50 nm.
- The pathogenic microorganism may have systemically infected the subject or on the surface of the subject. Where the microorganism is not on the subject, the is delivered to the site of infection by any suitable method, for example injection, oral administration, suppositories, and the like. In one embodiment the subject is an animal. In a further embodiment, the animal is a human.
- Exemplary infected states that can be treated or prevented with nanoemulsions include, but are not limited to, bacterial, fungal, protozoal, and/or viral vaginal infection, sexually transmitted diseases (STDs), skin infections such as, acne, impetigo, athlete's foot, onychomycosis, candidiasis and other acute fungal infections, herpes simplex and zoster and infections associated with psoriasis or other skin inflammatory diseases. In one embodiment, an infected state is particularly susceptible to topical treatment. As used herein, “infected states” is inclusive of contamination with pathogenic microorganisms, and treatment and prevention of such infected states includes, but is not limited to, wound decontamination, decontamination of skin, airways, and/or mucosal surfaces (e.g., with anthrax spores, viruses, bacteria, and/or fungi); and the like. Nanoemulsion compositions can also be used as a surgical irrigant. The emulsions can be used in the personal health care industry in deodorants, soaps, body wash, acne/dermatophyte treatment agents, treatments for halitosis, and skin disinfecting.
- Nanoemulsions can be used in a variety of combination therapies, particularly those directed to microorganisms. This approach is often advantageous in avoiding the problems encountered as a result of multidrug resistance, for example.
- In one embodiment, a nanoemulsion can be used in the prevention or treatment of genital infections. Such sexually transmitted genital infections include, but are not limited to genital herpes, human papilloma virus (HPV), human immunodeficiency virus (HIV), trichomoniasis, gonorrhea, syphilis, and chlamydia. A nanoemulsion can be applied to the genitals either before or after sexual intercourse or both before and after sexual intercourse. In one embodiment, a nanoemulsion is introduced into the vagina of a female, at about the time of sexual. In another embodiment, a nanoemulsion is introduced into the vagina of a female prior to intercourse. A nanoemulsion can also be administered to other mucous membranes. Application of a nanoemulsion composition to genitalia can be accomplished using any appropriate means including, for example, ointments, jellies, inserts (suppositories, sponges, and the like), foams, and douches.
- A nanoemulsion can also be used in the treatment of nonsexually transmitted genital infections, such as fungal, protozoan, bacterial infections. Fungal infections treatable with a nanoemulsion include, but are not limited, to tinea, candida (e.g., Candida albicans). Nonsexually treated bacterial infections treatable with a nanoemulation include, but are not limited, nonspecific vaginitis and bacterial vaginitis caused by, for example, Gardnerella vaginalis, Gardneralla mobiluncus, and Mycoplasma hominis.
- Nanoemulsion compositions can also be used for the prevention and treatment of respiratory infection. Nanoemulsion compositions can be used to prevent infection by, without limitation, the common cold, influenza, tuberculosis, legionnaire's disease, and acute respiratory syndrome (SARS). In one embodiment, a nanoemulsion composition is applied to the respiratory passages using, for example, a nasal spray, such that the spray coats the respiratory passages before exposure to these pathogens. In another embodiment, this use can substantially inactivate or eliminate a respiratory pathogen preventing the pathogen from inducing a pathogenic response. The use of a nanoemulsion in the prevention and treatment of a respiratory infection can also stimulate an immunological response against a specific pathogen which can protect from further exposure to the same pathogen.
- 2. Immunogenic Compositions and Vaccine Applications:
- A nanoemulsion can be mixed with a microorganism, a recombinant antigen, or a combination thereof to yield an immunogenic composition. The concentration of microorganism can range from approximately 102 to approximately 1010. The concentration of antigen can range from approximately 1 μg to approximately 1 mg, either alone or mixed with other adjuvants which include but are not limited to CpG oligonucleotides. As used herein “immunogenic composition” refers to any composition capable of eliciting an immune response. In one embodiment, the immune response results in production of protective antibodies.
- An immunogenic nanoemulsion composition can be administered topically on the skin or on mucosal membranes of a subject. Administration of an immunogenic composition can be performed using any appropriate means and using any appropriate formulation known in the art.
- In one embodiment, a nanoemulsion composition contains substantially inactivated B. anthracis. In one embodiment, a nanoemulsion composition contains a peptide comprising at least a portion of anthrax protective antigen (PA). PA is known to provide protection against infection in conventional vaccines. A vaccine can also contain an attenuated strain of B. anthracis. In one embodiment, PA is isolated from B. anthracis extract. In another embodiment, PA is recombinant PA. B. anthracis PA concentration can range from about 1 μg to about 1 mg. In one embodiment, B. anthracis PA concentration ranged from between about 2.3 μg to about 30 μg.
- In another embodiment, a nanoemulsion contains substantially inactivated vaccinia for use as can be used as a small pox vaccination. In a further embodiment, a nanoemulsion. In a further embodiment, a nanoemulsion can be used to create a vaccine against influenza virus. In an additional embodiment, a vaccine composition can contain an inactivated influenza virus or a portion thereof.
- A nanoemulsion composition can contain substantially inactivated Mycobateria tuberculosis or a portion thereof. In one embodiment, the Mycobateria tuberculosis-containing nanoemulsion composition is efficacious as a vaccine against tuberculosis.
- A nanoemulsion composition can contain substantially inactivated hepatitis virus or an portion thereof. In one embodiment, the hepatitis-containing nanoemulsion is efficacious as a vaccine against hepatitis infection. In another embodiment, the hepatitis virus is hepatitis A, hepatitis B, or hepatitis C, or a mixture thereof. In a further embodiment, the hepatitis virus is hepatitis B.
- A nanoemulsion composition can contain substantially inactivated HIV or a portion thereof. In one embodiment, the HIV-containing nanoemulsion is efficacious as a vaccine against HIV infection.
- A nanoemulsion composition can be applied to mucosa to prevent infection by a microorganism both as a prophylaxis and as a broad spectrum immunogenic composition. This administration results in a broad spectrum prophylactic immunogenic composition which can both prevent infection by a pathogenic microorganism and also cause an immune response against a pathogenic microorganism which comes in contact with the nanoemulsion-coated mucosa of a subject. In one embodiment, this immunogenic response can provide protection or future protection to the subject against a microorganism. In another embodiment, the microorganism causes influenza, tuberculosis, the common cold, SARS or other respiratory diseases.
- In one embodiment, a nanoemulsion composition can be administered prior to contact with microorganisms. Upon contact with a pathogenic microorganism, the microorganism is inactivated. The nanoemulsion-inactivated microorganism can stimulate an immune response in a subject. In other words, a nanoemulsion composition can inactivate a microorganism and also function an as an adjuvant to aid in stimulating an immune response against the microorganism or its antigens. In one embodiment, the immune response results in antibodies capable of neutralizing a microorganism and thus providing immunological protection of the subject against the microorganism. Examples of microorganisms which can be used in conjunction with a nanomemulsion include, but are not limited to bacteria, bacterial spores , viruses, protozoa, and fungi.
- 3. Decontamination of Medical Devices
- Nanoemulsion compositions are useful for decontaminating surfaces colonized or otherwise infected by pathogenic microorganisms. These applications include, for example, disinfecting or sterilizing medical devices, contact lenses and the like, particularly when the devices or lenses are intended to be used in contact with a patient or wearer. As used herein “medical devices” includes any material or device that is used on, in, or through a patient's body in the course of medical treatment, whether prophylactic or therapeutic treatment. Medical devices include, but are not limited to, such items as implants, for example urinary catheters, intravascular catheters, dialysis shunts, wound drain tubes, skin sutures, vascular grafts, implantable meshes, intraocular devices, heart valves, and the like; wound care devices, for example wound dressings, surgical sutures, biologic graft materials, tape closures and dressings, surgical incise drapes, and the like; drug delivery devices, for example skin patches, mucosal patches and medical sponges; and body cavity and personal protection devices, for example tampons, sponges, surgical and examination gloves, toothbrushes, birth control devices such as IUD's and IUD strings, diaphragms and condoms; and the like.
- For applications of this type, the compositions may be conveniently provided in the form of a liquid or foam, and may be provided with emulsifiers, surfactants, buffering agents, wetting agents, preservatives, and other components commonly found in compositions of this type. The nanoemulsion compositions can be impregnated into absorptive materials, such as sutures, bandages, and gauze, or coated onto the surface of solid phase materials, such as staples, zippers, and catheters to deliver the compositions to a site for the prevention or therapy.
- 4. Sterilization and Disinfectant Applications
- The present invention is also useful for disinfection and sterilization for medical, hospital, ambulance, institutional, educational, agricultural, food processing, and industrial applications.
- In one embodiment, a nanoemulsion composition can be used to prevent contamination, disinfect or sterilize other surfaces, including surfaces used in the food industry, for example equipment and areas where food is processed, packaged and stored; vehicles; machinery; household surfaces, and other surfaces. For example, a nanoemulsion composition can be used to eliminate contamination in meat processing plants, particularly of microorganisms such as Listeria monocytogenes, Salmonellae species and Escherichia species by cleaning slaughterhouses or food packaging facilities on a continual basis with the composition. In addition, nanoemulsion compositions can be formulated into sprays for hospital, food processing and serving facilities, and household uses such as cleaning and disinfecting patient rooms, household appliances, kitchen and bath surfaces, and the like.
- When used in liquid form to decontaminate surfaces, the emulsions can be admixed with an aqueous carrier liquid. The aqueous carrier liquid is preferably not toxic and is chemically compatible with the inventive emulsions. The aqueous carrier liquid can comprise solvents commonly used in hard surface cleaning compositions. Such solvents are preferably chemically stable at the pH of the emulsions, have good filming/residue properties, and are miscible with water. Preferred carrier liquids comprise water or a miscible mixture of a C2-C4 alcohol and water. The alcohol or glycerol can be used to adjust the viscosity of the compositions Preferably, the aqueous carrier liquid is water or a water-ethanol mixture containing from about 0 to about 50% ethanol or other solvents. Alternatively, when used to clean hard surfaces, the emulsions may be in the form of a gel, foam, or cream, preferably a gel, and may be provided with emulsifiers, surfactants, buffering agents, wetting agents, preservatives, and other components commonly found in compositions of this type.
- A nanoemulsion can also be used for mold remediation for building, equipment, and facilities. Examples of molds include, but are not limited to Cladosporium, Fusarium, Alternaria, Curvularia, Aspergillus, and Penicillium.
- A nanoemulsion composition can also be used in the food industry in preventing and treating food contaminated with pathogens. Thus, such compositions may be used to reduce or inhibit microbial growth or otherwise abrogate the deleterious effects of microbial contamination of food. For example, a nanoemulsion composition can be used to kill bacteria and fungus on poultry eggs, fruit, vegetables, and meat. Also, the inclusion of a nanoemulsion compositions within the food product itself would be effective in killing bacteria that may have been accidentally contaminated meat or poultry. A nanoemulsion composition can be included in juice products to prevent growth of certain fungi, which cause contamination and lead to production of mycotoxins. For these applications, the nanoemulsion compositions are applied in food industry acceptable forms such as washes, dips, additives, preservatives, or seasonings. The use of media and agents for additives, preservatives, and seasonings that are acceptable in food industry is well known in the art. Except insofar as any conventional additives, preservatives and seasonings are incompatible with the emulsions, their use in preventing or treating food born microbes and their toxic products is contemplated. Supplementary active ingredients may also be incorporated into the compositions.
- 5. Biodefense Applications
- Nanoemulsion compositions are also useful for biodefense applications, such as, for example, decontamination of a building, surface, garment, and personnel, and disinfection or sterilization of soil and/or waterways contaminated with a pathogenic microorganism, for example as a result of a biological warfare attack.
- Nanoemulsion compositions can be delivered and applied for detoxification and decontamination using any appropriate means. Such decontamination procedures are well known to those of skill in the art and may involve simple application of the formulation in the form of a liquid spray or may require a more rigorous regimen. For example, nanoemulsion compositions can be applied by, without limitation, spraying, fogging, misting, exposure to aerosols, wiping with a wet or saturated cloth or towlette for personal skin decontamination; drenching, immersing, spraying with a hand-held spray bottle or backpack-mounted spray apparatus, showering, spraying with a curtain spray, pouring, dripping, and bathing in the liquid formulation. Additionally, a nanoemulsion can be deployed in a semi-solid carrier, such as in gels, lotions, creams, and pastes. Deployment can be accomplished by people, deployed from aircraft, helicopters, trucks, tanks, railroad, boats, bicycle, or by automated systems, including mobile robots.
- Deployment can include applying the formulation to a surface inside of an industrial setting selected from, for example, a food processing plant, a hospital, an agricultural facility, an institutional building, an ambulance, and a cooking area.
- A fog (e.g., aerosols with particulate sizes ranging from 1-30 μm) can be used to achieve effective decontamination in areas where decontamination by a foam would be difficult, if not impossible. One example is the interior of air conditioning ducts. A fog can be generated at registers and other openings in the duct and travel a significant distance inside of the duct to decontaminate hard to reach places. A relatively automated fog-based decontamination system can be set-up at the scene of an attack. Remotely activated foggers can be placed inside of a facility and turned on at periodic intervals (from a remote location) to completely decontaminate the facility. This method greatly decreases the potential for decontamination personnel to be exposed to a biological warfare agent.
- A nanoemulsion can be used to decontaminate wounds contaminated with or suspected to be contaminated with bacteria, bacterial spores, virus, fungus, protazoa or combinations thereof. In one embodiment the bacteria is B. anthracis. In another embodiment, the virus is smallpox. In a further embodiment, the bacteria is a Yersinia species.
- A nanoemulsion can also be used to decontaminate skin contaminated with or suspected to be contaminated with bacteria, bacterial spores, virus, fungus, protazoa or combinations thereof. In one embodiment the bacteria is B. anthracis. In another embodiment, the virus is smallpox. In a further embodiment the bacteria is Yersinia species.
- A nanoemulsion is also useful for prophylaxis treatment of skin against bacteria, bacterial spores, virus, fungus, protazoa, or combinations thereof. In one embodiment the bacteria is B. anthracis. In a further embodiment, the bacterial spore is cutaneous B. anthracis spore. In another embodiment, the virus is smallpox. In a further embodiment, the bacteria is Yersinia species.
- A nanoemulsion is also useful for battlefield prophylaxis treatment of mucosa against bacteria, bacterial spores, virus, fungus, protazoa or combinations thereof. In one embodiment the bacteria is B. anthracis. In a further embodiment, the bacterial spore is B. anthracis spore. In another embodiment, the virus is smallpox. In a further embodiment, the bacteria is Yersinia species. In one embodiment, nanoemuslions can be applied intranasally prior to and/or immediately after suspected contamination by bacteria, bacterial spores, virus, fungus, or combinations thereof.
- A nanoemulsion composition is also useful for decontamination of surfaces contaminated by or suspected to be contaminated by bacteria, bacterial spores, virus, fungus, protazoa or combinations thereof as the result of, for example, a biological warfare attack. In one embodiment the bacteria is B. anthracis. In a further embodiment, the bacterial spore is B. anthracis spore. In another embodiment, the virus is smallpox. In a further embodiment, the bacteria is Yersinia species. In one embodiment, a nanoemulsion composition can be applied prior to and/or immediately after suspected contamination by bacteria, bacterial spores, virus, fungus, or combinations thereof. In a further embodiment, the nanoemulsion composition is applied intranasally. Nanoemulsion can be applied to surfaces using any appropriate means. In one embodiment, a nanoemulsion is delivered as a spray, liquid, fog, foam, or aerosol to contaminated or suspected contaminated surfaces.
- A nanoemulsion composition is also useful for decontamination buildings contaminated by or suspected to be contaminated by bacteria, bacterial spores, virus, fungus, or combinations thereof. In one embodiment the bacteria is B. anthracis. In a further embodiment, the bacterial spore is B. anthracis spore. In another embodiment, the virus is smallpox. In a fuirther embodiment, the virus is Yersinia species. In one embodiment, nanoemuslions can be applied intranasally prior to and/or immediately after suspected contamination by bacteria, bacterial spores, virus, fungus, or combinations thereof. Nanoemulsion can be applied to surfaces using any appropriate means. In one embodiment, a nanoemulsion is delivered as a spray, liquid, fog, foam, or aerosol to contaminated or suspected contaminated surfaces.
- The nanoemulsions are described by the components of the nanoemulsion according to Table 1. Unless otherwise noted, the oil is soybean oil. In the formulations, the detergent is listed first, followed by the volume percentage of the detergent (e.g.,
W 205 refers to 5 vol % of Tween 20). In the formulations, the designation L2 refers to a small particle size nanoemulsion produced by a microfluidizer, while the absence of the L2 designation refers to a standard nanoemulsion (i.e., average particle sizes of 250 nm to about 1 micrometer). The designation L3 refers to nanoemulsions produced using an Avesting high pressure homogenizer.TABLE 1 Component Symbol Tween 20 W20 Ethanol E Cetylpyridinium chloride C EDTA ED Triton X-100 X Tributyl phosphate P Glycerol G Benzalkonium chloride BA - A first nanoemulsion is produced from a mixture containing 548 milliliters of water, 2.24 grams of EDTA, 25 grams of cetylpyridiunium chloride, 125 milliliters of
Tween 20, 200 milliliters of ethanol and 1600 milliliters of soybean oil. The first nanoemulsion is pre-mixed with a Silverson L4RT mixer and a fine emulsifier screen for 10 minutes at 10,000±500 revolutions per minute. - The first nanoemulsion is then processed in a Microfluidics M-110EH microfluidizer processor using an H210Z (200 μm) chamber downstream of an H230Z (400 μm) chamber. The first nanoemulsion is passed through the
microfluidizer 3 to 4 times at a pressure of 3,500±500 pounds per square inch (psi) using cooling ice in the tray surrounding the chambers. The small particle size nanoemulsion produced is referred to as W20EC ED L2. - The second nanoemulsion is then diluted with distilled water to produce a series of diluted nanoemulsions. The water and the nanoemulsion can be mixed by shaking, for example, until the nanoemulsion is incorporated into the water. Exemplary diluted nanoemulsions are as shown in Table 2. The percentage shown refers to the volume percentage of the nanoemulsion in the dilution.
TABLE 2 Formulation water W20 5EC ED L2 50% W205EC ED L2 500 mL 500 mL 20% W205EC ED L2 800 mL 200 mL 10% W205EC ED L2 900 mL 100 mL 5% W205EC ED L2 950 mL 50 mL 2.5% W205EC ED L2 975 mL 25 mL - A standard nanoemulsion (i.e., particles sizes of 250 nm to 5 micrometers) is formed as follows. A mixture of 22 vol % distilled water, 1 wt/vol % cetylpyridinium chloride, 5 vol
% Tween 20, 64 vol % soybean oil, and 8 vol % ethanol based on the total volume of the mixture is formed. The nanoemulsion is formed by mixing for 5 minutes at 10,000±500 revolutions per minute with a Silverson L4RT mixer with a standard mixing assembly and a fine emulsion screen. The standard nanoemulsion is denoted as W205EC. - A small particle size nanoemulsion is formed by passing the W205EC nanoemulsion 4 times through a Microfluidics M-110EH microfluidizer processor using an H210Z (200 μm) chamber downstream of an H230Z (400 μm) chamber. The small particle size nanoemulsion is denoted as W205EC L2.
- After formation, the W205EC and W205EC L2 emulsions are diluted with water for further testing. Particle sizes are determined by Particle Sizing Systems (PSS) Nicomp Model 380. The samples are diluted 1/2000 in distilled water to measure the particle size. The formulations and data are shown in Table 3.
TABLE 3 Formulation Amount of Amount of Average Particle No. Formulation nanoemulsion water Size, nm 1 W205EC — — 421.4 2 50% W205EC 90 mL 90 mL 454 3 20% W205EC 36 mL 144 mL 437.5 4 10% W205EC 18 mL 162 mL 418.8 5 5% W205EC 9 mL 171 mL 427.4 6 2.5% W205EC 4.5 mL 175.5 mL 470.3 7 W205EC L2 — — 152 8 50% W205EC L2 90 mL 90 mL 99.3, 219.5* 9 20% W205EC L2 36 mL 144 mL 144.2 10 10% W205EC L2 18 mL 162 mL 153 11 5% W205EC L2 9 mL 171 mL 177.8 12 2.5% W205EC L2 4.5 mL 175.5 mL 157.7
*When there is wide range of particle sizes (Nicomp reading), two methods of calculation are used
- As shown in Table 3, dilution of the emulsions does not appreciably affect the particle size of either the standard nanoemulsion or the small particle size nanoemulsion. The average particle size for the W205EC emulsions is about 400 to about 500 nm (samples 1-6) and for the W205EC L2 emulsions is about 140 to about 220 nm (samples 7-12).
- A W205G BA2 nanoemulsion is passed through different combinations of microfluidizer chambers as shown in Table 4. The W205G BA2 L2 small particle size nanoemulsion is made with 1 pass with a Silverson L4RT mixer and 4 passes through a microfluidizer. Combinations of chamber having 75, 200, 400 micrometer microchannels are used to determine the relationship between the size of the microchannels and the size of the particles produced.
TABLE 4 First Second chamber, Particle Sample chamber, μm μm size, nm 1 75 100 174 2 100 75 165 3 75 200 185 4 200 75 180 5 75 400 211 6 400 75 199 - As shown in Table 4, the chamber size utilized in the microfluidizer, when varied between 75 and 400 μm, does not significantly affect the particle size of the emulsions. In all cases, the particle size is less than or equal to about 250 nm.
- A W205G BA2 nanoemulsion is formed using either a Silverson L4RT mixer (high shear) or a household hand mixer (low shear). The nanoemulsion is then passed through the microfluidizer for 1 to 6 passes and the particle size measured. The relationship between the number of passes in the microfluidizer and the particle size of the emulsions are shown in Table 5 and
FIG. 5 .TABLE 5 Nanoemulsion Particle Size (nm) (three independent Number of Passes experiments Type of First Through with different Sample Mixer Microfluidizer emulsion lots) 1 High shear 1 183, 221, 267 2 High shear 2 183, 205, 195 3 High shear 3 210, 202, 201 4 High shear 4 155, 156, 156 5 High shear 4 220, 157, 180 6 High shear 5 157, 132, 158 7 High shear 6 196, 161, 168 8 Low shear 0 426, 529, 522 9 Low shear 1 275, 210, 205 10 Low shear 2 218, 168, 218 11 Low shear 3 183, 151, 129 12 Low shear 4 182, 179, 180 - As shown in Table 5 and
FIG. 5 , the number of passes through the microfluidizer does not have a large effect on the nanoemulsion particle size. As shown inSample - The effect of both the number of passes through the microfluidizer and the chamber size in the microfluidizer are studied for different formulations. The starting emulsions are prepared using either a Silverson L4RT mixer (“Silv”) or a Ross HSM-410X high shear mixer with a 3 inch X-series rotor/stator pre-set to a 0.010 gap (Ross) in order to determine the effect of mixing method on the particle size of the starting nanoemulsion (i.e., prior to passage through the microfluidizer). The L2 emulsions are produced by passing a standard nanoemulsion produced by Silverson mixing through a microfluidizer. The particle sizes are shown in Table 6.
TABLE 6 Interactive Number High shear chamber of Particle size, Sample Formulation Mixer type used passages nm 1 Nanowash + alcohol* Silv — — 410-486 2 W205G BA2 Silv, 5 — — 304-371 minutes mixing 3 W205G BA2 Silv, 20 min — — 283-340 mixing 4 S8G Silv — — 350 5 W205EC Silv — — 381 6 W205G Silv — — 486 7 W205G BA2 Ross — 1 260 8 W205G BA2 Ross 2 247 9 W205G BA2 Ross 3 281 10 W205G BA2 Ross 4 229-254 11 W205G BA2 Microfluidizer 400, 200 2 196 12 W205G BA2 Microfluidizer 400, 200 3 195 13 W205G BA2 Microfluidizer 200, 200 3 173 14 W205G BA2 Microfluidizer 75, 200 3 210 15 W205G BA2 Microfluidizer 75, 200 3 235 16 W205G BA2 Microfluidizer 200, 400 3 179 then diluted using 75, 200 17 S8G** Microfluidizer 75, 200 3 161 18 W205EC Microfluidizer 75, 200 3 178 19 W205EC Microfluidizer 75, 200 3 158 20 W205G Microfluidizer 75, 200 3 223 21 W205GC*** Microfluidizer 400, 200 3 189, 200, 225, 226 22 X8GC Microfluidizer 400, 200 3 130, 145 23 X8E6G2**** Microfluidizer 400, 200 3 249
*1% W 205 GBA2 + 2 mM EDTA + 20% ethanol
**8% SDS, 6% glycerol, 64% soybean oil, 20% water
***5% Tween
****8% Triton X100, 6% ethanol, 2% glycerol, 64% soybean oil, 20% water
- As shown in Table 6, the Silverson high shear mixer (samples 1-6) produces particle sizes of about 300 nm to about 500 nm. The Ross high shear mixer (Samples 7-10) produces particle sizes of 260 nm after 1 pass to about 229 to 254 nm after 4 passes. The Ross high shear mixer is thus capable of producing smaller particle sizes than the Silverson mixer. Also shown in Table 6 is that the samples passed through the microfluidizer (samples 11-23) have smaller particle sizes than the samples mixed with either high shear mixer (samples 1 -10).
- Regarding the samples passed through the microfluidizer, as shown in samples 11 and 12, similar particle sizes are obtained with either 2 or 3 passes through the microfluidizer. Samples 13-16 show that changing the microchannel size of the microfluidizer chamber does not decrease the particle size of the emulsions. Samples 17-23 illustrate that, independent of the formulation of the emulsions, emulsions having particle sizes of less than about 250 nm can be formed by passing the emulsions through a microfluidizer.
- In this experiment, the particle sizes and zeta potentials for different small particle size nanoemulsion formulations are determined. The emulsions are formed by passing a starting nanoemulsion through the microfluidizer for 3 passes using the H230Z+H210Z chambers. The particle size and zeta potential are measured by Nicomp 380 Particle sizer. The data are shown in Table 7.
TABLE 7 Sample Formulation Particle Size Zeta (mV) 1 1% W205G BA2 L2 + 2 mM EDTA 186 11 2 W205G BA2 L2 in water 183 27 3 W205GC L2 168-236 30-33 4 W205G SA2 OA2 L2* 226 33 5 W205E SA3 L2 154 31 6 W205E SA3 L2 + 2 mM EDTA 131 12 7 W205G SA3 L2** 215 32 8 W205G SA3 L2 + 2 mM EDTA 187, 191 12 9 W205E L2 189 −25 10 W205EC L2, premixed 156, 182 31 11 W205EC L2 146 41
*5% Tween
**5% Tween
- As shown in Table 7, all of the formulations have particle sizes of less than or equal to about 250 nm.
- A W205EC nanoemulsion was formed containing 5% Tween-20, 8% ethanol, 1% cetylpyridinium chloride, 64% soybean oil, and the balance water. A W205EC L2 nanoemulsion is formed using 2 passes on a microfluidizer. A W205GC nanoemulsion is formed containing 5% Tween-20, 8% glycerol, 1% cetylpyridinium chloride, 64% soybean oil, and the balance water. A W205GC L2 nanoemulsion is formed using 2 passes on a microfluidizer. An X8P nanoemulsion is formed using 8% Triton X-100, 8% tributyl phosphate, and the balance water.
- Stability is determined by evaluating the physical appearance of the emulsions. As used herein, creaming is the presence of a white layer of creamy material on top of the nanoemulsion that is more opaque than the rest of the nanoemulsion. Settling is a gradual decrease in opacity of the nanoemulsion from top to bottom due to separation of the more dense diluent (water) at the bottom from the less dense nanoemulsion at the top. The water appears as transparent layer at the bottom of the vial. Settling is classified as follows: Mild settling: the nanoemulsion appears cloudy with a gradient of “cloudiness” where it gets more opaque as you go upwards. Moderate settling: a partially clear aqueous solution appears on the bottom of the sample. The rest of the nanoemulsion appears cloudy with a gradient of cloudiness getting more opaque as you go up. Some creaming may be on the surface. Severe settling: nanoemulsion has the appearance of three distinct layers, a partially clear bottom, cloudy middle, and creamy top. Extreme settling: only two layers, a thick partially clear bottom and a thin creamy top.
- Separation is the phase separation of the nanoemulsion ingredients. Separation is classified as follows: Mild separation: the surface of the nanoemulsion shows few visible oil droplets. Moderate separation: the surface of the nanoemulsion has a film of oil. The bottom of the nanoemulsion may have a clear aqueous layer. Severe separation: nanoemulsion has the appearance of three distinct layers, a clear aqueous layer on the bottom, a white or cloudy middle layer and a dense oily layer on the top. Extreme separation: total separation into an oil layer on top and water on bottom.
- The ambient storage stability test includes storing the neat emulsions in polypropylene bottles or centrifuge tubes at room temperature (22-25° C.). Containers may be mixed or opened during the observation period. The emulsions are observed for separation or any other changes in appearance. The observation period is varied due to different manufacturing dates of the emulsions. The data for W205EC emulsions are shown in Table 8.
TABLE 8 Days in Bottle Type of Sample storage fullness container Appearance 1 579 ¼ 125 ml PP severe separation 93%: <7% nanoemulsion between oil & water 2 619 ¼ 125 ml PP extreme separation 3 505 ⅔ 250 ml PP moderate separation- 6 % oil 4 585 ⅔ 250 ml PP moderate separation- 8 % oil 5 457 ⅔ 250 ml PP mild separation- 1 % oil 6 497 ⅔ 250 ml PP moderate separation- 1.5 % oil 7 184 full 125 ml PP mild-oil drop in air space 8 224 full 125 ml PP mild-oil drop in air space 9 184 ¾ 125 ml PP mild separation- 1 % oil film 10 224 ¾ 125 ml PP moderate separation- 2% oil film 11 184 ⅔ 125 ml PP mild separation- 4% oil 12 224 ⅔ 125 ml PP moderate separation- 6% oil 13 112 ¼ 500 ml PP intact 14 152 ¼ 500 ml PP moderate separation—3 % oil 15 33 full 30 ml PP intact 16 74 full 30 ml PP mild separation- 1 of 4 vials with oil film 17 74 ½ 250 ml PP mild separation
*PP = polypropylene
- The data for W205EC L2 emulsions are shown in Table 9.
TABLE 9 Days in Bottle Type of Sample storage fullness container Appearance 18 116 full 30 ml PP intact 19 157 full 30 ml PP intact 20 74 ¼ 60 ml PP intact 21 115 ¼ 60 ml PP intact 22 75 full 500 ml PP intact 23 115 full 500 ml PP intact 24 33 full 30 ml PP intact 25 74 full 30 ml PP intact - As shown in Tables 8 and 9, the small particle size nanoemulsions are more stable at room temperature than comparable standard emulsions. Batches of standard W205EC neat nanoemulsion stored at ambient temperatures longer than 5 months show oil forming a film or layer on the surface of the nanoemulsion. The thickness of the oil layer is variable and may be related in part to the amount of air in the storage container in addition to the number of times the container has been entered.
- Batches of smaller particle size W205EC L2 neat nanoemulsion are stored at ambient temperatures for up to 4 months. No settling or separation is observed in these batches.
- Accelerated stability testing is also performed as follows. Glass vials are filled with 20 milliliters of neat, 10% diluted and 2.5% diluted nanoemulsion. The emulsions are stored at 55° C. and observed 3 times a week for changes in physical apperrance. One additional set of vials for the W205EC L2 emulsions is filled completely (about 25 milliliters) to eliminate air during storage. These full vials are inverted at
day 7 to facilitate observation of creaming and separation. - Neat emulsions (100%) of standard W205EC and small particle size nanoemulsion W205EC L2 under accelerated stability testing at 55° C. show a film of oil separating after 4 and 5 days, respectively (
FIG. 1 and Table 10).TABLE 10 Average Days Average Days to Mild or to Severe or Moderate Separation Extreme Separation Nanoemulsion Neat 10% 2.50% Neat 10% 2.50% X8P 3 N N 10 N N W205EC 4.3 N N N N N W205EC L2 5.3 N N N N N W205EC L2 full* N N N N N N W205GC 5.7 N N N N N W205GC L2 8.7 N N N N N
N = No separation
- For comparison, the X8P neat nanoemulsion shows signs of instability with a distinct clear aqueous layer on the bottom and a 5% oil layer on the surface. Neat emulsions of both W205GC and W205GC L2 show yellowing of the oil film on the surface of the nanoemulsion, whereas for W205EC and W205EC L2, the oil film is colorless. The neat small particle size nanoemulsions are stable for 1-3 days longer than the standard emulsions.
- No diluted nanoemulsion (10% or 2.5%) shows separation of oil after 4 weeks observation at 55° C. (Table 10).
- Table 11 shows the settling observed for the nanoemulsions after accelerated aging.
TABLE 11 Average Days Average Days to Mild or to Severe or Moderate Settling Extreme Settling Nanoemulsion Neat 10% 2.50% Neat 10% 2.50 % X8P N 3 3 N 10 10 W205EC N 3 3 N 19 10 W205EC L2 N 10.6 5 N N N W205EC L2 full* N N 5 N N N W205GC N 5 3 N 26 19 W20 5GC L2 N 10 3 N N N - On average, the small particle size nanoemulsions exhibit less oil separation and less separation of the oil and water layers than the standard emulsions (Table 10). The small particle size nanoemulsions exhibit comparable settling and creaming to the standard emulsions when undiluted and improved stability when diluted to 10% or 2.5% (Table 11).
- Settling and creaming are more pronounced in the diluted large particle size emulsions compared to the diluted emulsions stored at 55° C. (
FIGS. 2-3 , Table 12). The 10% W205EC nanoemulsion is 83% settled after 4 weeks, whereas the 10% W205EC L2 nanoemulsion is only 9% settled. The onset of settling occurred later in the smaller particle size nanoemulsion, within 10 days for 10% W205EC L2 compared to only 3 days for 10% W205EC. Table 12 shows the creaming and settling of the emulsions. - Table 12 shows the separation and settling of emulsions under accelerated aging conditions
TABLE 12 Separation Settling Neat 10% 2.50% Nanoemulsion Oil Water Cream Settling Cream Settling X8P 9 17 13 86 6 94 W205EC 2 0 14 83 5 94 W205EC L2 3 0 2 9 2 42 W205EC L2 full* 0 0 2 <14 2 28 W205GC 0.3** 0 13 77 5 93 W205GC L2 0.7** 0 0 11 2 41 - The W20 5EC L2 nanoemulsion that is stored in vials that are completely full show no separation and less settling compared to the same nanoemulsion stored in vials containing an air space (Table 12). Interestingly, the bottom breaks off at the seam at
day 10 and day 21 for 2 of the full vials of diluted nanoemulsion. - The change in pH after accelerated stability testing is measured. The pH of each nanoemulsion is measured at the beginning and at the end of the accelerated stability incubation at 55° C. Diluted emulsions are measured using a 3-in-1 combination electrode and neat emulsions are measured with a semi-micro electrode. The initial pH of the neat W205EC, and W205EC L2, W205GC, and W205GC L2 emulsions is similar for each nanoemulsion, ranging from 4.2-4.4. The pH increases with increasing dilution of these nanoemulsion to a pH of 5.6 for the 2.5 % dilutions. After 4 weeks at 55° C., the pH of the neat emulsions remains unchanged, whereas the pH of the diluted emulsions decreases to a value similar to that of the neat nanoemulsion, (4.0-4.4). In contrast, W205EC L2 incubated in vials that are filled completely, slightly increased in pH after 4 weeks incubation at 55° C. The difference between the neat and diluted nanoemulsion is also maintained (
FIG. 4 ). - Additional stress testing is preformed by centrifugation, freezing and autoclaving. In the centrifugation test, neat (100%) and a 10% dilution of W205EC L2 nanoemulsion are centrifuged at 1,650×g for 30 minutes at room temperature, then stored at room temperature for observation. An additional sample of the 10% dilution of W205EC L2 is not centrifuged and is stored at room temperature for comparison. After storage at room temperature for 6 weeks, no separation of neat or diluted emulsions is observed. Only slight creaming is seen in the 10% diluted emulsions with no difference between the centrifuged and uncentrifuged sample.
- In the freezing test at −18° C. neat nanoemulsion and a 10% dilution of W205EC L2 are placed at −18° C. for 24 hours, and then left at room temperature for observation. The neat nanoemulsion W205EC L2 is frozen at −18° C. for 24 hours then thawed and observed. After 24 hours at room temperature no separation is observed in the neat or 10% diluted nanoemulsion. Creaming is observed in the 10% diluted nanoemulsion and no settling were noted.
- In the autoclaving test neat W205EC, W205EC L2, W205GC, and W205GC L2 emulsions are placed in a Yamato autoclave for 15 minutes at 121° C., and then stored at room temperature for observation. Both emulsions containing ethanol (W205EC and W205EC L2) boiled over in the autoclave and severe separation is observed immediately after autoclaving. The emulsions containing glycerol are intact after autoclaving and displayed no separation up to 3 days when stored at room temperature.
- This example demonstrates using a high pressure homogenizer (Avestin Emulsiflex C3) to reduce the particle size of a standard nanoemulsion to particles having a diameter of 50-150 nm. The size of the nanoemulsion particles depends on the pressure and number of passages.
- First, a standard nanoemulsion containing particles having an average diameter of 250 nm to 5 micrometers, preferably about 300 nanometer to 1 micrometer is formed. The standard nanoemulsion contains 22 vol % distilled water, 1 wt/vol % cetylpyridinium chloride, 5 vol
% Tween 20, 64 vol % soybean oil, 8 vol % ethanol and 2 mM EDTA, based on the total volume of the mixture formed. The nanoemulsion is formed by mixing for 5 minutes at 10,000±500 revolutions per minute with a Silverson L4RT mixer with a standard mixing assembly and a fine emulsion screen. The standard nanoemulsion is denoted as W205EC ED. - Small particle size nanoemulsions containing particles of various sizes are then formed by passing the standard nanoemulsion through an Avestin EmulsiFlex under different pressures ranging from 3,500-17,000 psi. The nanoemulsion was passed between 4-5 times under the same conditions. The machine applies high pressure to push the nanoemulsion through a dynamic homogenizing valve. Table 13 describes the different nanoemulsion particle size resulting from different passages into the emulsifier.
TABLE 13 Passages in the high pressure Pressure Particle size Name emulsifier (psi) (nm) W205EC ED None — 277 W20 5EC ED L3 1 17,000 111 W20 5EC ED L3 2 17,000 92 W20 5EC ED L3 3 17,000 91 W20 5EC ED L3 4 17,000 65 W20 5EC ED L3 1 3,500 164 W20 5EC ED L3 2 3,500 123 W20 5EC ED L3 3 3,500 110 W20 5EC ED L3 4 3,500 124 W20 5EC ED L3 5 3,500 130 - Table 13 and
FIG. 5 demonstrate that particle size is inversely dependent on the amount of pressure applied during homogenization as well as the number of passages to which the nanoemulsion is subjected. - Example 9 compares the efficacy of a standard nanoemulsion versus a small particle size nanoemulsion (denoted L2) as a disinfectant.
- The AOAC (Association of Official Analytical Chemist) dilution test is a carrier-based test. Carriers (i.e., stainless steel cylinders) are inoculated with a test microorganism, dried, exposed to a dilution of a disinfectant product, and cultured to assess the survival of the bacteria. A single test involves the evaluation of 60 inoculated carriers contaminated with one microorganism against one product sample. In addition to the 60 carriers, 6 carriers are required to estimate carrier bacterial load and 6 more are included as extras. Thus, a total of 72 seeded carriers are required to perform a single test.
- A contaminated dried cylinder carrier is added to the medication tubes. Immediately after placing carrier in medication tube, tubes are swirled 3 times before placing tube into bath. Ten minutes after each carrier is deposited into the disinfectant, each carrier is removed from the medication tube with a sterile hook, tapped against the interior sides of the tube to remove the excess disinfectant, and transferred into the primary subculture tube containing the appropriate neutralizer (Letheen broth, 10 mL in 20×150 mm tubes). The subculture tubes are swirled for 3-4 seconds. Transfer into the primary subculture tubes should be within ±5 seconds of the actual time of transfer (10 minutes). The bacterial carrier load on at least 2 carriers is assayed.
- After a minimum of 30 minutes from when the test carrier was deposited, each carrier is transferred using a sterile wire hook to a second subculture tube containing 10 mL of the appropriate neutralizer. The carriers are transferred in order, but the intervals do not have to be timed. The tubes are swirled for 3-4 seconds and the subcultures incubated at 37° C. for 48 hours. If the broth culture appears turbid, the result is positive. A negative result is one in which the broth appears clear. Each tube is shaken prior to recording results to determine the presence or absence of turbidity. The primary and secondary subculture tubes for each carrier represent a “carrier set.” A positive result in either the primary or secondary subculture tube is considered a positive result for a carrier set.
- Gram stains are performed on smears taken from the positive culture tubes. For additional confirmatory tests, a loop of broth is streaked on the selective media appropriate for the test microorganism and incubated for 24 hours at 37° C.
- Table 14. Gram staining and culture on selective media required to ensure the identity of the microorganism.
TABLE 14 S. choleraesuis S. aureus P. aeruginosa Gram stain Gram negative rods Gram positive Gram negative cocci arranged rods in clusters Selective media MacConkey agar Mannitol salt Pseudosel agar agar Morphology on Pale large colonies, Circular, small, Circular, small, selective media agar turning light fluorescent initially opaque, color. yellow turning colonies. fluorescent green over time. Regular media TSA* TSA TSA
*Tryptic soy agar
- Table 15 show the results for a W205G BA2+2 mM EDTA at pH 7.2 nanoemulsion and a W205G BA2 L2+2 mM EDTA at pH 7.2 nanoemulsion with Staphylococcus aureus.
TABLE 15 Carriers Total Number of Percentage Sample Formulation failed tested experiments failed 1 1% W205G 16 304 6 5.26% BA2 + 2 mM EDTA 2 1% W205G BA2 2 240 4 0.83% L2 + 2 mM EDTA 3 1% W20 5G BA2 L2 1 300 6 0.33% - As shown in Table 15, a disinfectant made with the small particle size nanoemulsions has a lower failure ratio than a standard nanoemulsion. The standard nanoemulsion has a failure rate of about 5%. The small particle size nanoemulsions have a failure rate of less than 1%.
- Table 16 also shows results obtained for various formulations exposed to Staphylococcus aureus.
TABLE 16 Number of No. of Sam- Ex- Failed Percentage ple Formulation periments Cylinders failed 1 1% W205G BA2 + 2 mM 6 304 5.3% EDTA pH 7.2 2 1% W205G BA2 + 2 mM 9 272 11.4% EDTA pH 8.0 3 1% W205G BA2 L2 + 2 mM 4 240 0.83% EDTA pH 7.2 4 1% W205G BA2 pH 7.2 6 300 0.33% - Table 16 demonstrates that the small particle size nanoemulsions (
Samples 3 and 4) show greater efficacy against Staphylococcus aureus than the standard emulsions (Samples 1 and 2). - Table 17 shows the results obtained for various formulations exposed to Salmonella choleraesuis.
TABLE 17 Number of No. of Sam- Ex- Cylinders Percentage ple Formulation periments tested failed 1 1% W205G BA2 + 2 mM 2 120 0% EDTA pH 7.2 2 1% W205G BA2 + 2 mM 1 30 0% EDTA pH 8.0 3 1% W205G BA2 L2 + 2 mM 1 60 0% EDTA pH 7.2 4 1% W205G BA2 (L2) pH 7.2 60 240 0% - Table 17 demonstrates that the small particle size nanoemulsions (
Samples 3 and 4) show similar efficacy against Salmonella choleraesuis compared to the standard emulsions (Samples 1 and 2). Overall in the disinfectant test, the small particle size nanoemulsions perform as well as or better than the standard emulsions. - The bactericidal activity of the nanoemulsions is tested using a tube rotation test. In this test, first a culture is prepared by picking one colony from the stock culture plate of Staphylococcus aureus, streaking fresh TSA and incubating overnight at 37° C. The next morning, one colony is picked from the agar plate and transferred into 25 mL of TSB in a 50 mL screw-cap tube and incubated at 37° C. on a tube rotator for 4-5 hours until the culture becomes turbid. Bacteria grown for 4-6 hours is added to 10 mL TSB until the culture media becomes slightly turbid.
- W205EC and W205EC L2 are used as previously described. The emulsions are then diluted to 2%, 1%, 0.2%, 0.1%, and 0.02% by volume with water.
- Bactericidal testing is performed as follows. In 1.7 mL microfuge tubes, 0.5 mL cell suspension and 0.5 mL of each of the nanoemulsion dilutions is mixed and the tubes capped. A positive control containing 0.5 mL of cell suspension and 0.5 mL of sterile distilled water is prepared in parallel. The tubes are incubated on a tube rotator at 37° C. for 10 minutes. Each of the preparations is serially diluted (5 log diluation) in a 96-well plate using PBS. 25 μL from each dilution on is incubated on TSA at 37° C. overnight. The colonies on the control and test plates are counted. The count on the control plate provides the initial bacterial count. The initial bacteria count is provided as:
Initial bacterial count=CFU×40×plate dilution
where CFU is the colony forming units per mL. The colonies on each of the test plates is counted. Plates having between 20-50 CFU are counted. The report log reduction is provided as:
Report Log reduction=Log (count on the control treatment)−Log (count on the treatment). - Small particle size nanoemulsions have several advantages over standard emulsions. First, the small particle size nanoemulsions can be more stable than the standard emulsions when stored at room temperature or at 55° C. The small particle size nanoemulsions are capable of resisting separation or settling when stored at room temperature for four months. The undiluted small particle size nanoemulsions can take about 1 to 3 days longer to exhibit moderate separation than the standard emulsions. The 2.5 % to 10 % diluted small particle size nanoemulsions can take about 2 to 7 days longer to exhibit moderate to extreme settling than the standard emulsions. In addition, the onset of phase separation in the small particle size nanoemulsions at 55° C. is later than for the standard emulsions.
- Second, the small particle size nanoemulsions perform equal to or better than standard emulsions in inactivating bacteria. In a disinfectant test, the small particle size nanoemulsions exhibit a less than 1% failure rate against Staphylococcus aureus compared to greater than 5% for a standard nanoemulsion. In the same test, both the and standard nanoemulsions have a 0% failure rate against Salmonella choleraesuis. In a tube rotation test, the small particle size nanoemulsions have a slightly improved killing compared with the standard emulsions against Staphylococcus aureus killing activity.
- While the invention is described with reference to exemplary embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention. All references and publications cited herein are incorporated by reference in their entireties.
Claims (81)
1. A composition comprising a nanoemulsion, the nanoemulsion comprising:
an aqueous phase;
an oil phase comprising an oil and an organic solvent; and
one or more surfactants;
wherein the nanoemulsion comprises nanoemulsion particles having an average diameter of from less than 150 nm
2. The composition of claim 1 , wherein the nanoemulsion particles have an average diameter of less than or equal to about 100 nm or less than or equal to about 50 nm.
3. The composition of claim 1 , wherein the organic solvent comprises a C1-C12 alcohol, diol, or triol, a dialkyl phosphate, a trialkyl phosphate or a combination thereof.
4. The composition of claim 1 , wherein the alcohol comprises ethanol, isopropyl alcohol, glycerol or a combination thereof.
5. The composition of claim 2 , wherein the trialkyl phosphate is tri-n-butyl phosphate.
6. The composition of claim 1 , wherein the oil comprises soybean oil, mineral oil, avocado oil, squalene oil, olive oil, canola oil, corn oil, rapeseed oil, safflower oil, sunflower oil, fish oils, flavor oils, cinnamon bark, coconut oil, cottonseed oil, faxseed oil, pine needle oil, silicon oil, essential oils, water insoluble vitamins, or a combination thereof.
7. The composition of claim 6 , wherein the oil is soybean oil.
8. The composition of claim 1 , wherein the surfactant is a nonionic surfactant.
9. The composition of claim 8 , wherein the nonionic surfactant is TWEEN® 20, Triton® X-100, nonoxynol-9, or a combination thereof.
10. The composition of claim 1 , wherein the surfactant is a cationic surfactant.
11. The composition of claim 10 , wherein the cationic surfactant is cetyl pyridium chloride, benzalkonium chloride or a combination thereof.
12. The composition of claim 1 comprising:
about 5 vol. % to about 50 vol. % of aqueous phase;
about 30 vol. % to about 90 vol. % of oil phase; and
about 3 vol. % to about 15 vol. % of surfactant.
13. The composition of claim 1 , further comprising an additive selected from the group consisting of activity modulators, gelling agents, auxiliary surfactants, and a combination comprising one or more of the foregoing additives.
14. The composition of claim 13 , wherein the activity modulator is an interaction enhancer, a germination enhancer, a therapeutic agent, or a combination comprising one or more of the foregoing enhancers.
15. The composition of claim 14 , wherein the germination enhancer comprises glucose, fructose, asparagine, sodium chloride, ammonium chloride, calcium chloride, and potassium chloride.
16. The composition of claim 14 , wherein the germination enhancer comprises L-alanine, inosine, PBS, and ammonium chloride.
17. The composition of claim 14 , wherein the therapeutic agent is an antimicrobial agent, an antifungal agent, an antiviral agent, an anti-mold agent, an anti-mildew agent, or a combination thereof.
18. The composition of claim 14 , wherein the therapeutic agent is a penicillin, a cephalosporin, cycloserine, vancomycin, bacitracin, miconazole, ketoconazole, clotrimazole, polymyxin, colistimethate, nystatin, amphotericin B, chloramphenicol, the tetracyclines, erythromycin, clindamycin, an aminoglycoside, a rifamycin, a quinolone, trimethoprim, a sulfonamide, zidovudine, gangcyclovir, vidarabine, acyclovir, phenylphenol, propyl paraben, poly(hexamethylene biguanide) or a combination comprising one or more of the foregoing therapeutic agents.
19. The composition of claim 1 , wherein the composition comprises from about 0.01% to about 90% nanoemulsion per milliliter of composition.
20. The composition of claim 1 , wherein the composition comprises greater than about 0.25%, about 1.0%, about 5%, about 10%, about 20%, about 35%, about 50%, about 65%, about 80%, about 90%, or about 95% nanoemulsion per milliliter of composition.
21. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier, an auxiliary surfactant, a suds suppressor, a detergent builder, or a combination thereof.
22. A method of reducing the average nanoemulsion particle size of a composition comprising a nanoemulsion, comprising treating a nanoemulsion comprising an aqueous phase, an oil phase comprising an oil and an organic solvent, and a surfactant, and having nanoemulsion particles of an average diameter of greater than or equal to about 250 nm, so as to reduce the average diameter of the nanoemulsion particles to less than 150 nm.
23. A method of making a nanoemulsion, comprising passing a first nanoemulsion comprising
an aqueous phase,
an oil phase comprising an oil and an organic solvent, and
one or more surfactants, wherein the nanoemulsion particles have an average diameter of greater than or equal to about 250 nm, through a microfluidizer or high pressure homogenizer under conditions effective to reduce the average diameter of the nanoemulsion particles to less than 150 nm.
24. The method of claim 22 , wherein the ratio of oil phase to aqueous phase is from about 1:9 to about 5:1, from about 5:1 to about 3:1, or from about 4:1.
25. The method of claim 23 , wherein the ratio of oil phase to aqueous phase is from about 1:9 to about 5:1, from about 5:1 to about 3:1, or from about 4:1.
26. The method of claims 22, wherein the nanoemulsion particles have an average diameter of less than or equal to about 100 nm or less than or equal to about 50 nm.
27. The method of claims 23, wherein the nanoemulsion particles have an average diameter of less than or equal to about 100 nm or less than or equal to about 50 nm.
28. A method of inactivating a microorganism, comprising contacting the microorganism with a composition comprising a nanoemulsion for a time effective to inactivate the microorganism, wherein the nanoemulsion comprises:
an aqueous phase;
an oil phase comprising an oil and an organic solvent;
and one or more surfactants; and wherein the nanoemulsion particles have an average diameter of less than 150 nm.
29. The method of claims 28, wherein the nanoemulsion particles have an average diameter of less than or equal to about 100 nm or less than or equal to about 50 nm.
30. The method of claim 28 , wherein the composition further comprises an activity modulator, wherein the activity modulator is an interaction enhancer, a germination enhancer, a therapeutic agent, or a combination comprising one or more of the foregoing.
31. The method of claim 28 , wherein the composition further comprises a pharmaceutically acceptable carrier.
32. The method of claim 28 , wherein the microorganism is a bacteria, a fungus, a protozoa, a virus, or a combination of one or more of the foregoing microorganisms.
33. The method of claim 32 , wherein the bacteria is a vegetative bacteria, a bacterial spore, or a combination thereof.
34. The method of claim 32 , wherein the bacteria comprises a Gram negative bacteria, a Gram positive bacteria, an acid fast bacilli, or a combination thereof.
35. The method of claim 33 , wherein the bacterial spore is B. anthracis.
36. The method of claim 32 , wherein the bacteria comprises comprises B. anthracis, B. cereus, B. circulans, B. megatertium, B. subtilis, C. botulinum, C. tetani, C. perfringens, H. influenzae, N. gonorrhoeae, S. agalactiae, S. pneumonia, S. pyogenes, V. cholerae, S. aureus, Yersinia species, G. vaginalis, G. mobiluncus, M. hominis, Salmonellae species, Shigellae species, Pseudomonas species, Eschericia species, Klebsiella species, Proteus species, Enterobacter species, Serratia species, Moraxella species, Legionella species, Bordetella species, Helicobacter species, Arthobacter species, Micrococcus species, Listeria species, Corynebacteria species, Planococcus species, Nocardia species, Rhodococcus species, Mycobacteria species, or a combination thereof.
37. The method of claim 32 , wherein the virus belongs to a family selected from the group consisting of Orthomyxoviridae, Retroviridae, African Swine Fever Viruses, Papovaviridae, Hepadnaviridae, Coronaviridae, Flaviviridae, Togaviridae, Picornaviridae, Filoviridae, Paramyxoviridae, or Rhabdoviridae.
38. The method of claim 37 , wherein the Orthomyxovirdae virus is influenza virus, herpes simplex, herpes zoster, sendai virus, sindbis virus, pox virus, small pox or vaccinia virus.
39. The method of claim 37 , wherein the Retroviridae is human immunodeficiency virus, west nile virus, hanta virus, or human papilloma virus.
40. The method of claim 32 , wherein the fungus is a yeast or a filamentous fungus.
41. The method of claim 40 , wherein filamentous fungus is selected from the group consisting of an Aspergillus species or a dermatophyte.
42. The method of claim 41 , wherein the dermatophyte is selected from the group consisting of Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum.
43. The method of claim 32 , wherein the fungus comprises Cladosporium, Fusarium, Alternaria, Curvularia, Aspergillus Penicillium or a combination thereof.
44. A method of inactivating a pathogenic microorganism comprising contacting a subject infected with the microorganism with a composition comprising a nanoemulsion comprising:
an aqueous phase;
an oil phase comprising an oil and an organic solvent; and
one or more surfactants;
wherein the nanoemulsion comprises particles having an average diameter less than 150 nm.
45. The method of claim 44 , wherein the particles have an average diameter of less than or equal to about 100 nm or less than or equal to about 50 nm.
46. The method of claim 44 , wherein the subject is a human, an animal, or a plant.
47. The method of claim 44 , wherein the composition further comprises an activity modulator, wherein the activity modulator is an interaction enhancer, a germination enhancer, a therapeutic agent, or a combination comprising one or more of the foregoing.
48. The method of claim 44 , wherein the composition further comprises a pharmaceutically acceptable carrier.
49. The method of claim 44 , wherein the microorganism is a bacteria, a fungus, a filamentous fungus, a protozoa, a virus, or a combination of one or more of the foregoing microorganisms.
50. The method of claim 49 , wherein the bacteria is a vegetative bacteria, a bacterial spore, or a combination thereof.
51. The method of claim 49 , wherein the fungus is a yeast.
52. The method of claim 49 , wherein the bacteria comprises a Gram negative bacteria, a Gram positive bacteria, an acid fast bacilli, or a combination thereof.
53. The method of claim 50 , wherein the bacterial spore is B. anthracis.
54. The method of claim 49 , wherein the bacteria is B. anthracis, B. cereus, B. circulans, B. megatertium, B. subtilis, C. botulinum, C. tetani, C. perfringens, H. influenzae, N. gonorrhoeae, S. agalactiae, S. pneumonia, S. pyogenes, V. cholerae, S. aureus, Yersinia species, G. vaginalis, G. mobiluncus, M. hominis, Salmonellae species, Shigellae species, Pseudomonas species, Eschericia species, Klebsiella species, Proteus species, Enterobacter species, Serratia species, Moraxella species, Legionella species, Bordetella species, Helicobacter species, Arthobacter species, Micrococcus species, Listeria species, Corynebacteria species, Planococcus species, Nocardia species, Rhodococcus species, Mycobacteria species, or a combination thereof.
55. The method of claim 49 , wherein the virus belongs to a family selected from the group consisting of Orthomyxoviridae, Retroviridae, African Swine Fever Viruses, Papovaviridae, Hepadnaviridae, Coronaviridae, Flaviviridae, Togaviridae, Picomaviridae, Filoviridae, Paramyxoviridae, or Rhabdoviridae.
56. The method of claim 55 , herein the Orthomyxovirdae virus is influenza virus, herpes simplex, herpes zoster, sendai virus, sindbis virus, pox virus, small pox or vaccinia virus.
57. The method of claim 55 , herein the Retroviridae is human immunodeficiency virus, west nile virus, hanta virus, or human papilloma virus.
58. The method of claim 49 , wherein the filamentous fungus comprises Aspergillus species or dermatophytes such as Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Microsporum gypseum or Epidermophyton floccosum.
59. The method of claim 49 wherein the fungus is selected from the group consisting of Cladosporium, Fusarium, Alternaria, Curvularia, Aspergillus and Penicillium.
60. A method of preventing an infected state caused by a microorganism, comprising administering to a subject, either before or after exposure to a microorganism, a composition comprising a nanoemulsion, wherein the nanoemulsion comprises:
an aqueous phase;
an oil phase comprising an oil and an organic solvent; and one or more surfactants;
wherein the nanoemulsion comprises particles having an average diameter less than 150 nm.
61. The method of claim 60 , wherein the infected state is a sexually transmitted genital infection.
62. The method of claim 61 , wherein the sexually transmitted genital infection is selected from the group consisting of genital herpes, human papilloma virus, human immunodeficiency virus, trichomoniasis, gonorrhea, syphilis, and Chlamydia.
63. The method of claim 60 , wherein the microorganism is selected from the group consisting of a pox virus, B. anthracis, and Yersinia species.
64. The method of claim 60 , wherein the step of administering comprises application of the composition to the mucosa of a subject.
65. An immunogenic composition comprising a nanoemulsion, wherein the nanoemulsion comprises:
an aqueous phase;
an oil phase comprising an oil and an organic solvent; and a surfactant;
and wherein the nanoemulsion comprises nanoemulsion particles having an average diameter of less than or equal to 250 nm and a microorganism or a portion thereof.
66. The immunogenic composition of claim 65 , wherein the particles have an average diameter of less than or equal to about 200 nm, less than or equal to about 150 nm, less than or equal to about 100 nm, or less than or equal to about 50 nm.
67. The immunogenic composition of claim 65 , wherein the composition further comprises a pharmaceutically acceptable carrier.
68. The immunogenic composition of claim 65 , wherein the microorganism or portion thereof comprises at least a portion of a bacteria, a fungus, a protozoa, a virus, or a combination of one or more of the foregoing microorganisms.
69. The immunogenic composition of claim 68 , wherein the bacteria is a vegetative bacteria, a bacterial spore, or a combination thereof.
70. The immunogenic composition of claim 68 , wherein the bacteria is a Gram negative bacteria, a Gram positive bacteria, an acid fast bacilli or a combination thereof.
71. The immunogenic composition of claim 69 , wherein the bacterial spore is B. anthracis.
72. The immunogenic composition of claim 68 , wherein the bacteria is a respiratory transmitted bacteria.
73. The immunogenic composition of claim 68 , wherein the virus is selected from the group consisting of herpes virus, sendai virus, sindbis virus, vaccinia virus, human immunodeficiency virus, west nile virus, hanta virus, human papilloma virus, vaccinia virus, SARS, respiratory transmitted viruses and combinations thereof.
74. The immunogenic composition of claim 65 , wherein the microbial antigen is mixed with the nanoemulsion alone or with an adjuvant.
75. The immunogenic composition of claim 74 , wherein the adjuvant is a CpG oligonucleotide.
76. The immunogenic composition of claim 65 , wherein administration of the immunogenic composition to a subject raises antibodies in the subject capable of neutralizing or inactivating the microorganism.
77. The immunogenic composition of claim 65 , wherein the microorganism or portion thereof is a PA of B. anthracis.
78. A method of vaccinating against a microorganism comprising administering to a subject the a composition comprising a nanoemulsion, wherein the nanoemulsion comprises:
an aqueous phase;
an oil phase comprising an oil and an organic solvent; and
one or more surfactants;
wherein the nanoemulsion comprises particles having an average diameter of less than 250 nm,
wherein the microorganism is inactivated by the composition and an immunological response by the subject is elicited.
79. A kit comprising a composition comprising the nanoemulsion of claim 1 , wherein the composition is provided in a single formulation or a binary formulation, wherein the binary formulation is mixed prior to using the composition.
80. The kit of claim 79 , further comprising instructions for using the composition.
81. The kit of claim 79 , wherein the composition is formulated for topical administration, said kit further including means for applying the composition topically.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/080,629 US20060251684A1 (en) | 2003-06-04 | 2005-03-16 | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
US11/930,535 US8703164B2 (en) | 2003-06-04 | 2007-10-31 | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
US13/407,695 US20120219602A1 (en) | 2003-06-04 | 2012-02-28 | Methods for treating herpes virus infections |
US14/242,728 US9131680B2 (en) | 2003-06-04 | 2014-04-01 | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47563303P | 2003-06-04 | 2003-06-04 | |
US86058204A | 2004-06-04 | 2004-06-04 | |
US11/067,626 US20050208083A1 (en) | 2003-06-04 | 2005-02-28 | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
US11/080,629 US20060251684A1 (en) | 2003-06-04 | 2005-03-16 | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US86058204A Continuation | 2003-06-04 | 2004-06-04 | |
US11/067,626 Continuation US20050208083A1 (en) | 2003-06-04 | 2005-02-28 | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/930,535 Continuation US8703164B2 (en) | 2003-06-04 | 2007-10-31 | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
US12/425,984 Continuation-In-Part US20100075914A1 (en) | 2003-06-04 | 2009-04-17 | Methods for treating herpes virus infections |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060251684A1 true US20060251684A1 (en) | 2006-11-09 |
Family
ID=34986577
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/067,626 Abandoned US20050208083A1 (en) | 2003-06-04 | 2005-02-28 | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
US11/080,629 Abandoned US20060251684A1 (en) | 2003-06-04 | 2005-03-16 | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
US11/930,535 Active 2028-04-01 US8703164B2 (en) | 2003-06-04 | 2007-10-31 | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
US14/242,728 Active US9131680B2 (en) | 2003-06-04 | 2014-04-01 | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/067,626 Abandoned US20050208083A1 (en) | 2003-06-04 | 2005-02-28 | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/930,535 Active 2028-04-01 US8703164B2 (en) | 2003-06-04 | 2007-10-31 | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
US14/242,728 Active US9131680B2 (en) | 2003-06-04 | 2014-04-01 | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
Country Status (1)
Country | Link |
---|---|
US (4) | US20050208083A1 (en) |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070238652A1 (en) * | 2006-02-08 | 2007-10-11 | Biosynexus Incorporated | Neutralization of bacterial spores |
US20080038295A1 (en) * | 2006-04-13 | 2008-02-14 | Regents Of The University Of Michigan | Compositions and methods for orthopox virus vaccination |
US20080060934A1 (en) * | 2005-02-11 | 2008-03-13 | Edgar Schmidlin | Process and device for the producing and recycling of nanoemulsions as well as for the surface treatment of parts by means of the same |
WO2008137747A1 (en) | 2007-05-02 | 2008-11-13 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
WO2009129470A2 (en) * | 2008-04-18 | 2009-10-22 | Nanobio Corporation | Methods for treating herpes virus infections |
US20090269380A1 (en) * | 2008-04-25 | 2009-10-29 | Nanobio Corporation | Methods of treating fungal, yeast and mold infections |
US20090269394A1 (en) * | 2008-04-25 | 2009-10-29 | Nanobio Corporation | Methods and compositions for treating onchomycosis |
US20090291095A1 (en) * | 2008-05-23 | 2009-11-26 | The Regents Of The University Of Michigan | Nanoemulsion adjuvants |
US20090304799A1 (en) * | 2008-04-21 | 2009-12-10 | Nanobio Corporation | Nanoemulsion influenza vaccine |
US20100028433A1 (en) * | 2008-05-23 | 2010-02-04 | The Regents Of The University Of Michigan | Immunogenic compositions comprising nanoemulsion and hepatitis b virus immunogen and methods of using the same |
WO2010087964A2 (en) | 2009-01-28 | 2010-08-05 | Nanobio Corporation | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof |
US20100203139A1 (en) * | 2008-09-26 | 2010-08-12 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US20100316673A1 (en) * | 2009-06-16 | 2010-12-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
ITFI20090244A1 (en) * | 2009-11-21 | 2011-05-22 | Francesca Serdoz | NANO-LIQUID LIPID SYSTEMS FOR VEHICULAR ACTIVE AND NUTRACEUTICAL PRINCIPLES IN FEEDS FOR LIVESTOCK USE. |
DE102009056883A1 (en) * | 2009-12-03 | 2011-06-09 | Novartis Ag | Vaccine adjuvants and improved methods of making the same |
US20110162982A1 (en) * | 2009-12-03 | 2011-07-07 | Novartis Vaccines and Diagnostic, GmbH & Co. KG | Methods for producing vaccine adjuvants |
US20110165193A1 (en) * | 2009-12-03 | 2011-07-07 | Novartis Vaccines and Diagnostics, GmbH & Co. KG | Methods for producing vaccine adjuvants |
US20110200657A1 (en) * | 2005-08-09 | 2011-08-18 | Nanobio Corporation | Methods of using nanoemulsion compositions having anti-inflammatory activity |
EP2380558A1 (en) * | 2009-12-03 | 2011-10-26 | Novartis AG | Arranging interaction and back pressure chambers for microfluidization |
US8114385B2 (en) | 2003-08-04 | 2012-02-14 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US8119106B2 (en) | 2003-04-28 | 2012-02-21 | Foamix Ltd | Foamable iodine compositions |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
WO2011067673A3 (en) * | 2009-12-03 | 2012-05-10 | Novartis Ag | Circulation of components during microfluidization and/or homogenization emulsions |
US20120128719A1 (en) * | 2009-05-14 | 2012-05-24 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
US20120270909A1 (en) * | 2011-04-19 | 2012-10-25 | Brian Vincent Sokol | Method of inhibiting harmful microorganisms and barrier-forming composition therefor |
US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
WO2013006797A1 (en) | 2011-07-06 | 2013-01-10 | Nanobio Corporation | Human respiratory syncytial virus vaccine |
US8362091B2 (en) | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8703164B2 (en) | 2003-06-04 | 2014-04-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
US8760906B2 (en) | 2009-11-24 | 2014-06-24 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor memory device |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
WO2016057921A1 (en) | 2014-10-10 | 2016-04-14 | Baker Jr James R | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US9561271B2 (en) | 2011-09-09 | 2017-02-07 | Nanobio Corporation | Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
EP3329936A1 (en) | 2011-08-22 | 2018-06-06 | Nanobio Corporation | Herpes simplex virus nanoemulsion vaccine |
USRE46906E1 (en) | 2009-12-03 | 2018-06-26 | Novartis Ag | Methods for producing vaccine adjuvants |
US10213383B2 (en) | 2009-12-03 | 2019-02-26 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10426761B2 (en) | 2011-04-19 | 2019-10-01 | Arms Pharmaceutical, Llc | Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof |
US11173207B2 (en) | 2016-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Adjuvant compositions |
US11642405B2 (en) * | 2017-06-19 | 2023-05-09 | Washington University | Nanoemulsion and methods of use thereof |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
GB0427568D0 (en) * | 2004-12-16 | 2005-01-19 | Resolution Chemicals Ltd | Particle-size reduction apparatus, and the use thereof |
JP5368793B2 (en) | 2005-07-18 | 2013-12-18 | ユニバーシティ オブ マサチューセッツ ロウエル | Compositions and methods for making and using nanoemulsions |
DK3295955T3 (en) | 2005-12-01 | 2021-07-05 | Univ Massachusetts Lowell | BOTULINUM NANOEMULSIONS |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US20070166403A1 (en) * | 2006-01-11 | 2007-07-19 | Amino Solutions, Llc | Method and Compound for Treating Mold |
WO2007103294A2 (en) * | 2006-03-07 | 2007-09-13 | Novavax, Inc. | Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same |
US11311477B2 (en) | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
US10137083B2 (en) | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
JP2009533341A (en) * | 2006-04-07 | 2009-09-17 | ノババックス,インコーポレイテッド | Nanostructured compositions having antibacterial, antifungal, antiyeast, and / or antiviral properties |
US10138279B2 (en) | 2006-04-13 | 2018-11-27 | Regents Of The University Of Michigan | Compositions and methods for Bacillus anthracis vaccination |
US9839685B2 (en) * | 2006-04-13 | 2017-12-12 | The Regents Of The University Of Michigan | Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen |
FR2907012B1 (en) | 2006-10-12 | 2012-09-21 | Galderma Sa | DERMATOLOGICAL COMPOSITION COMPRISING AVERMECTIN NANOCAPSULES, PROCESS FOR PREPARING THE SAME AND USE THEREOF |
KR100904226B1 (en) | 2006-11-08 | 2009-06-25 | (주)인터리스 | Adjuvant of Nanosome Form Comprising Pseudo Lecithin Emulsifier and Vaccine Composition Comprising same |
CA2671447A1 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Amphiphilic entity nanoparticles |
KR20150028308A (en) | 2006-12-01 | 2015-03-13 | 안테리오스, 인코퍼레이티드 | Peptide nanoparticles and uses therefor |
EP1938801A1 (en) * | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
US7863350B2 (en) | 2007-01-22 | 2011-01-04 | Maxwell Chase Technologies, Llc | Food preservation compositions and methods of use thereof |
US7596836B2 (en) * | 2007-05-02 | 2009-10-06 | Schwartz Steve W | Nose and throat anti-influenza solution and method of use |
CA2688415C (en) | 2007-05-31 | 2015-11-10 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
NZ597016A (en) * | 2009-06-05 | 2013-10-25 | Sunev Pharma Solution Ltd | Topical micro-emulsions for the treatment of rheumatic disorders |
DE202010004750U1 (en) * | 2010-04-09 | 2011-10-11 | Biofrontera Bioscience Gmbh | Pharmaceutical and / or cosmetic composition for the treatment of the skin |
US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
CN103405593A (en) * | 2013-05-30 | 2013-11-27 | 李娜 | Water soluble human lubricant capable of enhancing libido and preparation method thereof as well as condom |
US20160089320A1 (en) * | 2014-09-29 | 2016-03-31 | Barrie Tan | Non-Synthetic Emulsion-Based Lipid Formulations and Methods of Use |
US11172675B2 (en) * | 2014-12-22 | 2021-11-16 | Oro Agri Inc. | Nano particulate delivery system |
US20160262411A1 (en) * | 2015-03-13 | 2016-09-15 | Reoxcyn Discoveries Group, Inc. | Methods, systems, and compositions for treating fresh produce |
WO2016182926A1 (en) * | 2015-05-08 | 2016-11-17 | Affinsci Inc. | Preparation of nanoemulsions |
WO2016196989A1 (en) * | 2015-06-03 | 2016-12-08 | Senju Usa, Inc. | Topical composition |
WO2017007835A1 (en) | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for nanoemulsion vaccine formulations |
DE202015006671U1 (en) * | 2015-09-21 | 2016-12-22 | Rosemarie Hübsch | Formulation for the medical treatment of nail fungus infestation |
US11311496B2 (en) | 2016-11-21 | 2022-04-26 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
US11511928B2 (en) | 2017-05-09 | 2022-11-29 | Cold Chain Technologies, Llc | Shipping system for storing and/or transporting temperature-sensitive materials |
US11499770B2 (en) | 2017-05-09 | 2022-11-15 | Cold Chain Technologies, Llc | Shipping system for storing and/or transporting temperature-sensitive materials |
JP2022507451A (en) | 2018-11-15 | 2022-01-18 | ブルーウィロー バイオロジクス、インコーポレイテッド | Nanoemulsion composition with enhanced permeability |
CA3081963A1 (en) | 2019-05-31 | 2020-11-30 | American River Nutrition, Llc | Compositions comprising quillaja extract and methods of preparations and use thereof |
US11629081B2 (en) * | 2019-05-31 | 2023-04-18 | Halliburton Energy Services, Inc. | Water treatment for removing oxidation agents |
Citations (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3912666A (en) * | 1969-02-06 | 1975-10-14 | Spitzer Joseph G | Emulsified propellant compositions for foamed structures such as applicator pads, and process |
US3954967A (en) * | 1971-08-05 | 1976-05-04 | Vanguard Chemical Company, Inc. | Method of producing microcolloidal aqueous emulsions of unsaturated organic insecticidal compounds |
US4020183A (en) * | 1974-12-03 | 1977-04-26 | Ortho Pharmaceutical Corporation | Nonionic surface active anti-herpes simplex viral agents |
US4451267A (en) * | 1982-09-29 | 1984-05-29 | The United States Of America As Represented By The Secretary Of Agriculture | Microemulsions from vegetable oil and aqueous alcohol with trialkylamine surfactant as alternative fuel for diesel engines |
US4481188A (en) * | 1981-08-28 | 1984-11-06 | Gist-Brocades N.V. | Vaccines |
US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
US4599088A (en) * | 1984-08-30 | 1986-07-08 | Texaco Inc. | Clear stable gasoline-alcohol-water motor fuel composition |
US4895452A (en) * | 1988-03-03 | 1990-01-23 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
US4909940A (en) * | 1987-12-30 | 1990-03-20 | New York Blood Center, Inc. | Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons |
US5073372A (en) * | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
US5103497A (en) * | 1989-11-14 | 1992-04-07 | Hicks John W | Flying spot endoscope |
US5108660A (en) * | 1990-01-29 | 1992-04-28 | The Procter & Gamble Company | Hard surface liquid detergent compositions containing hydrocarbyl amidoalkylenesulfobetaine |
US5186945A (en) * | 1988-11-23 | 1993-02-16 | Edward Shanbrom | Blood plasma antiviral process and composition |
US5188822A (en) * | 1991-08-07 | 1993-02-23 | Chesebrough-Pond's Usa Co., Division Of Conopco Inc. | Oral compositions containing an aminosilicone and a lipophilic compound |
US5368837A (en) * | 1994-04-14 | 1994-11-29 | Sterling Winthrop Inc. | X-ray contrast compositions containing an organic crystalline X-ray contrast agent and a cellulose derivative |
US5380530A (en) * | 1992-12-29 | 1995-01-10 | Whitehill Oral Technologies | Oral care composition coated gum |
US5405602A (en) * | 1989-01-31 | 1995-04-11 | Simmons; Paul L. | Nonaqueous cold sterilant |
US5405604A (en) * | 1992-10-16 | 1995-04-11 | The Procter & Gamble Company | Concentrated mouthrinse for efficient delivery of antimicrobials |
US5510104A (en) * | 1991-02-21 | 1996-04-23 | Exoxemis, Inc. | Method for killing or inhabiting the growth of sporulating microorganisms with haloperoxidase-containing compositions |
US5547677A (en) * | 1994-05-20 | 1996-08-20 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
US5549901A (en) * | 1994-05-20 | 1996-08-27 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
US5618840A (en) * | 1994-05-20 | 1997-04-08 | Novavax, Inc. | Antibacterial oil-in-water emulsions |
US5635491A (en) * | 1990-11-06 | 1997-06-03 | Nippon Shinyaku Co., Ltd. | Lyophilized fatty emulsions and a process for the production thereof |
US5651959A (en) * | 1995-06-05 | 1997-07-29 | Whitehill Oral Technologies, Inc. | Ultramulsion based oral care compositions |
US5656280A (en) * | 1994-12-06 | 1997-08-12 | Helene Curtis, Inc. | Water-in-oil-in-water compositions |
US5662932A (en) * | 1993-05-18 | 1997-09-02 | Pharmos Corporation | Solid fat nanoemulsions |
US5662957A (en) * | 1996-05-03 | 1997-09-02 | Novavax, Inc. | Oil containing lipid vesicles with marine applications |
US5700679A (en) * | 1996-06-07 | 1997-12-23 | Novavax, Inc. | Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity |
US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
US5942237A (en) * | 1993-02-15 | 1999-08-24 | Lyfjathroun H.F. | Pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
US5961958A (en) * | 1996-07-16 | 1999-10-05 | Four Star Partners | Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US6015832A (en) * | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
US6039936A (en) * | 1996-11-15 | 2000-03-21 | L'oreal | Nanoemulsion based on non-ionic and cationic amphiphilic lipids and uses thereof |
US6117415A (en) * | 1999-06-17 | 2000-09-12 | Alpharx Inc. | Toothpaste comprising bioadhesive submicron emulsion for improved delivery of antibacterial and anticaries agents |
US6127364A (en) * | 1996-03-29 | 2000-10-03 | Bayer Aktiengesellschaft | 1,3,4-oxadiazine derivatives and their use as pesticides |
US20010028887A1 (en) * | 2000-01-21 | 2001-10-11 | Veronique Douin | Nanoemulsions comprising at least one amphiphilic lipid, at least one oil, and at least one cationic polymer, and uses thereof |
US6348187B1 (en) * | 1996-01-24 | 2002-02-19 | Warner-Lambert Company | Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems |
US6361787B1 (en) * | 1998-05-27 | 2002-03-26 | The Clorox Company | Enhanced antimicrobial composition |
US20020045667A1 (en) * | 1999-04-28 | 2002-04-18 | The Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US20020119207A1 (en) * | 1999-04-28 | 2002-08-29 | The Regent Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US6506803B1 (en) * | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
US6541001B1 (en) * | 1999-08-24 | 2003-04-01 | Teva Pharmaceutical Industries, Ltd. | Vaccine composition and method of using the same |
US20030194412A1 (en) * | 2001-06-05 | 2003-10-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
US20040115159A1 (en) * | 2002-03-29 | 2004-06-17 | Tadlock Charles C | Novel nanoemulsions |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4262007A (en) * | 1979-04-13 | 1981-04-14 | George F. Sherrill | Method for the treatment of viral skin diseases |
FR2608988B1 (en) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES |
EP0278996A1 (en) | 1987-02-17 | 1988-08-24 | Ibm Deutschland Gmbh | Process for improving the adherence of photoresist materials |
CA2017507C (en) * | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
CH677886A5 (en) * | 1989-06-26 | 1991-07-15 | Hans Georg Prof Dr Weder | |
JP2912426B2 (en) | 1990-06-15 | 1999-06-28 | 鐘紡株式会社 | Micronized emulsion composition |
US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
US6348503B1 (en) * | 1996-02-12 | 2002-02-19 | Meryl J. Squires | Method and topical treatment composition for herpesvirus hominis |
US5997904A (en) * | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US6113921A (en) * | 1993-03-23 | 2000-09-05 | Pharmos Corp. | Topical and transdermal delivery system utilizing submicron oil spheres |
US5951988A (en) * | 1993-03-30 | 1999-09-14 | University Of Saskatchewan | Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods |
US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
DZ1966A1 (en) * | 1995-02-06 | 2002-10-15 | Astra Ab | New pharmaceutical combination. |
US6034073A (en) | 1995-04-24 | 2000-03-07 | Novavax, Inc. | Solvent detergent emulsions having antiviral activity |
AU701554B2 (en) | 1995-06-07 | 1999-01-28 | Taisho Pharmaceutical Co., Ltd. | Antifungal compositions |
TW504387B (en) * | 1995-09-06 | 2002-10-01 | Kao Corp | Emulsified, water-in-oil type composition and skin cosmetic preparation |
US6147047A (en) * | 1996-08-09 | 2000-11-14 | The Clorox Company | Microemulsion dilutable cleaner |
US5925241A (en) | 1996-10-25 | 1999-07-20 | Calgon Carbon Corporation | Floor drain odor control device |
FR2755851B1 (en) * | 1996-11-15 | 1998-12-24 | Oreal | DETERGENT COSMETIC COMPOSITIONS AND USE |
FR2760970B1 (en) * | 1997-03-18 | 2000-03-10 | Oreal | NANOEMULSIONS BASED ON NON-IONIC AMPHIPHILIC LIPIDS AND AMINO SILICONES AND USES |
US6761914B2 (en) * | 1997-05-27 | 2004-07-13 | Sembiosys Genetics Inc. | Immunogenic formulations comprising oil bodies |
US5902227A (en) * | 1997-07-17 | 1999-05-11 | Intevep, S.A. | Multiple emulsion and method for preparing same |
DE19752552A1 (en) * | 1997-11-27 | 1999-06-02 | Hoechst Schering Agrevo Gmbh | Surfactant systems for liquid aqueous preparations |
DE19842787A1 (en) * | 1998-09-18 | 2000-03-23 | Beiersdorf Ag | Emulsifier-free finely dispersed systems of the oil-in-water and water-in-oil type |
US7223387B2 (en) * | 1998-11-18 | 2007-05-29 | Medivir Ab | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
WO2000050006A2 (en) | 1999-02-26 | 2000-08-31 | Chiron Corporation | Microemulsions with adsorbed macromoelecules and microparticles |
DE19918324A1 (en) | 1999-04-22 | 2000-10-26 | Mann Gerhard Chem Pharm Fab | Bactericidal, virucidal, fungicidal and antiprotozoal pharmaceutical composition, especially for ophthalmological use, contains benzalkonium salt |
DE19924277A1 (en) * | 1999-05-27 | 2000-11-30 | Beiersdorf Ag | Preparations of emulsion type W / O with increased water content containing medium polar lipids and silicone emulsifiers and optionally cationic polymers |
KR100541753B1 (en) * | 1999-07-27 | 2006-01-10 | 가부시키가이샤 시세이도 | Microcapsule and a process for its preparation |
US6720001B2 (en) * | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US20020155084A1 (en) * | 2000-06-02 | 2002-10-24 | The Regents Of The University Of The Michigan | Nanoemulsion formulations |
CA2431888C (en) | 2000-12-27 | 2010-06-01 | Ares Trading S.A. | Amphiphilic lipid nanoparticles for peptide and/or protein incorporation |
AU2002258644B2 (en) | 2001-03-30 | 2006-12-14 | Color Access, Inc. | Novel nanoemulsions |
US6355229B1 (en) * | 2001-06-27 | 2002-03-12 | Church & Dwight Co., Inc. | Oral composition containing cetylpyridinium chloride and guar hydroxypropyltrimonium chloride and method of using the same |
EP1429749A2 (en) * | 2001-09-26 | 2004-06-23 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US6797685B2 (en) * | 2002-04-26 | 2004-09-28 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Liquid laundry detergent with emulsion layer |
JP2006522090A (en) * | 2003-04-04 | 2006-09-28 | ファイザー・プロダクツ・インク | Microfluidized oil-in-water emulsion and vaccine composition |
US20050208083A1 (en) * | 2003-06-04 | 2005-09-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof |
US20050196416A1 (en) * | 2004-02-05 | 2005-09-08 | Kipp James E. | Dispersions prepared by use of self-stabilizing agents |
US20070292523A1 (en) | 2004-09-27 | 2007-12-20 | Joey Moodley | Dihydropyrimidine Formulations |
DE602004017477D1 (en) * | 2004-11-09 | 2008-12-11 | Novagali Pharma Sa | Oil-in-water emulsion with low concentration of cationic agent and positive zeta potential |
US20060110415A1 (en) * | 2004-11-22 | 2006-05-25 | Bioderm Research | Topical Delivery System for Cosmetic and Pharmaceutical Agents |
US20070054834A1 (en) | 2005-04-11 | 2007-03-08 | Nanobio Corporation | Quaternary ammonium halides for treatment of infectious conditions |
CA2618974C (en) | 2005-08-09 | 2014-01-28 | Nanobio Corporation | Nanoemulsion compositions having anti-inflammatory activity |
DK3295955T3 (en) | 2005-12-01 | 2021-07-05 | Univ Massachusetts Lowell | BOTULINUM NANOEMULSIONS |
-
2005
- 2005-02-28 US US11/067,626 patent/US20050208083A1/en not_active Abandoned
- 2005-03-16 US US11/080,629 patent/US20060251684A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/930,535 patent/US8703164B2/en active Active
-
2014
- 2014-04-01 US US14/242,728 patent/US9131680B2/en active Active
Patent Citations (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3912666A (en) * | 1969-02-06 | 1975-10-14 | Spitzer Joseph G | Emulsified propellant compositions for foamed structures such as applicator pads, and process |
US3954967A (en) * | 1971-08-05 | 1976-05-04 | Vanguard Chemical Company, Inc. | Method of producing microcolloidal aqueous emulsions of unsaturated organic insecticidal compounds |
US4020183A (en) * | 1974-12-03 | 1977-04-26 | Ortho Pharmaceutical Corporation | Nonionic surface active anti-herpes simplex viral agents |
US4481188A (en) * | 1981-08-28 | 1984-11-06 | Gist-Brocades N.V. | Vaccines |
US4451267A (en) * | 1982-09-29 | 1984-05-29 | The United States Of America As Represented By The Secretary Of Agriculture | Microemulsions from vegetable oil and aqueous alcohol with trialkylamine surfactant as alternative fuel for diesel engines |
US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
US4599088A (en) * | 1984-08-30 | 1986-07-08 | Texaco Inc. | Clear stable gasoline-alcohol-water motor fuel composition |
US4909940A (en) * | 1987-12-30 | 1990-03-20 | New York Blood Center, Inc. | Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons |
US4895452A (en) * | 1988-03-03 | 1990-01-23 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
US5186945A (en) * | 1988-11-23 | 1993-02-16 | Edward Shanbrom | Blood plasma antiviral process and composition |
US5405602A (en) * | 1989-01-31 | 1995-04-11 | Simmons; Paul L. | Nonaqueous cold sterilant |
US5103497A (en) * | 1989-11-14 | 1992-04-07 | Hicks John W | Flying spot endoscope |
US5108660B1 (en) * | 1990-01-29 | 1993-04-27 | W Michael Daniel | |
US5108660A (en) * | 1990-01-29 | 1992-04-28 | The Procter & Gamble Company | Hard surface liquid detergent compositions containing hydrocarbyl amidoalkylenesulfobetaine |
US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
US5635491A (en) * | 1990-11-06 | 1997-06-03 | Nippon Shinyaku Co., Ltd. | Lyophilized fatty emulsions and a process for the production thereof |
US5073372A (en) * | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
US5510104A (en) * | 1991-02-21 | 1996-04-23 | Exoxemis, Inc. | Method for killing or inhabiting the growth of sporulating microorganisms with haloperoxidase-containing compositions |
US5188822A (en) * | 1991-08-07 | 1993-02-23 | Chesebrough-Pond's Usa Co., Division Of Conopco Inc. | Oral compositions containing an aminosilicone and a lipophilic compound |
US5405604A (en) * | 1992-10-16 | 1995-04-11 | The Procter & Gamble Company | Concentrated mouthrinse for efficient delivery of antimicrobials |
US5380530A (en) * | 1992-12-29 | 1995-01-10 | Whitehill Oral Technologies | Oral care composition coated gum |
US5942237A (en) * | 1993-02-15 | 1999-08-24 | Lyfjathroun H.F. | Pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane |
US5662932A (en) * | 1993-05-18 | 1997-09-02 | Pharmos Corporation | Solid fat nanoemulsions |
US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
US5368837A (en) * | 1994-04-14 | 1994-11-29 | Sterling Winthrop Inc. | X-ray contrast compositions containing an organic crystalline X-ray contrast agent and a cellulose derivative |
US5549901A (en) * | 1994-05-20 | 1996-08-27 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
US5618840A (en) * | 1994-05-20 | 1997-04-08 | Novavax, Inc. | Antibacterial oil-in-water emulsions |
US5547677A (en) * | 1994-05-20 | 1996-08-20 | Novavax, Inc. | Antimicrobial oil-in-water emulsions |
US5656280A (en) * | 1994-12-06 | 1997-08-12 | Helene Curtis, Inc. | Water-in-oil-in-water compositions |
US5651959A (en) * | 1995-06-05 | 1997-07-29 | Whitehill Oral Technologies, Inc. | Ultramulsion based oral care compositions |
US6348187B1 (en) * | 1996-01-24 | 2002-02-19 | Warner-Lambert Company | Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems |
US6127364A (en) * | 1996-03-29 | 2000-10-03 | Bayer Aktiengesellschaft | 1,3,4-oxadiazine derivatives and their use as pesticides |
US5662957A (en) * | 1996-05-03 | 1997-09-02 | Novavax, Inc. | Oil containing lipid vesicles with marine applications |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5700679A (en) * | 1996-06-07 | 1997-12-23 | Novavax, Inc. | Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity |
US5961958A (en) * | 1996-07-16 | 1999-10-05 | Four Star Partners | Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth |
US6039936A (en) * | 1996-11-15 | 2000-03-21 | L'oreal | Nanoemulsion based on non-ionic and cationic amphiphilic lipids and uses thereof |
US6015832A (en) * | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
US6361787B1 (en) * | 1998-05-27 | 2002-03-26 | The Clorox Company | Enhanced antimicrobial composition |
US20020045667A1 (en) * | 1999-04-28 | 2002-04-18 | The Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US20020119207A1 (en) * | 1999-04-28 | 2002-08-29 | The Regent Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US6506803B1 (en) * | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
US6559189B2 (en) * | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US6635676B2 (en) * | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US6117415A (en) * | 1999-06-17 | 2000-09-12 | Alpharx Inc. | Toothpaste comprising bioadhesive submicron emulsion for improved delivery of antibacterial and anticaries agents |
US6541001B1 (en) * | 1999-08-24 | 2003-04-01 | Teva Pharmaceutical Industries, Ltd. | Vaccine composition and method of using the same |
US20010028887A1 (en) * | 2000-01-21 | 2001-10-11 | Veronique Douin | Nanoemulsions comprising at least one amphiphilic lipid, at least one oil, and at least one cationic polymer, and uses thereof |
US20030194412A1 (en) * | 2001-06-05 | 2003-10-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
US20060257426A1 (en) * | 2001-06-05 | 2006-11-16 | Regents Of The University Of Michigan | Nanoemulsion vaccines |
US20040115159A1 (en) * | 2002-03-29 | 2004-06-17 | Tadlock Charles C | Novel nanoemulsions |
Cited By (169)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8741265B2 (en) | 2002-10-25 | 2014-06-03 | Foamix Ltd. | Penetrating pharmaceutical foam |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8486375B2 (en) | 2003-04-28 | 2013-07-16 | Foamix Ltd. | Foamable compositions |
US8119106B2 (en) | 2003-04-28 | 2012-02-21 | Foamix Ltd | Foamable iodine compositions |
US8703164B2 (en) | 2003-06-04 | 2014-04-22 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
US9131680B2 (en) | 2003-06-04 | 2015-09-15 | Nanobio Corporation | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
US8703105B2 (en) | 2003-08-04 | 2014-04-22 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8518378B2 (en) | 2003-08-04 | 2013-08-27 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8114385B2 (en) | 2003-08-04 | 2012-02-14 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8362091B2 (en) | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US20080060934A1 (en) * | 2005-02-11 | 2008-03-13 | Edgar Schmidlin | Process and device for the producing and recycling of nanoemulsions as well as for the surface treatment of parts by means of the same |
US8083918B2 (en) * | 2005-02-11 | 2011-12-27 | Claudia Marcoli | Process and device for the producing and recycling of nanoemulsions as well as for the surface treatment of parts by means of the same |
US20110200657A1 (en) * | 2005-08-09 | 2011-08-18 | Nanobio Corporation | Methods of using nanoemulsion compositions having anti-inflammatory activity |
US20070238652A1 (en) * | 2006-02-08 | 2007-10-11 | Biosynexus Incorporated | Neutralization of bacterial spores |
US20080038295A1 (en) * | 2006-04-13 | 2008-02-14 | Regents Of The University Of Michigan | Compositions and methods for orthopox virus vaccination |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US9801842B2 (en) | 2007-05-02 | 2017-10-31 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US8747872B2 (en) | 2007-05-02 | 2014-06-10 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US20080317799A1 (en) * | 2007-05-02 | 2008-12-25 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
WO2008137747A1 (en) | 2007-05-02 | 2008-11-13 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US9549898B2 (en) | 2007-12-07 | 2017-01-24 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
WO2009129470A2 (en) * | 2008-04-18 | 2009-10-22 | Nanobio Corporation | Methods for treating herpes virus infections |
US20100075914A1 (en) * | 2008-04-18 | 2010-03-25 | Nanobio Corporation | Methods for treating herpes virus infections |
WO2009129470A3 (en) * | 2008-04-18 | 2010-12-02 | Nanobio Corporation | Methods for treating herpes virus infections |
US9144606B2 (en) | 2008-04-21 | 2015-09-29 | Nanobio Corporation | Nanoemulsion influenza vaccine |
US20090304799A1 (en) * | 2008-04-21 | 2009-12-10 | Nanobio Corporation | Nanoemulsion influenza vaccine |
EP3023107A1 (en) | 2008-04-21 | 2016-05-25 | Nanobio Corporation | Nanoemulsion influenza vaccine |
US10525121B2 (en) | 2008-04-21 | 2020-01-07 | Nanobio Corporation | Nanoemulsion influenza vaccine |
US20090269394A1 (en) * | 2008-04-25 | 2009-10-29 | Nanobio Corporation | Methods and compositions for treating onchomycosis |
US8226965B2 (en) * | 2008-04-25 | 2012-07-24 | Nanobio Corporation | Methods of treating fungal, yeast and mold infections |
US20120276182A1 (en) * | 2008-04-25 | 2012-11-01 | Nanobio Corporation | Methods of treating fungal, yeast and mold infections |
US20090269380A1 (en) * | 2008-04-25 | 2009-10-29 | Nanobio Corporation | Methods of treating fungal, yeast and mold infections |
US8877208B2 (en) | 2008-05-23 | 2014-11-04 | The Regents Of The University Of Michigan | Multivalent nanoemulsion vaccines |
US9415006B2 (en) * | 2008-05-23 | 2016-08-16 | The Regents Of The University Of Michigan | Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same |
US20090291095A1 (en) * | 2008-05-23 | 2009-11-26 | The Regents Of The University Of Michigan | Nanoemulsion adjuvants |
WO2010033274A3 (en) * | 2008-05-23 | 2010-07-08 | The Regents Of The University Of Michigan | Nanoemulsion adjuvants |
US20100028433A1 (en) * | 2008-05-23 | 2010-02-04 | The Regents Of The University Of Michigan | Immunogenic compositions comprising nanoemulsion and hepatitis b virus immunogen and methods of using the same |
US8962026B2 (en) | 2008-09-26 | 2015-02-24 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US20100203139A1 (en) * | 2008-09-26 | 2010-08-12 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US9259407B2 (en) | 2008-09-26 | 2016-02-16 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
US20100226983A1 (en) * | 2009-01-28 | 2010-09-09 | Nanobio Corporation | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof |
WO2010087964A2 (en) | 2009-01-28 | 2010-08-05 | Nanobio Corporation | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof |
US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US20120128719A1 (en) * | 2009-05-14 | 2012-05-24 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
US8668911B2 (en) * | 2009-05-14 | 2014-03-11 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
US20100316673A1 (en) * | 2009-06-16 | 2010-12-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9572775B2 (en) | 2009-07-29 | 2017-02-21 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US8992896B2 (en) | 2009-10-02 | 2015-03-31 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
ITFI20090244A1 (en) * | 2009-11-21 | 2011-05-22 | Francesca Serdoz | NANO-LIQUID LIPID SYSTEMS FOR VEHICULAR ACTIVE AND NUTRACEUTICAL PRINCIPLES IN FEEDS FOR LIVESTOCK USE. |
US9812179B2 (en) | 2009-11-24 | 2017-11-07 | Ovonyx Memory Technology, Llc | Techniques for reducing disturbance in a semiconductor memory device |
US8760906B2 (en) | 2009-11-24 | 2014-06-24 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor memory device |
CN105055311A (en) * | 2009-12-03 | 2015-11-18 | 诺华股份有限公司 | Circulation of components during homogenization /microfluidisation of emulsions |
EP2380558A1 (en) * | 2009-12-03 | 2011-10-26 | Novartis AG | Arranging interaction and back pressure chambers for microfluidization |
US9700616B2 (en) | 2009-12-03 | 2017-07-11 | Novartis Ag | Arranging interaction and back pressure chambers for microfluidization |
USRE46441E1 (en) | 2009-12-03 | 2017-06-20 | Novartis Ag | Circulation of components during homogenization of emulsions |
US8778275B2 (en) | 2009-12-03 | 2014-07-15 | Novartis Ag | Methods for producing vaccine adjuvants |
US8678184B2 (en) | 2009-12-03 | 2014-03-25 | Novartis Ag | Methods for producing vaccine adjuvants |
USRE46906E1 (en) | 2009-12-03 | 2018-06-26 | Novartis Ag | Methods for producing vaccine adjuvants |
DE102009056883A1 (en) * | 2009-12-03 | 2011-06-09 | Novartis Ag | Vaccine adjuvants and improved methods of making the same |
US20110162982A1 (en) * | 2009-12-03 | 2011-07-07 | Novartis Vaccines and Diagnostic, GmbH & Co. KG | Methods for producing vaccine adjuvants |
US20110165193A1 (en) * | 2009-12-03 | 2011-07-07 | Novartis Vaccines and Diagnostics, GmbH & Co. KG | Methods for producing vaccine adjuvants |
US20110165192A1 (en) * | 2009-12-03 | 2011-07-07 | Novartis Vaccines and Diagnostics, GmbH & Co. KG | Methods for producing vaccine adjuvants |
US11141376B2 (en) | 2009-12-03 | 2021-10-12 | Novartis Ag | Circulation of components during microfluidization and/or homogenization of emulsions |
EA031593B1 (en) * | 2009-12-03 | 2019-01-31 | Новартис Аг | Method for the manufacture of an oil-in-water emulsion |
US8871816B2 (en) | 2009-12-03 | 2014-10-28 | Novartis Ag | Methods for producing vaccine adjuvants |
US10213383B2 (en) | 2009-12-03 | 2019-02-26 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
CN102753149A (en) * | 2009-12-03 | 2012-10-24 | 诺华有限公司 | Circulation of components during homogenization /microfluidisation of emulsions |
WO2011067672A3 (en) * | 2009-12-03 | 2011-12-01 | Novartis Ag | Arranging interaction and back pressure chambers for microfluidization |
US8895629B2 (en) | 2009-12-03 | 2014-11-25 | Novartis Ag | Circulation of components during homogenization of emulsions |
WO2011067673A3 (en) * | 2009-12-03 | 2012-05-10 | Novartis Ag | Circulation of components during microfluidization and/or homogenization emulsions |
DE102009056884B4 (en) * | 2009-12-03 | 2021-03-18 | Novartis Ag | Vaccine Adjuvants and Improved Methods for Making Same |
EA024770B1 (en) * | 2009-12-03 | 2016-10-31 | Новартис Аг | Method for manufacture of a vaccine adjuvant |
US9463240B2 (en) | 2009-12-03 | 2016-10-11 | Novartis Ag | Arranging interaction and back pressure chambers for microfluidization |
US20130189311A1 (en) * | 2009-12-03 | 2013-07-25 | Novartis Ag | Arranging interaction and back pressure chambers for microfluidization |
DE102009056883B4 (en) * | 2009-12-03 | 2012-08-16 | Novartis Ag | Vaccine adjuvants and improved methods of making the same |
CN102740832A (en) * | 2009-12-03 | 2012-10-17 | 诺华有限公司 | Arranging interaction and back pressure chambers for microfluidization |
US10799454B2 (en) | 2009-12-03 | 2020-10-13 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
US20150258191A1 (en) * | 2009-12-03 | 2015-09-17 | Novartis Ag | Arranging interaction and back pressure chambers for microfluidization |
US9750690B2 (en) | 2009-12-03 | 2017-09-05 | Novartis Ag | Circulation of components during microfluidization and/or homogenization of emulsions |
US10463615B2 (en) | 2009-12-03 | 2019-11-05 | Novartis Ag | Circulation of components during microfluidization and/or homogenization of emulsions |
CN104997730A (en) * | 2009-12-03 | 2015-10-28 | 诺华股份有限公司 | Arranging interaction and back pressure chambers for microfluidization |
US10426761B2 (en) | 2011-04-19 | 2019-10-01 | Arms Pharmaceutical, Llc | Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof |
US8535646B2 (en) * | 2011-04-19 | 2013-09-17 | ARMS Pharmaceutical LLC | Method of inhibiting harmful microorganisms and barrier-forming composition therefor |
AU2012245665B2 (en) * | 2011-04-19 | 2017-06-15 | Arms Pharmaceutical Llc. | Method of inhibiting harmful microorganisms and barrier-forming composition therefor |
US20120270909A1 (en) * | 2011-04-19 | 2012-10-25 | Brian Vincent Sokol | Method of inhibiting harmful microorganisms and barrier-forming composition therefor |
US8992893B2 (en) * | 2011-04-19 | 2015-03-31 | Arms Pharmaceutical, Llc | Method of inhibiting harmful microorganisms and barrier-forming composition therefor |
US10398645B2 (en) | 2011-04-19 | 2019-09-03 | Arms Pharmaceutical, Llc | Method of inhibiting harmful microorganisms and barrier-forming composition therefor |
US20130028848A1 (en) * | 2011-04-19 | 2013-01-31 | Brian Vincent Sokol | Method of inhibiting harmful microorganisms and barrier-forming composition therefor |
US9492525B2 (en) | 2011-07-06 | 2016-11-15 | Nanobio Corporation | Human respiratory syncytial virus vaccine |
WO2013006797A1 (en) | 2011-07-06 | 2013-01-10 | Nanobio Corporation | Human respiratory syncytial virus vaccine |
EP3329936A1 (en) | 2011-08-22 | 2018-06-06 | Nanobio Corporation | Herpes simplex virus nanoemulsion vaccine |
US11147869B2 (en) | 2011-08-22 | 2021-10-19 | Bluewillow Biologics, Inc. | Herpes simplex virus nanoemulsion vaccine |
US10206996B2 (en) | 2011-08-22 | 2019-02-19 | Nanobio Corporation | Herpes simplex virus nanoemulsion vaccine |
US9561271B2 (en) | 2011-09-09 | 2017-02-07 | Nanobio Corporation | Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine |
US10596251B2 (en) | 2011-09-09 | 2020-03-24 | Nanobio Corporation | Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine |
EP3488863A1 (en) | 2011-09-09 | 2019-05-29 | Nanobio Corporation | Nanoemulsion respiratory syncytial virus (rsv) subunit vaccine |
US11083788B2 (en) | 2014-10-10 | 2021-08-10 | The Regents Of The University Of Michigan | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease |
WO2016057921A1 (en) | 2014-10-10 | 2016-04-14 | Baker Jr James R | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease |
EP4112076A1 (en) | 2014-10-10 | 2023-01-04 | The Regents of The University of Michigan | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease |
US11806318B2 (en) | 2014-10-10 | 2023-11-07 | The Regents Of The University Of Michigan | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease |
US11173207B2 (en) | 2016-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Adjuvant compositions |
US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US11642405B2 (en) * | 2017-06-19 | 2023-05-09 | Washington University | Nanoemulsion and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
US8703164B2 (en) | 2014-04-22 |
US20140212463A1 (en) | 2014-07-31 |
US20050208083A1 (en) | 2005-09-22 |
US20120171249A1 (en) | 2012-07-05 |
US9131680B2 (en) | 2015-09-15 |
US20150150244A9 (en) | 2015-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9131680B2 (en) | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof | |
AU2004273779B2 (en) | Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof | |
CA2618974C (en) | Nanoemulsion compositions having anti-inflammatory activity | |
CA2395678C (en) | Antimicrobial compositions and methods of use | |
US7767216B2 (en) | Antimicrobial compositions and methods of use | |
AU2002350587B2 (en) | Antimicrobial nanoemulsion compositions and methods | |
US6559189B2 (en) | Non-toxic antimicrobial compositions and methods of use | |
US8771731B2 (en) | Antimicrobial nanoemulsion compositions and methods | |
US8236335B2 (en) | Antimicrobial nanoemulsion compositions and methods | |
WO2005030172A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
JP2010209109A (en) | Composition and method for anti-microbial nanoemulsion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NANOBIO CORPORATION, MICHIGAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAKER, JAMES R.;ANNIS, TED C.;HAMOUDA, TAREK;REEL/FRAME:016579/0145;SIGNING DATES FROM 20050318 TO 20050322 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |